











Manuscript version: Author’s Accepted Manuscript 
The version presented in WRAP is the author’s accepted manuscript and may differ from the 
published version or Version of Record. 
 
Persistent WRAP URL: 
http://wrap.warwick.ac.uk/140909                                   
 
How to cite: 
Please refer to published version for the most recent bibliographic citation information.  
If a published version is known of, the repository item page linked to above, will contain 
details on accessing it. 
 
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the 
University of Warwick available open access under the following conditions.  
 
Copyright © and all moral rights to the version of the paper presented here belong to the 
individual author(s) and/or other copyright owners. To the extent reasonable and 
practicable the material made available in WRAP has been checked for eligibility before 
being made available. 
 
Copies of full items can be used for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge. Provided that the authors, title and full 
bibliographic details are credited, a hyperlink and/or URL is given for the original metadata 
page and the content is not changed in any way. 
 
Publisher’s statement: 
Please refer to the repository item page, publisher’s statement section, for further 
information. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk. 
 
Asymmetric Transfer Hydrogenation - Dynamic Kinetic Resolution 
of -Amino Ketones 
Shweta K. Gediya, Guy J. Clarkson and Martin Wills.* 
Department of Chemistry, The University of Warwick, Coventry, CV4 7AL, UK. 
Corresponding author: m.wills@warwick.ac.uk 
Supporting Information Placeholder 
 
 
ABSTRACT: A series of -amino ketones were reduced using asymmetric transfer hydrogenation (ATH) through a dynamic 
kinetic resolution (DKR). The protecting group was matched to the reducing agent and following optimization, a series of 
substrates were investigated, giving products in high diastereoselectivity, over 99% ee in several cases and full conversion. 
The methodology was applied to the enantioselective synthesis of a MDM2–p53 inhibitor precursor. 
 
Introduction 1 
Asymmetric Transfer Hydrogenation (ATH), using 2 
[(arene)Ru(TsDPEN)Cl] pre-catalysts 1, including the class of 3 
complexes 2 and 3, is a powerful method for the asymmetric 4 
reduction of ketones (Figure 1).1-3 The pre-catalyst forms a hy-5 
dride which transfers hydrogen to the substrate in a stereochem-6 
ically-predictable manner (Figure 1).4 7 
 8 
9 
Figure 1. Asymmetric Transfer Hydrogenation (ATH) of aceto-10 
phenones by [(arene)Ru((R,R)-TsDPEN)Cl] catalysts 1-3 and ori-11 
entation of substrate to catalyst in reduction step. 12 
 13 
ATH in combination with dynamic kinetic resolution (DKR), 14 
has been used to good effect.5-12 For -amino ketones,6-12  ATH-15 
DKR of amino--keto esters have been reported (Figure 16 
2A).6-9 In an example by Echeverria et al., reduction of a -keto-17 
-amino ester  gave 4 in up to 83/17 anti/syn and 98% ee using 18 
catalyst 2.6 Researchers at Takasago described the large scale 19 
ATH-DKR of -N-acylamino--keto esters using ATH to 5 us-20 
ing catalyst 3.7 An efficient DKR-ATH was achieved in the syn-21 
thesis of enantiomeric pure syn-β-hydroxy-α-dibenzylamino es-22 
ters8 to make 6. 23 
Products of ATH-DKR of -amino--keto-esters:24 
25 
 26 
Products of ATH-DKR of other -amino ketones:27 
 28 




Figure 2. Products of ATH-DKR of -amino ketones of differ-1 
ent classes. 2 
 3 
Amino ketones in which racemisation is slower have been 4 
less investigated.10-12 The ATH-DKR of a Boc-protected -5 
amino ketone to alcohol 7 was employed in the synthesis of the 6 
type 2 diabetes drug omariglyptin (Figure 2B).10 The 7 
ATH/DKR, using a range of catalysts including 2 and 3 gave 8 
amino alcohol 8 in 97-98% ee and a dr of >200:1 (Figure 2B).11 9 
Intramolecular cyclisation, with inversion of configuration, led 10 
to the mGluR5 9.11 Other relevant ATH-DKRs of -amino ke-11 
tones have led to cis--azolo--cycloalkanols 10 and 11 (Figure 12 
2B).12 We were interested in establishing the scope of the 13 
ATH/DKR of -amino ketones (Figure 2C), as the extension of 14 
the methodology would provide access to a range of valuable 15 
target molecules.  16 
Results and Discussion 17 
Compounds 12a-14a (Table 1)were prepared via bromination 18 
of -phenylacetophenone, reaction with potassium 19 
phthalimide, then deprotection and addition of the N-protecting 20 
group, whereas 15a was prepared through the reaction of an 21 
acylimine with benzaldehyde using a thiazolium catalyst13 22 
(Supporting Information). A series of conditions were tested us-23 
ing catalyst (R,R)-2. Racemic standards were prepared by re-24 
duction with NaBH4, which was less diastereoselective than the 25 
ATH-DKR and allowed the minor diastereomers to be identi-26 
fied by HPLC (other than for 16a). In all cases, the anti- prod-27 
ucts 16a-19a (Table S1, Table 1) were predominantly formed.14 28 
Using FA/TEA azeotrope (5:2) with DCM (A, Table S1), the 29 
medium in the reduction of 12a became heterogeneous after 30 
24h. Both precipitate and filtrate from the reaction contained 31 
product of high dr, however of differing ee. Using a 1:1 ratio of 32 
FA:TEA (B, Table S1), conversion was incomplete and the ees 33 
were lower. Using a combination of 5:3 DABCO/FA (C, Table 34 
S1).11 gave a product in improved ee, which did not change sig-35 
nificantly when a 5:6 ratio of reagents was used (D, Table S1).  36 
Reduction of N-Boc-protected substrate 13a using both TEA 37 
and DABCO as base with catalyst (R,R)-2 (A and C, Table S1) 38 
also revealed that the latter base gave the best result. Working 39 
up the reductions of 12a and 13a with a DCM extraction gave 40 
a product which reflected the overall ee of the reaction (Table 41 
S1, Table 1). The N-Ts-protected substrate 14a was reduced in 42 
an excellent 99% ee under conditions C (Table S1, Table 1) 43 
with catalyst (R,R)-2 whereas the best ee for the reduction of 44 
the N-Cbz-protected substrate 15a was just 44% (Table S1, Ta-45 
ble 1); the reactions for the formation of both 18a and 19a re-46 
mained homogeneous. The X-ray crystallographic structure of 47 
the major enantiomer of 18a (Supporting Information) con-48 
firmed both its absolute configuration and the anti-diastereose-49 
lectivity matches the related product 8 containing a Cbz group.11 50 
Since slow racemisation can reduce the potential for the for-51 
mation of high ee products in DKR reactions, they were fol-52 
lowed over time. The substrates (with the exception of 18a) re-53 
mained essentially racemic throughout (Scheme S1, Table S2), 54 
confirming that racemisation is rapid. The product ees remained 55 
consistent (within ca. 5%) throughout the reductions. Hence the 56 
catalyst controls the reduction of one enantiomer of ketone sub-57 
strate over the other, however the N-protecting group also has 58 
an influence on the selectivity.  59 
 60 
Table 1. Catalyst screening on substrates 12a-15a, and catalysts 61 





t/h Conva  
/%  (dr)b yield 
Eec   
/% 
(R,R)-2  12a 24 100 (>99.9:<0.1d) 60% yield 25  
(R,R)-1 12a  72 95 (>99.9:<0.1d) 76 
(R,R)-20 12a 72 70 (>99.9:<0.1d) 94 
(R,R)-21 12a 24 100 (>99.9:<0.1d) 61 
(R,R)-22 12a 48 63 (>99.9:<0.1d) 69 e 
(R,R)-2  13a 24 100 (>99.9:<0.1) 65% yield 73  
(R,R)-1 13a  72 91 (>99.9:<0.1f) 94 
(R,R)-20 13a 72 96 (>99.9:<0.1) 93 
(R,R)-21 13a 24 100 (>99.9:<0.1) 76 
(R,R)-22 13a 48 46 (ca. 95:5g) 12 e 
(R,R)-2  14a 24 100 (>99.9:<0.1) 69% yield 99  
(R,R)-1 14a 72 89 (>99.9:<0.1h) >99 
(R,R)-20 14a 72 97 (>99.9:<0.1) 98 
(R,R)-21 14a 24 100 (>99.9:<0.1) 94 
(R,R)-22 14a 48 21 (>99.9:<0.1h) 69 
(R,R)-2  15a 24 100 (>99.9:<0.1) 59% yield 44  
(R,R)-1 15a  72 39 (>99.9:<0.1) 71 
(R,R)-20 15a 48 98 (>99.9:<0.1) 85 
(R,R)-21 15a 24 100 (>99.9:<0.1) 67 
(R,R)-22 15a 48 54 (>99.9:<0.1) 60 d 
a. HPLC conversions and ee of isolated product using (R,R)-2 and of  crude 65 
product for other catalysts; b. >99.9:<0.1 indicates only one diastereoisomer 66 
observed by chiral HPLC. c. ee of major diastereoisomer. d. Minor diaster-67 
eoisomer not detected in racemic reduction. e. opposite enantiomer of prod-68 
uct formed. f. tentative as HPLC did not run to minor isomer.  g. Estimated 69 
as minor diastereoisomer was not integrated. h. tentatively assigned as some 70 
small HPLC peaks are of similar RT to minor diastereomer. 71 
 72 
We evaluated a series of catalysts; (R,R)-1 and (R,R)-20,9e 73 
(R,R)-21,3f and (R,R)-22,3g under the same conditions for each 74 
substrate (Table 1). Catalyst 1 and the pentafluorinated (R,R)-75 
20 gave product 16a in good ee however they were slow com-76 
pared to the CH2(C6H4)-linked catalyst (R,R)-21. Catalyst 77 
(R,R)-20 generated a product of 94% ee in the reduction of 12a 78 
compared to just 25% ee with catalyst (R,R)-2. The tosyl sub-79 
strate 14a gave a product in >90% ee with all the catalysts ex-80 
cept (R,R)-22. Catalysts (R,R)-1 and (R,R)-20 gave similar re-81 
sults with N-Boc-protected13a. Although there is no direct ev-82 
idence, there is potential for a reduction product such as 18a to 83 
replace the ligand in the catalysts, and this is likely to happen 84 
more rapidly with untethered complexes.2b Catalyst (R,R)-22 85 
was found to be the least active and in several cases gave the 86 
opposite enantiomer of product, although still a high dr. Aceto-87 
phenone reduction with catalyst (R,R)-22 gave the (R)-alcohol, 88 
3 
 
as expected. As a result of this study, two catalyst/substrate sys-1 
tems were selected for further study; fluorinated catalyst (R,R)-2 
20 with N-Boc-protected substrate 13a and complex (R,R)-2 3 
with N-Ts-protected compound 14a. A solvent study was car-4 
ried out (Supporting information, Table S3) however none of 5 
the alternative solvents, or solvent–free conditions, improved 6 
the results. 7 
The reduction of a range of substrates; 13b-13l and 14b--14l 8 
and the precursors to 23-27, were undertaken (Figure 3). The 9 
N-Boc-protected ketones,13 were prepared initially, then the N-10 
Ts-protected ketones were prepared via their deprotection fol-11 
lowed by N-tosylation. A representative series of substrates 12 
were prepared with electron-donating (OMe) and electron-with-13 
drawing (Cl) substituents at the o-, m- and p- positions of each 14 
aromatic ring Ar1/Ar2. In addition, one NMs product (23) was 15 
formed by reduction of the corresponding ketone, as were 24-16 







Figure 3. Reduction products of ketones 13b-13l (using (R,R)-24 
20) and 14b-14l (using (R,R)-2). Conditions are as in Figure 25 
2/Table 1 except that 2 mol% catalyst was used for the for-26 
mation of 17b, 17d, 17g and 17h. Ees are of major diastereoi-27 
somers except where indicated. a. Overlap of peaks in HPLC 28 
limits the accuracy of this measurement.  29 
 30 
Substrates containing substituents on the aromatic rings adja-31 
cent to the ketone (Ar1), leading to products 17b-17f and 18b-32 
18f, were fully reduced in most cases and in high dr and ee, 33 
although the o- and p-chloro substituted products were formed 34 
in slightly lower ee. Although the configurations of products 35 
were generally assigned by analogy to 17a/18a, the X-ray crys-36 
tallographic structure of 17d was determined and served to con-37 
firm the assignment (Supporting Information).  38 
 39 
 40 
Substrates with substituted aromatic rings proximal to the 41 
amine (Ar2) were generally reduced to 17g-17k and 18g-/18k 42 
in high dr although the ee was dependent on both the nature and 43 
position of the substituents. The o-chloro N-Ts-protected sub-44 
strate 14i gave product 18i in a poor dr however sub-45 
strates13k/14k, containing a combination of p- substituents 46 
gave a product in high dr and eeThe furyl-containing products 47 
17l/18l were formed in poor dr and ee.  NMs product 23 was 48 
formed in an excellent 96.4% ee and high dr, indicating that the 49 
aromatic ring of the Ts is not required for high selectivity. When 50 
the aromatic ring proximal to the amine (Ar2) was replaced by 51 
a methyl group, products 24 and 25 were formed in poor dr and 52 
low ee. On the other hand, replacement of the Ph adjacent to the 53 
ketone followed by ATH-DKR gave a high dr and ee for the N-54 
Boc-protected product 26, but the N-Ts-protected product 27 in 55 
much lower dr. The formation of two products, N-Boc-prtected 56 
17e and N-Ts-protected 18h were carried out on 1.0g scale with 57 
respect to starting material ketone. In both cases the reductions 58 
proceeded cleanly to give products in 88.7% and 89.4% yields 59 
respectively, and with 94.9% and 89.4% ee respectively (previ-60 
ously 96.8% and 90.2% ee) (see the Supporting Information).  61 
The results indicate that the reductions proceed with preferen-62 
tial formation of the anti-diastereoisomers.11,14 The results ob-63 
served for products 24-27 indicate that the aromatic ring adja-64 
cent to the protected amine (Ar2) is required for control of dr 65 
and ee in the reductions whereas the aromatic ring adjacent to 66 
the ketone (Ar1) is not. Previous studies have indicated that a H-67 
bond between the substrate and the SO2 of the sulfonamido 68 
group can play an important part in the control of the ATH of 69 
imines15a,b and -amino ketones,12c as can an interaction be-70 
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tween an amido on the substrate and the 6-arene of the cata-1 
lyst.15c Considering the related studies, and our observations, 2 
the stereochemical outcome can be explained by a transition 3 
state (Figure 4) for hydride transfer which is stabilised by a hy-4 
drogen bond between an N-H in the substrate and the sulfon-5 
amido group, coupled with a CH/ edge/face interaction as il-6 
lustrated. This results in the formation of the observed product 7 
and agrees with previous reports for this class of substrate (Fig-8 
ure 1)11 and for a reported -amino acetophenone reduction.16a 9 
However it is not consistent with other observations on the re-10 
duction of non--substituted -amino ketones16b and related 11 
products of non-DKR ATH reductions using Rh(III) catalysts.17  12 
The reduction of analogous compounds lacking the N-H func-13 
tion generally give products with the opposite diastereoselectiv-14 
ity to ours, indicating the importance of this group in the direc-15 
tion of the reduction.9 In order to investigate this factor in our 16 
compounds, we investigated the ATH of N-methylated ana-17 
logues of 13a and 14a. In the event, the NMe derivative of 13a 18 
was prepared in low yield however its reduction proceded in 19 
low conversion and purity and it was not possible to analyse the 20 
products by HPLC. Compound 14aMe, which is the NMe de-21 
rivative of NTs ketone 14a, was prepared and was successfully 22 
reduced to give 18aMe in 47% yield,  dr: 83:17 with 90.2% and 23 
35% ee respectively. i.e. lower than for 14a (Figure 5). The con-24 
figuration of the major product is not known. This again evi-25 
dences the importance of the NH group in the reduction selec-26 
tivity. The different protecting groups will also have a moder-27 
ating influence on the selectivity, presumably due to their dif-28 
fering bulk and electronic properties.  29 
 30 
Hence the detailed and complex controlling factors in the ATH 31 
reaction of -amino ketones described herein remain to be fully 32 
understood and are the subject of ongong studies In addition, 33 
the reversal of configuration using catalyst (R,R)-22 in several 34 
cases is not fully understood (Table 1) but reflects the potential 35 
for subtle additional interactions between the substrates de-36 
scribed herein and the groups on the 6-arene ring. 37 
 38 
 39 
Figure 4. Proposed mode of reduction of 14a and 13d to 18a 40 
and 17d respectively, stabilised by hydrogen bonding and the 41 
known CH/ edge/face interaction.  42 
 43 
 44 
Figure 5.  N-methylated derivative substrate 14aMe and redu-45 
cation product 18aMe. 46 
 47 
As an example of the value of the ATH-DKR, we reduced ke-48 
tone 28 to each enantiomer of amino alcohol 29 using catalyst 49 
(R,R)-20. In both cases a product of high dr and ee was formed 50 
(Figure 6). Cyclisation of (1S,2R)-29 with inversion of config-51 
uration, following the reported precedent,18 gave oxazolidinone 52 
(4S,5S)-30, a precursor of a recently reported MDM2–p53 in-53 
hibitor molecule which had previously been prepared in asym-54 
metric form through a chiral resolution.18 55 
   56 
57 
 58 
Figure 6. Synthesis of MDM2–p53 inhibitor precursor 30 via 59 
ATH-DKR of -N-Boc-protected ketone 28.  60 
 61 
Conclusions 62 
In conclusion, we report the optimization and scope expansion 63 
of the ATH-DKR of -aminoketones with varying N-protecting 64 
groups and substitution patterns. We have identified the most 65 
suitable catalysts from a series for the N-Boc-protected and N–66 
Ts-protected substrates and have explored the scope of the ap-67 
plications. This study allowed us to identify a suitable catalyst 68 
for a very concise synthesis of an MDM2–p53 inihibitor pre-69 
cursor in high ee, representing a valuable approach to this class 70 
of target molecule. 71 
 72 
EXPERIMENTAL SECTION 73 
General procedures for the syntheses.  74 
Solvents and reagents for the synthesis of complexes and cata-75 
lytic reactions were degassed prior to use and all reactions were 76 
carried out under either a nitrogen or argon atmosphere. Reac-77 
tions were monitored by TLC using aluminum backed silica gel 78 
60 (F254) plates, visualized using UV 254 nm and phosphomo-79 
lybdic acid (PMA), potassium permanganate or vanillin dips as 80 
appropriate. Flash column chromatography was carried out rou-81 
tinely using 60 micrometer silica gel. Reagents were used as 82 
received from commercial sources unless otherwise stated. 1H 83 
NMR spectra were recorded on a Bruker DPX (300, 400 or 500 84 
MHz) spectrometer. Chemical shifts are reported in δ units, 85 
parts per million relative to the singlet at 7.26 ppm for chloro-86 
form and 0.00 ppm for TMS. Coupling constants (J) are meas-87 
ured in Hertz. Structural assignments were made with addi-88 
tional information from gCOSY, gHSQC, and gHMBC experi-89 
ments. IR spectra were recorded on a Perkin-Elmer Spectrum 90 
One FT-IR Golden Gate. Mass spectra were recorded on a 91 
Bruker Esquire2000 or a Bruker MicroTOF mass spectrometer. 92 
Melting points were recorded on a Stuart Scientific SMP 1 in-93 
strument and are uncorrected. Dry solvents were purchased and 94 
used as received. HPLC analyses were carried out on a Hewlett-95 
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Packard 1050 instrument. Optical rotations were measured on 1 
an AA-1000 polarimeter. The X-ray crystallographic structures 2 
were recorded on a Rigaku Oxford Diffraction SuperNova dif-3 
fractometer with a duel source (Cu at zero) equipped with an 4 
AtlasS2 CCD area detector. Enantiomeric excesses were meas-5 
ured to one decimal place, however the results in Table 1 in the 6 
paper have been rounded to whole numbers or to >99% ee 7 
where the measured ee was 99.5% or above, and drs are given 8 
as >99.9:<0.1 where only one  diastereoisomer was observed. 9 
 10 
General procedure A for the synthesis of racemic alcohols.  11 
To a solution of ketone (1.0 eq.) in MeOH ([S] = 0.1 M) was 12 
added NaBH4 (2.0 eq.) portion-wise. The solution was stirred at 13 
rt until the ketone had been consumed. The solvent was then 14 
removed under reduced pressure and the residue partitioned be-15 
tween water and EtOAc. The organic extract was collected and 16 
the aqueous layer extracted a further 2 times with EtOAc. The 17 
organic layers were combined, dried over MgSO4, filtered and 18 
the solvent removed under reduced pressure to afford racemic 19 
alcohols. 20 
 21 
Section on initial substrates 12a-15a and their reductions. 22 
2-Bromo-1, 2-diphenylethan-1-one. 23 
This compound is known and has been previously character-24 
ised.19 N-Bromosuccinimide (4.50 g, 38.3 mmol, 1.5 eq) and p-25 
toluenesulphonic acid (0.88 g, 5.1 mmol, 0.20 eq) were dis-26 
solved in anhydrous DCM (50 mL) and the reaction mixture 27 
was cooled to 0 ºC. To the cold reaction mixture, a solution of 28 
1, 2-diphenylethan-1-one (5.00 g, 25.5 mmol, 1.0 eq) in dry 29 
DCM (25 mL) was added dropwise over a period of 1h. After 30 
the addition, the reaction mixture was stirred under N2 for 8 31 
hours at 40 ºC. The completion of the reaction was confirmed 32 
by 1H NMR. After the completion of the reaction, the reaction 33 
mixture was cooled to rt and H2O (100 mL) and DCM (25 mL) 34 
were added and organic layer was separated. The aqueous layer 35 
was extracted with DCM (2 x 30 mL). The combined organic 36 
layers were washed with brine (50 mL) and dried over MgSO4. 37 
The organic layer was concentrated under reduced pressure to 38 
afford the product as an off-white solid (6.9 g, 25 mmol, 98%) 39 
which was used in the next step without further purification. 40 
TLC: Rf ca 0.5 (9:1, Hexane: EtOAc), strong UV active;max 41 
1678, 1593, 1446, 1171, 991, 754, 677, 611 cm-1; 1H NMR 42 
(CDCl3, 400 MHz):  7.99 (d, 2H,  J = 7.2 Hz), 7.57-7.53 (m, 43 
3H) , 7.47-7.45 (m, 2H), 7.38-7.36 (m, 3H), 6.38 (s, 1H) ;  44 
13C{1H} NMR (CDCl3, 101 MHz,):  191.2, 136.0 134.31, 45 




This compound is known and has been previously character-50 
ised.20 2-Bromo-1, 2-diphenylethan-1-one (5.0 g, 18 mmol, 1.0 51 
eq) and potassium phthalimide (5.07 g, 27.3 mmol, 1.5 eq) were 52 
dissolved in anhydrous DMF (50 mL) and the resulting reaction 53 
mixture was stirred under N2 for 24 hours at rt. After the com-54 
pletion of the reaction, indicated by TLC, the reaction mixture 55 
was quenched with ice-cold water H2O (1 L). The obtained solid 56 
was filtered through Buchner filtration and washed with ice cold 57 
water (1 L) and dried to afford the product as a white solid (6.02 58 
g, 17.6 mmol, 97.7%) which was used in next step without fur-59 
ther purification. TLC: Rf ca 0.3 (9:1, Hexane: EtOAc), strong 60 
UV active;max 1711, 1684,1382, 1358, 1115, 713, 703, 688, 61 
625, 528 cm-1; 1H NMR (CDCl3, 400 MHz):  7.86 (d, 2H, J = 62 
7.4 Hz), 7.83-7.82 (m, 2H), 7.77-7.76 (m, 1H), 7.71-7.70 (m, 63 
2H), 7.51 - 7.47 (m, 3H), 7.39-7.32 (m, 4H), 6.78 (s, 1H);  64 
13C{1H} NMR (CDCl3, 101 MHz):  193.2, 167.6, 135.1, 134.6, 65 
134.5, 134.3, 133.4, 131.9, 130.5, 128.9, 128.8, 128.8, 123. 8, 66 
123.7, 60.4; m/z (ESI) 364.2 [(M+Na)+, 100%]. The data 67 
matches the reported data.  68 
 69 
2-Oxo-1,2-diphenylethan-1-aminium chloride. 70 
This compound is known and has been previously character-71 
ised.20 2-(2-Oxo-1,2-diphenylethyl)isoindoline-1,3-dione (6.00 72 
g, 17.5 mmol) in acetic acid (45 mL) and 6N HCl (45 mL) was 73 
stirred at 100 ºC for 3 days. The reaction mixture was cooled to 74 
rt and washed with DCM (30 mL).  The aqueous layer was con-75 
centrated under reduced pressure to afford the product as a 76 
white solid. (3.01 g, 12.1 mmol, 69.1%) which was used in the 77 
next step without further purification. 1H NMR (D2O ,400 78 
MHz):  7.97 (d, 2H, J = 7.6 Hz), 7.79-7.77 (m, 1H), 7.66-7.61 79 
(m, 2H), 7.48-7.47 (m, 5H),  6.27 (s, 1H);   13C{1H} NMR (D2O, 80 
101 MHz):  194.5, 135.1, 132.4, 131.7 131.3, 130.4, 129.9, 81 
129.2, 129.0, 128.4, 128.7, 59.7; m/z (ESI) 212.2 [(M+H)+, 82 
100%]. The data matches the reported data. 83 
 84 
 85 
N-(2-Oxo-1,2-diphenylethyl)benzamide 12a. 86 
This compound is known and has been previously character-87 
ised.21 2-Oxo-1, 2-diphenylethan-1-aminium chloride (1.0 g, 88 
4.0 mmol, 1.0 eq) was suspended in DCM (15 mL) and cooled 89 
to 0 ºC in an ice bath. Triethylamine (1.6 g, 2.2 mL, 16 mmol, 90 
4.0 eq) was added dropwise to the reaction mixture and stirred 91 
at same temperature for 30 minutes. During the addition of  tri-92 
ethylamine, the initially cloudy reaction mixture became clear. 93 
To the reaction mixture, benzoyl chloride (0.84 g, 0.76 mL, 6.0 94 
mmol, 1.5 eq) was added dropwise and the resulting reaction 95 
mixture was stirred at 0 ºC for 30 minutes followed by overnight 96 
stirring at rt. Once the reaction was complete (assessed by 97 
TLC), water (50 mL) and DCM (25 mL) were added and or-98 
ganic layer was separated. The aqueous layer was extracted 99 
with DCM (2 x 30 mL). The combined organic layers were 100 
washed with brine (50 mL), dried over MgSO4 and concentrated 101 
under reduced pressure to give the crude product. The crude 102 
material was purified by column chromatography (30% EtOAc 103 
in petroleum ether (40-60)) to afford the product 12a as a white 104 
solid (0.60 g, 1.9 mmol, 47%).TLC: Rf ca 0.4 (7:3, Hexane: 105 
EtOAc), strong UV active;max 3388, 3056, 3031, 1716, 1685, 106 
1647, 1509, 1481, 1447, 1297, 1252, 706, 690, 531  cm-1;  1H 107 
NMR (CDCl3, 400 MHz):  7.97 (d, 2H, J = 7.1 Hz), 7.79 (d, 108 
2H, J = 6.9 Hz), 7.68 (d, 1H, J = 4.4 Hz) 7.47-7.36 (m,  8H), 109 
7.28-7.24 (m, 2H), 7.19 (s, 1H), 6.70 (d, 1H,  J = 6.7 Hz); 110 
13C{1H}  NMR (CDCl3, 101 MHz):  196.0, 166.4, 137.4, 134.4, 111 
134.0, 131.9, 130.3, 129.4, 129.3, 128.9, 128.7, 128.6, 128.5, 112 
127.3, 59.0; m/z (ESI) 338.2 [(M+Na)+, 100%]. The data 113 
matches the reported data.  114 
 115 
t-Butyl (2-oxo-1,2-diphenylethyl)carbamate) 13a. 116 
This compound is known and has been previously character-117 
ised.22 2-Oxo-1,2-diphenylethan-1-aminium chloride (0.70 g, 118 
2.8 mmol, 1.0 eq) was suspended in THF (10 mL) and cooled 119 
to 0 ºC in an ice salt bath. Triethylamine (1.8 g, 2.5 mL, 18 120 
mmol, 6.5 eq) was added dropwise to the reaction mixture and 121 
stirred at same temperature for 30 minutes. During the addition 122 
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of triethylamine, the initially cloudy reaction mixture became 1 
clear. To the reaction mixture, Boc anhydride (1.23 g, 5.66 2 
mmol, 2.0 eq) in THF (5 mL) was added dropwise and the re-3 
sulting reaction mixture was stirred at 0 oC for 30 minutes fol-4 
lowed by overnight stirring at rt. Once the reaction was com-5 
plete (assessed by TLC), water (150 mL) and DCM (50 mL) 6 
were added and the organic layer was separated. The aqueous 7 
layer was extracted with DCM (3 x 50 mL). The combined or-8 
ganic layers were washed with brine (50 mL) and dried over 9 
MgSO4 and concentrated under reduced pressure to give the 10 
crude product. The crude material was purified by column chro-11 
matography (20% EtOAc in petroleum ether (40-60)) to afford 12 
the product 13a as a white solid (0.410 g, 1.31 mmol, 13 
46.6%).TLC: Rf ca 0.3 (8:2, Hexane: EtOAc), strong UV active; 14 
max 3384, 3364, 2980, 2934, 1703, 1694, 1675, 1493, 1158, 15 
752, 693, cm-1; 1H NMR (CDCl3, 400 MHz): δ 7.96 (d, 2H, J = 16 
6.4 Hz), 7.49 (d, 2H, J = 6.4 Hz), 7.39-7.37 (m, 4H) 7.30-7.24 17 
(m, 2H), 6.28 (d, 1H, J = 6.2 Hz), 6.04 (1H, s), 1.37 (s, 9H); 18 
13C{1H} NMR (CDCl3, 101 MHz): δ 196.2, 155.1, 137.6, 134.6, 19 
133.7, 129.3, 129.1, 128.7, 128.5, 128.2, 80.0, 59.9, 28.5; m/z 20 
(ESI) 334.2 [(M+Na)+, 100%]. The data matches the reported 21 




This compound is known and has been previously character-26 
ised.23 2-Oxo-1, 2-diphenylethan-1-aminium chloride (1.0 g, 27 
4.0 mmol, 1 eq) was suspended in DCM (20 mL) and cooled to 28 
0 ºC in an ice bath. Triethylamine (1.6 g, 2.2 mL, 16 mmol, 4 29 
eq) was added dropwise to the reaction mixture and stirred at 30 
the same temperature for 30 minutes. During the addition of tri-31 
ethylamine, the initially cloudy reaction mixture became clear. 32 
To the reaction mixture, tosyl chloride (1.5 g, 8.1 mmol, 2 eq) i 33 
n DCM (5 mL) was added dropwise and the resulting reaction 34 
mixture was stirred at 0 ºC for 30 minutes followed by overnight 35 
stirring at rt. Once the reaction was complete (assessed by 36 
TLC), water (50 mL) and DCM (25 mL) were added and the 37 
organic layer was separated. The aqueous layer was extracted 38 
with DCM (2 x 30 mL). The combined organic layers were 39 
washed with brine (50 mL) and dried over MgSO4 and concen-40 
trated under reduced pressure to give the crude product. The 41 
crude material was purified by column chromatography (40% 42 
EtOAc in petroleum ether (40-60)) to afford the product 14a as 43 
a white solid (0.57 g, 16 mmol, 39%). TLC: Rf ca 0.3 (7:3, Pe-44 
troleum ether (40-60): EtOAc), strong UV active; max 3286, 45 
1715, 1290, 1258, 1216, 1115, 665, 628, 646, 494 cm-1; 1H 46 
NMR (CDCl3, 400 MHz):) δ  7.80 (d, 2H,  J = 7.0 Hz),  7.53 (d, 47 
2H, J = 7.8 Hz), 7.48 (d, 1H, J = 6.9 Hz), 7.37-7.35 (m, 2H), 48 
7.18 (m, 5H), 7.05 (d, 2H, J = 7.5 Hz), 6.26 (d, 1H, J = 6.0 Hz), 49 
6.00 (d, 1H, J = 8.0 Hz), 2.29 (s, 3H); 13C{1H} NMR  (CDCl3, 50 
101 MHz): δ 194.7, 143.3 143.2, 137.5, 135.7, 134.1, 133.9, 51 
129.4, 129.2, 129.1, 128.8, 128.6, 128.2, 127.1, 61.9, 21.1; m/z 52 
(ESI) 388.2 [(M+Na)+, 100%]. The data matches the reported 53 
data. 54 
 55 
Benzyl (2-oxo-1,2-diphenylethyl)carbamate 15a. 56 
This compound is known however it has not been fully charac-57 
terized previously.24 Benzyl (phenyl(benzenesulfonyl)me-58 
thyl)carbamate (0.70 g, 1.8 mmol, 1.0 eq) and 3-benzyl-5-(2-59 
hydroxyethyl)-4-methylthiazolium chloride (0.15 g, 0.55 60 
mmol, 0.3 eq) were degassed and purged with nitrogen for 15 61 
min. To this mixture was added CH2Cl2 (30 mL) followed by 62 
benzaldehyde (0.30 g, 2.8 mmol, 1.5 eq) and the resulting mix-63 
ture was stirred and heated to 35 ºC. Triethylamine (3.8 mL, 2.8 64 
g, 27 mmol, 15 eq) was added in one portion via syringe and the 65 
reaction mixture was stirred at 35 °C for 24 h. After the reaction 66 
was complete (assessed by TLC), it was cooled to 25 °C and 67 
water (50 mL) and DCM (25 mL) were added and organic layer 68 
was separated. The aqueous layer was extracted with DCM (2 69 
x 30 mL). The combined organic layers were washed with brine 70 
(50 mL) and dried over MgSO4 and concentrated under reduced 71 
pressure to give the crude product. The crude material was pu-72 
rified by column chromatography (30% EtOAc in petroleum 73 
ether (40-60)) to afford the product 15a as a pale yellow solid 74 
(0.28 g, 0.81 mmol, 45%). TLC: Rf ca 0.3 (8:2, Hexane: 75 
EtOAc), strong UV active; M.P. 92-93 ºC; HRMS (ESI): found 76 
[M+Na]+ 368.1261, C22H19NNaO3 requires [M+Na]+ 368.1257, 77 
(error 1.1 ppm);max 3386, 1719, 1676, 1502, 1231, 1028, 694 78 
cm-1;  1H NMR (CDCl3, 400 MHz): 7.95 (d, 2H, J = 7.6 Hz), 79 
7.50 (m, 1H), 7.41-7.37 (m, 4H), 7.35 – 7.24 (m, 8H), -) 6.33-80 
6.23 (m, 2H), 5.14 (d, 1H, J = 12.2 Hz),  5.04 (d, 1H, J = 12.6 81 
Hz) ; 13C{1H} NMR  (CDCl3, 101 MHz): 195.6, 155.6, 137.4, 82 
137.3 136.4, 124.4, 134.4 133.8, 129.3, 129.2, 128.8, 128.6, 83 
128.6, 128.3, 128.3, 67.1, 60.3; m/z (ESI) 368.2 [(M+Na)+, 84 
100%].  85 
 86 
N-((1S,2R)-2-hydroxy-1,2-diphenylethyl)benzamide 16a. 87 
This compound is known and has been previously characterised 88 
in racemic form.14a t-Butyl (2-oxo-1, 2-diphenylethyl) carba-89 
mate) 12a (0.100 g, 0.317 mmol, 1.0 eq) and DABCO (0.181 g, 90 
1.61 mmol, 5.0 eq) were dissolved in acetonitrile (2 mL). Once 91 
the reaction became clear, catalyst (R,R)-2 (3.0 mg, 4.8 µmol, 92 
0.015 eq) in MeCN (1 mL) followed by formic acid (36 μL, 93 
0.96 mmol,  3.0 eq) were added and the resulting reaction mix-94 
ture was stirred at room temperature for 24 h. After overnight 95 
stirring, the reaction mixture was concentrated. The residue was 96 
dissolved in DCM (50 mL) and organic layer was washed with 97 
water (30 mL). The aqueous layer was extracted with DCM (2 98 
x 50 mL). The combined organic layers were washed with brine 99 
(50 mL), dried over MgSO4 and concentrated under reduced 100 
pressure to give the crude product. The crude material was pu-101 
rified by trituration in diethyl ether to afford the product 16a as 102 
a white solid (0.060 g, 0.189 mmol, 59.7%). TLC: Rf ca 0.4 103 
(6:4, Hexane: EtOAc), less UV active, strong KMnO4 & PMA 104 
reactive; [α]D25 = -33.5 (c = 0.05, CHCl3) 24.8 % ee;  Enantio-105 
meric excess and conversion determined by HPLC analysis 106 
(Chiralpak IC, 250 mm x 4.6 mm column, iPrOH: hexane 8:92, 107 
1 mL/min, 210 nm, T = 25 ºC), major diastereomer 25.4 min 108 
and 27.5 min; minor diastereomer 17.0 min and 20.3 min, 109 
>99.9:<0.1 dr; HRMS (ESI): found [M+Na]+ 340.1308, 110 
C21H19NNaO2 requires [M+Na]+ 340.1308 (error 0.0 ppm); 111 
max 3342, 3036, 3032, 1633, 1523, 1303, 754, 699, 602 cm-1;  112 
1H NMR (DMSO-d6, 400 MHz): δ 8.62 (d, 1H, J = 8.9 Hz), 7.63 113 
(d, 2H,  J = 7.0 Hz), 7.50 – 7.36 (m, 7H), 7.28-7.24 (m, 4H), 114 
7.21-7.19 (m, 2H), 5.45 (s, 1H), 5.13 (t, 1H, J = 8.6 Hz), 4.92 115 
(d, 1H,  J = 4.5 Hz);  13C{1H} NMR (DMSO-d6, 101 MHz): δ 116 
165.2, 143.7, 141.4, 134.6, 131.0, 128.4 128.1, 127.6, 127.6, 117 
127.1, 127.0 126.9 126.7, 74.6, 59.1; m/z (ESI) 340.2 118 
[(M+Na)+, 100%]. The data matches the reported data. A race-119 
mic standard was prepared by reduction with NaBH4 via proce-120 




t-Butyl ((1S,2R)-2-hydroxy-1,2-diphenylethyl)carbamate 1 
17a. 2 
This compound is known and has been previously character-3 
ised.14b,14c t-Butyl (2-oxo-1, 2-diphenylethyl) carbamate) 13a 4 
(0.100 g, 0.321 mmol, 1.0 eq) and DABCO (0.181 g, 1.61 5 
mmol, 5.0 eq) were dissolved in 2 mL acetonitrile. Once the 6 
reaction became clear solution, catalyst (R,R)-2 (3.0 mg, 4.8 7 
µmol, 0.015 eq) in MeCN (1 mL) followed by formic acid (36 8 
μL, 0.96 mmol, 0.030 eq) were added and the resulting reaction 9 
mixture was stirred at room temperature for 24 h. After over-10 
night stirring, the reaction mixture was concentrated. The resi-11 
due was dissolved in DCM (20 mL) and the organic layer was 12 
washed with water (30 mL). The aqueous layer was extracted 13 
with DCM (2 x 15 mL). The combined organic layers were 14 
washed with brine (50 mL) and dried over MgSO4 and concen-15 
trated under reduced pressure to give the crude product. The 16 
crude material was purified by trituration in diethyl ether to af-17 
ford the product 17a as a white solid. (0.065 g, 0.207 mmol, 18 
64.5%). TLC: Rf ca 0.4 (6:4, Hexane: EtOAc), less UV active, 19 
strong KMnO4 & PMA reactive; [α]D25 = -21.6 (c = 0.1, CHCl3) 20 
73.4% ee [lit14c [α]D25 = -57.6 (c = 1, CHCl3) 100% ee]; Enan-21 
tiomeric excess and conversion determined by HPLC analysis 22 
(Chiralpak IC, 250 mm x 4.6 mm column, iPrOH: hexane 23 
10:90, 1 mL/min, 210 nm, T = 25 ºC), (1S,2R) 6.4 min, (1R,2S) 24 
8.2 min, other diastereomer 18.8 min and 21.9 min, >99.9:<0.1 25 
dr; HRMS (ESI): found [M+Na]+ 336.1570, C19H23NNaO3 re-26 
quires [M+Na]+ 336.1570 (error 0.0 ppm); max 3378, 2978, 27 
1680, 1645, 1519, 1250, 1170, 997, 698, 603 cm-1; 1H NMR 28 
(CDCl3, 400 MHz): δ 7.26- 7.23 (m, 6H), 7.06-7.02 (m, 4H), 29 
5.30 (br.s., 1H), 5.04 (s, 1H) 4.96 (br.s., 1H), 2.70 (br.s., 1H), 30 
1.40 (s, 9H); 1H NMR (DMSO-d6, 400 MHz): δ 7.31-7.20 (m, 31 
11H), 5.29 (s, 1H), 4.66 (s, 1H), 4.58 (t, 1H,  J = 8.3 Hz), 1.21 32 
(s, 9H); 13C{1H} NMR (DMSO-d6, 101 MHz): δ 154.5, 143.4, 33 
141.5, 128.1 127.4, 127.0, 126.8, 126.5, 77.6, 75.2, 60.1, 40.1, 34 
28.1; m/z (ESI) 336.2 [(M+Na)+, 100%]. The data matches the 35 
reported data. A racemic standard was prepared by reduction 36 
with NaBH4 via procedure A. 37 
 38 
N-((1S,2R)-2-Hydroxy-1,2-diphenylethyl)-4-methylben-39 
zenesulfonamide 18a. 40 
This compound is known and has been previously character-41 
ised.14c,14d, 4-Methyl-N-(2-oxo-1,2-diphenylethyl) benzene sul-42 
fonamide 14a (0.100 g, 0.274 mmol, 1.0 eq) and DABCO 43 
(0.153 g, 1.37 mmol, 5.0 eq) were dissolved in acetonitrile (2 44 
mL). Once the reaction became clear, catalyst (R,R)-2 (2.5 mg, 45 
4.1 µmol, 0.015 eq) in MeCN (0.7 mL), followed by formic acid 46 
(30 μL, 0.82 mmol, 3.0 eq) were added and the resulting reac-47 
tion mixture was stirred at room temperature for 24 h. After this 48 
time, the reaction mixture was concentrated. The residue was 49 
dissolved in DCM (20 mL) and the organic layer was washed 50 
with water (20 mL). The aqueous layer was extracted with 51 
DCM (2 x 15 mL). The combined organic layers were washed 52 
with brine (50 mL) and dried over MgSO4 and concentrated un-53 
der reduced pressure to give the crude product. The crude ma-54 
terial was purified by trituration in diethyl ether to afford prod-55 
uct 18a as a white solid (0.69 g, 0.19 mmol, 69 %). TLC: Rf ca 56 
0.4 (5:5, Hexane: EtOAc), less UV active, strong KMnO4 & 57 
PMA reactive; [α]D25 = -45 (c = 0.1, THF) 98.8 % ee [lit14d 58 
[α]D25 = -97.0 (c = 0.1, THF) 100% ee]; Enantiomeric excess 59 
and conversion determined by HPLC analysis (Chiralpak IC, 60 
250 mm x 4.6 mm column, iPrOH: hexane 20:80, 1 mL/min, 61 
210 nm, T = 25 ºC), (1S,2R) 14.9 min, (1R,2S) 18.0 min, other 62 
diastereomer 12.0 min and 13.6 min, >99.9:<0.1 dr; HRMS 63 
(ESI): found [M+Na]+ 390.1136, C21H21NNaO3S requires 64 
[M+Na]+ 390.1134 (error 0.5 ppm);max 3459, 3322, 3063, 65 
1402, 1303, 1254, 1150, 699, 560, 539 cm-1; 1H NMR (CDCl3, 66 
400 MHz): δ 7.48 (d, 2H, J = 8.2 Hz), 7.22-7.05 (m, 8H), 6.95 67 
– 6.93 (m, 2H), 6.82 (d, 2H,  J = 7.2 Hz), 5.30-5.28 (m, 1H), 68 
5.00 (d, 1H, J = 4.3 Hz), 4.55 (dd, 1H,  J = 7.8, 4.4 Hz), 2.33 (s, 69 
4H); 1H NMR (DMSO-d6, 400 MHz): δ 8.12 (d, 1H, J = 8.0 70 
Hz), 7.29 (d, 2H, J = 8.0 Hz), 7.18 (s, 3H), 7.13 (s, 2H),  7.09-71 
6.98 (m, 7H),  5.38 (s, 1H), 4.61 (s, 1H), 4.28 (t, 1H, J = 7.6 72 
Hz), 2.26 (s, 3H);  13C{1H} NMR (DMSO-d6, 101 MHz): δ 73 
142.7, 141.7, 138.9, 138.6, 128.9, 128.3, 127.6, 127.1 127.0, 74 
126.7, 126.4, 126.2, 75.4, 63.4, 20.9; m/z (ESI) 390.2 [(M+H)+, 75 
100%]. The data matches the reported data. A racemic standard 76 
was prepared by reduction with NaBH4 via procedure A. 77 
 78 
Benzyl ((1S,2R)-2-hydroxy-1,2-diphenylethyl)carbamate 79 
19a.  80 
This compound is known and has been previously character-81 
ised.14c.14e  Benzyl (2-oxo-1, 2-diphenylethyl) carbamate) 15a 82 
(0.100 g, 0.289 mmol, 1.0 eq) and DABCO (0.162 g, 1.45 83 
mmol, 5.0 eq) were dissolved in 2 mL acetonitrile. Once the 84 
reaction became clear, catalyst (R,R)-2 (2.6 mg, 4.3 µmol, 0.015 85 
eq) in MeCN (1 mL) followed by formic acid (33 μL, 0.87 86 
mmol, 3.0 eq) were added and the resulting reaction mixture 87 
was stirred at room temperature for 24 h. After overnight stir-88 
ring, the reaction mixture was concentrated. The residue weas 89 
dissolved in DCM (20 mL) and organic layer was washed with 90 
water (30 mL). The aqueous layer was extracted with DCM (2 91 
x 15 mL). The combined organic layers were washed with brine 92 
(50 mL) and dried over MgSO4 and concentrated under reduced 93 
pressure to give the crude product. The crude material was pu-94 
rified by trituration in diethyl ether to afford the product 19a as 95 
a white solid (0.050 g, 0.144 mmol, 49.8 %). TLC: Rf ca 0.4 96 
(6:4, Hexane: EtOAc), less UV active, strong KMnO4 & PMA 97 
reactive; [α]D25 = -28.4 (c = 0.05, CHCl3) 44% ee [lit14c [α]D25 98 
= -67.4 (c = 0.1, CHCl3) 100% ee]; Enantiomeric excess and 99 
conversion determined by HPLC analysis (Chiralpak IG, 250 100 
mm x 4.6 mm column, iPrOH: hexane 10:90, 1 mL/min, 210 101 
nm, T = 25 ºC), (1S,2R) 11.1 min, (1R,2S) 15.5 min, other dia-102 
stereomer 7.1 min and 10.1 min, >99.9:<0.1 dr; HRMS (ESI): 103 
found [M+Na]+ 370.1117, C22H21NNaO3 requires [M+Na]+ 104 
370.1414 (error 0.8 ppm); max 3346, 3061, 3034, 1687, 1535, 105 
1254, 1009, 697 cm-1;  1H NMR (CDCl3, 400 MHz): δ 7.33 (s, 106 
5H), 7.26-7.23 (m, 6H), 7.04-7.03 (m, 4H), 5.56 (br.s., 1H), 107 
5.12-5.09 (m, 4H), 2.46 (br.s., 1H); 1H NMR (DMSO-d6, 400 108 
MHz): δ 7.73 (d, 1H, J = 8.7 Hz), 7.42 – 7.17 (m, 13H), 7.12-109 
7.13 (m, 2H), 5.35 (s, 1H), 4.91 (d, 1H, J = 12.6 Hz),  4.82 (d, 110 
1H,  J = 12.6 Hz), 4.69 (s, 1H), 4.65-4.61 (m, 1H, ); 13C{1H} 111 
NMR (DMSO-d6, 101 MHz): δ 155.1 143.4, 141.4, 137.1, 112 
128.3, 128.1, 127.3, 127.6, 127.3, 127.0, 126.7, 75.0, 65.0  60.8; 113 
m/z (ESI) 370.3 [(M+H)+, 100%]. The data matches the re-114 
ported data.  A racemic standard was prepared by reduction with 115 
NaBH4 via procedure A. 116 
 117 
Section on the later derivatives (Figure 3). 118 
General procedure B for formation of -NBoc amino ke-119 
tones. 120 
Substituted tert-butyl (phenyl (benzenesulfonyl) methyl) carba-121 
mate and 3-benzyl-5-(2-hydroxyethyl)-4-methylthiazolium 122 
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chloride were degassed and purged with nitrogen for 15 min. 1 
To this mixture was added DCM followed by the corresponding 2 
aldehyde and the resulting mixture was stirred and heated to 35 3 
°C. Triethylamine was added in one portion via syringe and the 4 
reaction mixture was stirred at 35 °C for 24 h. After the reaction 5 
was complete (assessed by TLC), it was cooled to 25 °C and 6 
water and DCM were added and organic layer was separated. 7 
The aqueous layer was extracted with DCM. The organic layer 8 
was washed with 2% aqueous HCl solution to remove triethyl-9 
amine. The combined organic layers were washed with brine 10 
and dried over MgSO4 and concentrated under reduced pressure 11 
to give the crude product, which was purified by column chro-12 
matography to afford the -N-Boc-protected amino ketone.  13 
 14 
t-Butyl-(2-(2-methoxyphenyl)-2-oxo-1-phenylethyl) carba-15 
mate 13b. 16 
This compound is novel and was prepared following the stand-17 
ard procedure B using 2-tert-butyl(phenyl(benzenesul-18 
fonyl)methyl)carbamate  (3.00 g, 8.64 mmol, 1.0 eq) in DCM 19 
(60 mL), 2-methoxybenzaldehyde (1.29 g, 9.51 mmol, 1.1 eq), 20 
3-benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride 21 
(0.700 g, 2.59 mmol, 0.3 eq) and triethylamine (13.1 g, 18 mL, 22 
129 mmol, 15 eq) for 48 h, water (100 mL) to quench and was 23 
washed twice with 5% aqueous HCl (250 mL) to generate the 24 
crude product which was purified by  column chromatography 25 
(30% EtOAc in petroleum ether (40-60)) to give 13b as a yel-26 
low liquid (1.89 g, 5.54 mmol, 64.1%). TLC: Rf ca 0.3 (8:2, 27 
Hexane: EtOAc), strong UV active; HRMS (ESI): found 28 
[M+Na]+ 364.1516, C20H23NNaO4 requires [M+Na]+ 364.1519 29 
(error 0.9 ppm); max 3369, 2980, 1700, 1660, 1505, 1486, 1240, 30 
698 cm-1; 1H NMR (CDCl3, 500 MHz): δ 7.67 (d, 1H, J = 7.5 31 
Hz), 7.39 (t, 1H, J = 7.8 Hz), 7.26-7.17 (m, 5H) 6.91 (t, 1H, J = 32 
7.5 Hz), 6.84 (d, 1H, J = 8.3 Hz), 6.41 (d, 1H, J = 7.6 Hz), 6.04 33 
(d, 1H, J = 6.8 Hz), 3.83 (s, 3H), 1.43 (s, 9H); 13C{1H} NMR 34 
(CDCl3, 126 MHz): δ 197.7, 158.4 155.1, 134.4, 131.4, 128.9, 35 
128.7, 128.2, 127.9, 127.6, 120.8, 111.6, 79.7, 63.5, 55.5, 28.5; 36 
m/z (ESI) 364.3 [(M+Na)+, 100%]. 37 
38 
t-Butyl-(2-(3-methoxyphenyl)-2-oxo-1-phenylethyl) carba-39 
mate 13c. 40 
This compound is known and has been previously character-41 
ised.13a This compound was prepared following the standard 42 
procedure  B using 2-tert-butyl (phenyl(benzenesulfonyl)me-43 
thyl)carbamate  (1.00 g, 2.88 mmol, 1.0 eq) in DCM (20 mL), 44 
3-methoxybenzaldehyde (0.431 g, 3.17 mmol, 1.1 eq), 3-ben-45 
zyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride (0.233 g, 46 
0.864 mmol, 0.3 eq) and triethylamine (4.37 g, 6 mL, 43.2 47 
mmol, 15 eq) for 24 h, water (50 mL) to quench and was washed 48 
twice with 5% aqueous HCl (80 mL) to generate the crude prod-49 
uct which was purified by  column chromatography (10% 50 
EtOAc in petroleum ether (40-60)) to give  13c as a yellow solid 51 
(0.645 g, 1.89 mmol, 65.6%). TLC: Rf ca 0.3 (8:2, Hexane: 52 
EtOAc), strong UV active; MP: 102-104 ºC; HRMS (ESI): 53 
found [M+Na]+ 364.1522, C20H23NNaO4 requires [M+Na]+ 54 
364.1519 (error -0.8 ppm);max 3395, 2973, 1703, 1674, 1581, 55 
1493, 1287, 1160, 702 cm-1; 1H NMR (CDCl3, 500 MHz): δ 7.47 56 
(d, 1H,  J = 7.6 Hz), 7.39 (s, 1H), 7.30 – 7.28 (m, 2H), 7.24-7.16 57 
(m, 4H), 6.97 (dd, 1H, J = 8.2, 2.3 Hz), 6.18 (d, 1H, J = 7.5 Hz), 58 
5.93 (d, 1H,  J = 7.0 Hz), 3.72 (s, 3H),  1.36 (s, 9H) 13C{1H} 59 
NMR (CDCl3,126 MHz): δ 196.1, 159.9, 155.1, 137.7, 135.9 60 
129.8, 129.3, 128.4, 128.2, 121.8, 120.4, 113.2, 80.1, 60.0, 55.5, 61 
28.5; m/z (ESI) 364.3 [(M+Na)+, 100%]. The data matches the 62 
reported data.  63 
64 
t-Butyl-(2-(2-chlorophenyl)-2-oxo-1-phenylethyl)carba-65 
mate 13d. 66 
This compound is novel and was prepared following the general  67 
procedure B using 2-tert-butyl (phenyl(benzenesulfonyl)me-68 
thyl)carbamate  (3.00 g, 8.64 mmol, 1.0 eq) in DCM (60 mL), 69 
2-chlorobenzaldehyde (1.33 g, 9.51 mmol, 1.1 eq), 3-benzyl-5-70 
(2-hydroxyethyl)-4-methylthiazolium chloride (0.700 g, 2.59 71 
mmol, 0.3 eq) and triethylamine (13.1g, 18 mL, 129 mmol, 15 72 
eq) for 24 h, water (100 mL) to quench and was washed twice 73 
with 5% aqueous HCl (250 mL) to generate the crude product 74 
which was purified by  column chromatography (30% EtOAc 75 
in petroleum ether (40-60)) to give 13d as a yellow solid (1.88 76 
g, 5.44 mmol, 63.1%). TLC: Rf ca 0.5 (8:2, Hexane: EtOAc), 77 
strong UV active; MP: 94-96 ºC; HRMS (ESI): found [M+Na]+ 78 
368.1021, C19H20ClNNaO3 requires [M+Na]+ 368.1024 (error 79 
0.9 ppm);max 3329, 2970, 1692, 1587, 1156, 699 cm-1;  1H 80 
NMR (CDCl3, 500 MHz): δ 7.37-7.29 (m, 3H), 7.26-7.20 (m, 81 
6H), 6.12 (d, 1H, J = 7.0 Hz), 6.01 (d, 1H, J = 6.0 Hz), 1.44 (s, 82 
9H); 13C{1H} NMR (CDCl3, 126 MHz): δ 198.3, 155.1, 136.8, 83 
135.7, 132.2, 130.7, 129.5, 129.1, 128.6, 128.2, 126.7, 80.2, 84 
63.4, 28.5; m/z (ESI) 368.2 [(M+Na)+, 100%] 370.2 85 
[(M+2+Na)+, 40%]. 86 
 87 
t-Butyl-(2-(3-chlorophenyl)-2-oxo-1-phenylethyl)carba-88 
mate 13e. 89 
This compound is novel and was prepared following the general  90 
procedure B using 2-tert-butyl (phenyl(benzenesulfonyl)me-91 
thyl)carbamate  (3.00 g, 8.64 mmol, 1.0 eq) in DCM (60 mL), 92 
3-chlorobenzaldehyde (1.33 g, 9.51 mmol, 1.1 eq), 3-benzyl-5-93 
(2-hydroxyethyl)-4-methylthiazolium chloride (0.700 g, 2.59 94 
mmol, 0.3 eq) and triethylamine (13.1 g, 18 mL, 129 mmol, 15 95 
eq) for 24 h, water (100 mL) to quench and was washed twice 96 
with 5% aqueous HCl (250 mL) to generate the crude product 97 
which was purified by  column chromatography (10% EtOAc 98 
in petroleum ether (40-60)) to give 13e as a yellow solid (2.45 99 
g, 7.10 mmol, 82.2%).TLC: Rf ca 0.3 (8:2, Hexane: EtOAc), 100 
strong UV active; MP: 121-123 ºC; HRMS (ESI): found 101 
[M+Na]+ 368.1021, C19H20ClNNaO3 requires [M+Na]+ 102 
368.1024 (error 0.8 ppm);max 3391,1680, 1492, 1243, 1090, 103 
695 cm-1; 1H NMR (CDCl3, 500 MHz): δ 7.94 (s, 1H), 7.80 (d, 104 
1H, J = 7.8 Hz), 7.47 (d, 1H, J = 8.0 Hz), 7.35-7.30 (m, 5H), 105 
7.28 -7.25 (m, 1H), 6.21 (d, 1H, J = 7.5 Hz), 5.92 (d, 1H, J = 106 
7.1 Hz), 1.43 (s, 9H); 13C{1H} NMR (CDCl3, 126 MHz): δ 107 
195.2, 155.1, 136.9, 136.3, 135.2, 133.6, 130.1 129.5, 129.1, 108 
128.7, 128.2, 127.2, 80.2, 60.1, 28.5; m/z (ESI) 368.2 109 
[(M+Na)+, 100%], 370.2 [(M+2+Na)+, 30%].  110 
 111 
t-Butyl-(2-(4-chlorophenyl)-2-oxo-1-phenylethyl)carba-112 
mate 13f. 113 
This compound is novel and was prepared following the general  114 
procedure B using 2-tert-butyl (phenyl(benzenesulfonyl)me-115 
thyl)carbamate  (3.00 g, 8.64 mmol, 1.0 eq) in DCM (60 mL), 116 
4-chlorobenzaldehyde (1.33 g, 9.51 mmol, 1.1 eq), 3-benzyl-5-117 
(2-hydroxyethyl)-4-methylthiazolium chloride (0.700 g, 2.59 118 
mmol, 0.3 eq) and triethylamine (13.1 g, 18 mL, 129 mmol, 15 119 
eq) for 24 h, water (100 mL) to quench and was washed twice 120 
with 5% aqueous HCl (250 mL) to generate the crude product 121 
which was purified by  column chromatography (20% EtOAc 122 
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in petroleum ether (40-60)) to give 13f as a yellow solid (2.20 1 
g, 6.38 mmol, 73.8%). TLC: Rf ca 0.3 (9:1, petroleum ether (40-2 
60): EtOAc), strong UV active; MP: 115-117 ºC; HRMS (ESI): 3 
found [M+Na]+ 368.1021, C19H20ClNNaO3 requires [M+Na]+ 4 
368.1024 (error 0.8 ppm); max 3393, 2977, 1702, 1675, 1493, 5 
1242, 1092, 699, 534 cm-1; 1H NMR (CDCl3, 500 MHz): δ 7.89 6 
(d, 2H, J = 8.5 Hz), 7.37- 7.24 (m, 7H), 6.21 (d, 1H, J = 7.5 Hz), 7 
5.94 (d, 1H, J = 7.1 Hz), 1.43 (s, 9H); 13C{1H} NMR  (CDCl3, 8 
126 MHz): δ 195.1, 155.1, 140.2, 137.3, 133.0, 130.5, 129.4, 9 
129.2, 128.6, 128.2, 80.2, 60.0, 28.5; m/z (ESI) 368.2 10 
[(M+Na)+, 100%], 370.2 [(M+2+Na)+, 40%]. 11 
 12 
t-Butyl-(1-(2-methoxyphenyl)-2-oxo-2-phenylethyl)carba-13 
mate 13g. 14 
This compound is novel and was prepared following the general  15 
procedure B using tert-butyl ((2-methoxyphenyl)(benzenesul-16 
fonyl)methyl)carbamate  (3.00 g, 7.95 mmol, 1.0 eq) in DCM 17 
(60 mL), benzaldehyde (1.26 g, 11.9 mmol, 1.5 eq), 3-benzyl-18 
5-(2-hydroxyethyl)-4-methylthiazolium chloride  (0.644 g, 2.38 19 
mmol, 0.3 eq) and triethylamine (12.0 g, 17 mL, 119 mmol, 15 20 
eq) for 24 h, water (100 mL) to quench and was washed twice 21 
with 5% aqueous HCl (250 mL) to generate the crude product 22 
which was purified by  column chromatography (20% EtOAc 23 
in petroleum ether (40-60)) to give 13g as a yellow solid (2.10 24 
g, 6.15 mmol, 77.5%). TLC: Rf ca 0.3 (8:2, Hexane: EtOAc), 25 
strong UV active; MP: 126-129 ºC; HRMS (ESI): found 26 
[M+Na]+ 364.1520, C20H23NNaO4 requires [M+Na]+ 364.1519 27 
(error -0.2 ppm);max 3375, 2983, 1685, 1493, 1240, 1161, 690, 28 
532 cm-1; 1H NMR (CDCl3, 500 MHz): δ 7.96 (d, 2H,  J = 7.7 29 
Hz), 7.46 (t, 1H,  J = 7.3 Hz), 7.34 (t,  2H, J = 7.6 Hz), 7.29 (d, 30 
1H, J = 7.4 Hz), 7.21 (t, 1H, J = 7.8 Hz), 6.89 (t, 1H, J = 7.5 31 
Hz), 6.81 (d, 1H, J = 8.2 Hz), 6.50 (d, 1H, J = 8.1 Hz), 5.86 (d, 32 
1H, J = 7.5 Hz), 3.83 (s, 3H), 1.44 (s, 9H); 13C{1H} NMR 33 
(CDCl3, 126 MHz): δ 196.9 156.7, 155.3, 135.1, 133.3, 129.8, 34 
129.5, 128.8, 128.5, 126.2, 121.2, 111.6, 79.8, 55.7, 55.3, 28.5; 35 
m/z (ESI) 364.2 [(M+Na)+, 100%]. 36 
 37 
t-Butyl-(1-(4-methoxyphenyl)-2-oxo-2-phenylethyl)carba-38 
mate 13h. 39 
This compound is known however it has not been fully charac-40 
terized previously.25 This compound was prepared following the 41 
general  procedure B using tert-butyl ((4-methoxyphenyl)(ben-42 
zenesulfonyl)methyl)carbamate (2.55 g, 6.63 mmol, 1.0 eq) in 43 
DCM (60 mL), benzaldehyde (1.05 g, 9.49 mmol, 1.5 eq), 3-44 
benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride (0.537 45 
g, 1.98 mmol, 0.3 eq) and triethylamine (10.0 g, 14 mL, 99.5 46 
mmol, 15 eq) for 24 h, water (100 mL) to quench and was 47 
washed twice with 5% aqueous HCl (250 mL) to generate the 48 
crude product which was purified by  column chromatography 49 
(20% EtOAc in petroleum ether (40-60)) to give 13h as a yel-50 
low solid (1.60 g, 4.68 mmol, 70.7%). TLC: Rf ca 0.2 (8:2, Hex-51 
ane: EtOAc), strong UV active; MP: 126-129 ºC; HRMS (ESI): 52 
found [M+Na]+ 364.1518, C20H23NNaO4 requires [M+Na]+ 53 
364.1519 (error 0.3 ppm);max 3375, 1702, 1675, 1510, 1248, 54 
1159, 688, 585 cm-1; 1H NMR (CDCl3, 500 MHz): δ 7.95-7.91 55 
(m, 2H), 7.49-7.32 (m, 4H),  7.29-7.26 (m, 1H), 6.82 (d, 2H, J 56 
= 8.7 Hz), 6.22 (d, 1H, J = 7.5 Hz), 5.98-5.95 (m, 1H), 3.74 (s, 57 
3H), 1.43 (s, 9H); 13C{1H} NMR (CDCl3, 126 MHz): δ 196.3, 58 
159.6, 155.1, 134.7, 134.0, 133.6, 129.7, 129.5, 129.2, 129.2, 59 
129.1, 128.8, 128.7, 127.9, 114.6, 79.9, 59.3, 55.3, 28.5; m/z 60 
(ESI) 364.2 [(M+Na)+, 100%].  61 
 62 
t-Butyl-(1-(2-chlorophenyl)-2-oxo-2-phenylethyl)carba-63 
mate 13i. 64 
This compound is novel and was prepared following the general  65 
procedure B using tert-butyl ((2-chlorophenyl)(benzenesul-66 
fonyl)methyl)carbamate (3.00 g, 7.87 mmol, 1.0 eq) in DCM 67 
(60 mL), benzaldehyde (1.25 g, 11.8 mmol, 1.5 eq), 3-benzyl-68 
5-(2-hydroxyethyl)-4-methylthiazolium chloride (0.637 g, 2.36 69 
mmol, 0.3 eq) and triethylamine (11.9 g, 16 mL, 118 mmol, 15 70 
eq), water (100 mL) to quench and was washed twice with 5% 71 
aqueous HCl (250 mL) to generate the crude product which was 72 
purified by  column chromatography (20% EtOAc in petroleum 73 
ether (40-60)) to give 13i as a white solid (0.897 g, 2.60 mmol, 74 
31.4%). TLC: Rf ca 0.3 (8:2, Hexane: EtOAc), strong UV ac-75 
tive; MP: 114-117 ºC; HRMS (ESI): found [M+Na]+ 368.1020, 76 
C19H20ClNNaO3 requires [M+Na]+ 368.1024 (error 1.0 77 
ppm);max 3370, 2971, 1712, 1680, 1520, 1244, 1158, 750, 590 78 
cm-1; 1H NMR (CDCl3, 500 MHz): δ 7.98 (d, 2H, J = 7.6 Hz), 79 
7.51 (t, 1H , J = 7.3 Hz), 7.41-7.37 (m, 3H), 7.27-7.17 (m, 3H), 80 
6.64 (d, 1H, J = 7.6 Hz), 5.82 (d, 1H, J = 6.7 Hz), 1.44 (s, 9H); 81 
13C{1H} NMR  (CDCl3, 126 MHz): δ 196.2, 155.0, 135.3, 82 
134.7, 133.9, 133.8, 130.6, 129.8, 129.5, 128.9, 128.8, 127.6, 83 
80.2, 57.2, 28.5; m/z (ESI) 368.2 [(M+Na)+,100%], 370.2 84 
[(M+2+Na)+, 40%]. 85 
 86 
t-Butyl-(1-(4-chlorophenyl)-2-oxo-2-phenylethyl)carba-87 
mate 13j. 88 
This compound is novel and was prepared following the general  89 
procedure B using tert-butyl ((4-chlorophenyl)(benzenesul-90 
fonyl)methyl)carbamate (3.00 g, 7.87 mmol, 1.0 eq) in DCM 91 
(60 mL), benzaldehyde (1.25  g, 11.8 mmol, 1.5 eq), 3-benzyl-92 
5-(2-hydroxyethyl)-4-methylthiazolium chloride (0.637 g, 2.36 93 
mmol, 0.3 eq) and triethylamine (11.9 g, 16 mL, 118 mmol, 15 94 
eq) for 24 h, water (100 mL) to quench and was washed twice 95 
with 5% aqueous HCl (250 mL) to generate the crude product 96 
which was purified by  column chromatography (10% EtOAc 97 
in petroleum ether (40-60)) to give 13j as a white solid (1.50 g, 98 
4.34 mmol, 55.2%). TLC: Rf ca 0.4 (8:2, Hexane: EtOAc), 99 
strong UV active; MP: 148-151 ºC; HRMS (ESI): found 100 
[M+Na]+ 368.1028, C19H20ClNNaO3 requires [M+Na]+ 101 
368.1024 (error -1.1 ppm);max 3373, 2981, 1703, 1673, 1520, 102 
1491, 1239, 1158, 719, 580 cm-1; 1H NMR (CDCl3, 600 MHz): 103 
δ 7.93 (d, 2H, J = 7.7 Hz), 7.52 (t, 1H, J = 7.4 Hz), 7.42-7.39 104 
(m, 2H), 7.31-7.26 (m, 4H), 6.24 (d, 1H, J = 7.2 Hz), 6.09 (d, 105 
1H, J = 6.8 Hz), 1.43 (s, 9H); 13C{1H} NMR  (CDCl3, 151 106 
MHz): δ 195.8, 155.0, 136.3, 134.4, 134.0, 129.6, 129.4, 129.1, 107 
128.9, 80.2, 59.1, 28.5; m/z (ESI) 368.2 [(M+Na)+, 80%], 370.2 108 
[(M+2+Na)+, 30%]. 109 
 110 
tert-Butyl-(2-(4-chlorophenyl)-1-(4-methoxyphenyl)-2-ox-111 
oethyl)carbamate 13k.  112 
This compound is novel and was prepared following the general  113 
procedure B using tert-butyl ((4-methoxyphenyl)(benzenesul-114 
fonyl)methyl)carbamate (3.00 g, 7.95 mmol, 1.0 eq) in DCM 115 
(60 mL), 4-chlorobenzaldehyde (1.67 g, 11.9 mmol, 1.5 eq), 3-16 
benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride (0.644 117 
g, 2.38 mmol, 0.3 eq) and triethylamine (12.0 g, 17 mL, 119 118 
mmol, 15 eq) for 48 h, water (100 mL) to quench and was 119 
washed twice with 5% aqueous HCl (250 mL) to generate the 120 
crude product which was purified by  column chromatography 121 
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(15% EtOAc in petroleum ether (40-60)) to give 13k as a yel-1 
low solid (1.77 g, 4.98 mmol, 62.7%). TLC: Rf ca 0.4 (8:2, Hex-2 
ane: EtOAc), strong UV active; MP: 134-137 ºC; HRMS (ESI): 3 
found [M+Na]+ 398.1132, C20H22ClNNaO4 requires [M+Na]+ 4 
398.1130 (error -0.6 ppm);max 3380, 2977, 1702, 1676, 1509, 5 
1239, 1159, 824, 532 cm-1; 1H NMR (CDCl3, 600 MHz): δ 7.88 6 
(d, 2H, J = 8.4 Hz), 7.36 (d, 2H, J = 8.4 Hz), 7.25 (d, 2H, J = 7 
11.0 Hz), 6.83 (d, 2H, J = 8.6 Hz), 6.15 (d, 1H, J = 7.4 Hz), 5.90 8 
(d, 1H, J = 7.2 Hz), 3.75 (s, 3H), 1.43 (s, 9H); 13C{1H} NMR 9 
(CDCl3, 151 MHz): δ 195.2, 159.8, 155.1, 140.1, 133.1, 130.5, 10 
129.5, 129.3, 129.1, 114.8, 80.1, 59.4, 55.4, 28.5; m/z (ESI) 11 
398.3 [(M+Na)+, 100%], 400.2 [(M+2+Na)+, 40%]. 12 
 13 
t-Butyl-(2-(furan-2-yl)-2-oxo-1-phenylethyl)carbamate 13l. 14 
This compound is known and has been previously character-15 
ised.13a This compound was prepared following the general  pro-16 
cedure B using 2-tert-butyl (phenyl(benzenesulfonyl)me-17 
thyl)carbamate  (3.00 g, 8.64 mmol, 1.0 eq) in DCM (60 mL), 18 
furan-2-carbaldehyde (0.931 g, 9.51 mmol, 1.1 eq), 3-benzyl-5-19 
(2-hydroxyethyl)-4-methylthiazolium chloride (0.700 g, 2.59 20 
mmol, 0.3 eq) and triethylamine (13.1 g, 18 mL, 129 mmol, 15 21 
eq) for 48 h, water (100 mL) to quench and was washed twice 22 
with 5% aqueous HCl (250 mL) to generate the crude product 23 
which was purified by  column chromatography (40% EtOAc 24 
in petroleum ether (40-60)) to give 13l as a yellow solid (2.20 25 
g, 7.31 mmol, 84.6%). TLC: Rf ca 0.4 (7:3, Hexane: EtOAc), 26 
strong UV active; HRMS (ESI): found [M+Na]+ 324.1209, 27 
C17H19NNaO4 requires [M+Na]+ 324.1206 (error -0.9 ppm); 28 
max 3400, 2976, 1706, 1663, 1490, 1465, 1392, 1161, 762, 528 29 
cm-1; 1H NMR (CDCl3, 500 MHz): δ 7.55 (s, 1H), 7.41 (d, 2H, 30 
J = 7.5 Hz), 7.33-7.30 (m, 2H), 7.28 – 7.23 (m, 2H), 6.48 (s, 31 
1H), 6.06 (d, 1H, J = 7.5 Hz), 5.92 (d, 1H, J = 6.4 Hz), 1.42 (s, 32 
9H); 13C{1H} NMR (CDCl3, 126 MHz): δ 184.9, 155.0, 150.8, 33 
147.2 137.2 129.1, 128.5, 128.1, 119.4, 113.2, 112.7, 80.1, 60.0, 34 
28.4; m/z (ESI) 324.2 [(M+Na)+, 100%]. The data matches the 35 
reported data.  36 
  37 
2-Bromo-1-phenylpropan-1-one (route to 24 and 25). 38 
This compound has been reported and fully characterised.26 39 
To a stirred ice cold solution of propiophenone (3.00 g, 22.3 40 
mmol, 1.0 eq) in DCM (50 mL) was added bromine (1.1 mL, 41 
22 mmol, 1.0 eq) dropwise under N2 atmosphere and stirred at 42 
0o C for 1h and then at room temperature for 30 minutes (colour 43 
changed from dark red to orange. The completion of the reac-44 
tion was confirmed by 1H NMR. After the completion, the re-45 
action was quenched with saturated NaHCO3 solution (200 mL) 46 
and DCM (50 mL) were added and organic layer was separated. 47 
The aqueous layer was extracted with DCM (2 x 30 mL). The 48 
combined organic layers were washed with brine (80 mL) and 49 
dried over MgSO4. The organic layer was concentrated under 50 
reduced pressure to afford the product as a dark brown viscous 51 
liquid (4.50 g, 21.2 mmol, 96.0%) which was used in the next 52 
step without further purification. TLC: Rf ca 0.4 (9:1, Hexane: 53 
EtOAc), strong UV active;max 1682, 1447, 1235, 948, 704, 54 
683 cm-1; 1H NMR (CDCl3, 400 MHz): δ 8.03 (d, 2H, J = 8.6 55 
Hz), 7.60 (t, 1H, J = 7.4 Hz), 7.51-7.47 (m, 2H), 5.30 (q, 1H, J 56 
= 6.6 Hz), 1.91 (d, 3H, J = 6.6 Hz); 13C{1H} NMR  (CDCl3, 101 57 
MHz): δ 193.5, 134.2, 133.8, 129.1 128.9, 41.6, 20.3. The data 58 
matches the reported data. 59 
 60 
2-(1-Oxo-1-phenylpropan-2-yl) isoindoline-1,3-dione (route 61 
to 24 and 25). 62 
This compound has been reported and fully characterised.27 63 
This compound was prepared following the same procedure as 64 
used for 2-(2-oxo-1,2-diphenylethyl)isoindoline-1,3-dione us-65 
ing 2-bromo-1-phenylpropan-1-one (4.50 g, 21.2 mmol, 1.0 eq) 66 
in DMF (60 mL) and potassium phthalimide (5.60 g, 31.8 67 
mmol, 1.5 eq) and ice cold water (1 L) to quench and was 68 
washed twice with ice cold water (300 mL) to give the product 69 
as a white solid (5.10 g, 18.3 mmol, 86.2%). TLC: Rf ca 0.3 70 
(7:3, Hexane: EtOAc), strong UV active;HRMS (ESI): found 71 
[M+Na]+ 302.0788, C17H13NNaO3 requires [M+Na]+ 302.0788 72 
(error -0.1 ppm); max 1706, 1693, 1384, 1231, 1139, 971, 712, 73 
692 cm-1; 1H NMR (CDCl3, 400 MHz): δ 7.83-7.79 (m, 4H), 74 
7.72-7.68 (m, 2H), 7.51-7.47 (m, 1H), 7.41-7.38 (m, 2H), 5.66 75 
(q, 1H, J = 7.1 Hz), 1.73 (d, 3H, J = 7.1 Hz); 13C{1H} NMR  76 
(CDCl3, 101 MHz): δ 196.2, 167.6, 135.4, 134.3, 133.2, 131.9, 77 
128.8 128.1, 123.6, 51.1, 15.0; m/z (ESI) 302.2 [(M+Na)+, 78 
100%]. The data matches the reported data.  79 
 80 
1-Oxo-1-phenylpropan-2-aminium hydrochloride (route to 81 
24 and 25). 82 
This compound has been reported and fully characterised.28 83 
This compound was prepared following the same procedure as 84 
used for 2-oxo-1,2-diphenylethan-1-aminium chloride using 2-85 
(1-oxo-1-phenylpropan-2-yl) isoindoline-1,3-dione (5.10 g, 86 
18.3 mmol, 1.0 eq) in 6N HCl (60 mL) and glacial acetic acid 87 
(60 mL) to generate the crude product which was stirred in ac-88 
etone (3 x 30 mL) to give the product as a white solid (2.10 g, 89 
11.3 mmol, 61.7%). HRMS (ESI): found [M+Na]+ 172.0732, 90 
C9H11NNaO requires [M+Na]+ 172.0733 (error 0.3 ppm) This 91 
corresponds to the RNH2Na ion;max 1688, 1597, 1499, 1451, 92 
1242, 1217, 1104, 973, 698 cm-1; 1H NMR (D2O, 400 MHz): δ 93 
8.03 (d, 2H, J = 7.3 Hz), 7.79 (t, 1H, J = 7.5 Hz), 7.65-7.61 (m, 94 
2H), 5.21 (q, 1H, J = 7.3 Hz), 1.61 (d, 3H, J = 7.3 Hz); 13C{1H} 95 
NMR (D2O, 101 MHz): δ 198.1, 135.2, 132.3, 129.2, 128.8, 96 
51.9, 16.6; m/z (ESI) 150.1 [(M+1)+, 100%], 172.2 [(M+Na)+, 97 
35%]. The data matches the reported data.  98 
99 
t-Butyl-(1-oxo-1-phenylpropan-2-yl)carbamate (precursor 100 
of 24). 101 
This compound has been reported and fully characterised.29 102 
This compound was prepared following the same procedure as 103 
used for t-butyl-(2-oxo-1,2-diphenylethyl)carbamate) 13a us-104 
ing 1-oxo-1-phenylpropan-2-aminium hydrochloride (0.700 g, 105 
3.78 mmol, 1.0 eq) in DCM (20 mL), triethylamine (1.53 g, 106 
2.1mL, 15.1 mmol, 4 eq) and boc anhydride (1.65g, 7.56  mmol, 107 
1.5 eq),  water (100 mL) to quench and DCM (2 x 30 mL) for 108 
extraction to generate the crude product which was purified by 109 
column chromatography (30% EtOAc in petroleum ether (40-110 
60)) to give the prodcut as a white solid (0.55 g, 2.20 mmol, 111 
58.4%). TLC: Rf ca 0.3 (8:2, Hexane: EtOAc), less UV active, 112 
strong KMnO4; MP: 72-74 ºC;  HRMS (ESI): found [M+Na]+ 113 
272.1257, C14H19NNaO3 requires [M+Na]+ 272.1257 (error 0.0 114 
ppm); max 3333, 2973, 1708, 1679, 1523, 1234, 1158, 682 cm-115 
1; 1H NMR (CDCl3, 500 MHz): δ 7.98 (d, 2H, J = 7.7 Hz), 7.60 116 
(t, 1H, J = 7.4 Hz), 7.49 (t, 2H, J = 7.7 Hz), 5.58 (d, 1H, J = 6.5 17 
Hz), 5.33 – 5.27 (m, 1H), 1.46 (s, 9H), 1.40 (d, 3H, J = 7.1 Hz); 118 
13C{1H} NMR  (CDCl3, 126 MHz): δ 199.6, 155.3, 134.3, 119 
133.8. 128.9, 128.8, 79.8, 51.2, 28.5, 20.0; m/z (ESI) 272.2 120 




t-Butyl-(2-oxo-1-phenylpropyl)carbamate (precursor to 2 
26). 3 
This compound is known and has been previously character-4 
ised.13abThis compound was prepared following the general  5 
procedure B using 2-tert-butyl (phenyl(benzenesulfonyl)me-6 
thyl)carbamate  (2.00 g, 5.76 mmol, 1.0 eq) in DCM (40 mL), 7 
acetaldehyde (0.633 g, 14.4 mmol, 2.5 eq), 3-benzyl-5-(2-hy-8 
droxyethyl)-4-methylthiazolium chloride (0.46 g, 1.78 mmol, 9 
0.3 eq) and triethylamine (5.71 g, 12 mL, 86.4 mmol, 15 eq) for 10 
48 h, water (150 mL) to quench and was washed twice with 5% 11 
aqueous HCl (200 mL) to generate the crude product which was 12 
purified by  column chromatography (20% EtOAc in petroleum 13 
ether (40-60)) to give the product as a yellow solid (0.800 g, 14 
3.21 mmol, 55.7%).TLC: Rf ca 0.3 (8:2, Hexane: EtOAc), less 15 
UV active, strong KMnO4 active; HRMS (ESI): found [M+Na]+ 16 
272.1257, C14H19NNaO3 requires [M+Na]+ 272.1257 (error 0.0 17 
ppm);max 3399, 29601693, 1493, 1309, 1154, 702 cm-1; 1H 18 
NMR (CDCl3, 500 MHz): δ 7.38 – 7.28 (m, 5H), 5.90 (s, 1H), 19 
5.29 (d, 1H, J = 5.8 Hz), 2.08 (s, 3H), 1.40 (s, 9H); 13C{1H} 20 
NMR (126 MHz, CDCl3): δ 203.7, 155.0 137.0, 129.3, 128.6, 21 
127.9, 79.9, 64.8, 28.4, 27.1; m/z (ESI) 272.2 [(M+Na)+, 22 
100%]. The data matches the reported data.  23 
 24 
Synthesis of amine salts for N-Ts protection. 25 
General procedure C for N-Boc deprotection. 26 
N-Boc intermediate was dissolved in dichloromethane and 27 
cooled to 0 ºC using an ice bath. To this stirred solution was 28 
added trifluoroacetic acid dropwise under a nitrogen atmos-29 
phere and the resulting reaction mixture was stirred at 0 ºC for 30 
30 minutes followed by stirring at rt for 6h. Once the reaction 31 
was complete (assessed by TLC), the reaction mixture was con-32 
centrated under reduced pressure to give the crude amine tri-33 
fluoroacaetic acid salt. The crude material was purified by trit-34 
uration using n-pentane: ethyl acetate (8:2) to afford the corre-35 
sponding amines as a trifluoroacetate salt. HRMS (ESI) corre-36 




This compound is novel and was prepared following general  41 
procedure C using tert-butyl (2-(2-methoxyphenyl)-2-oxo-1-42 
phenylethyl)carbamate (1.30 g, 3.81 mmol, 1.0 eq) and tri-43 
fluoroacetic acid (4.35 g, 38.1 mmol, 10 eq)  in DCM (30 mL) 44 
and generated crude product was purified by trituration using n-45 
pentane : EtOAc (8:2 v/v, 60 mL) to give the product as a brown 46 
solid (1.05 g, 2.95 mmol, 77.8%). TLC: Rf 0.0 (8:2, Hexane: 47 
EtOAc), strong UV active, TLC checked to confirm the con-48 
sumption of starting material; MP: 158-160 ºC; HRMS (ESI): 49 
found [M+ H]+ 242.1174, C15H16NO2 requires [M+H]+ 50 
242.1176 (error 0.7 ppm); max 1656, 1596, 1532, 1186, 762, 51 
700 cm-1; 1H NMR (D2O, 500 MHz): δ 7.82 (dd, 1H, J = 7.9, 52 
1.5 Hz), 7.53-7.49 (m, 1H), 7.40 (s, 5H), 7.01 (t, 1H, J = 7.6 53 
Hz), 6.96 (d, 1H, J = 8.5 Hz), 6.26 (s, 1H), 3.81 (s, 3H); 13C{1H} 54 
NMR (D2O, 126 MHz): δ 195.2, 158.7, 136.5, 131.2, 131.0, 55 
130.1, 129.4, 128.9, 122.5, 120.9, 112.4, 62.6, 55.3; m/z (ESI) 56 




This compound is novel and  was prepared following the gen-61 
eral  procedure C using tert-butyl (2-(3-methoxyphenyl)-2-oxo-62 
1-phenylethyl)carbamate (0.341 g, 1.00 mmol, 1.0 eq.) and tri-63 
fluoroacetic acid (1.14 g, 10 mmol, 10 eq)  in DCM (5 mL) and 64 
the crude product was purified by trituration using n-pentane : 65 
EtOAc (8:2 v/v, 30 mL) to give the product as a brown solid 66 
(0.44 g, 1.23 mmol, quantitative yield, excess TFA present). 67 
TLC: Rf 0.0 (7:3, Hexane: EtOAc), strong UV active, TLC 68 
checked to confirm the consumption of starting material; MP: 69 
90-101 ºC; HRMS (ESI): found [M+H]+ 242.1172, C15H16NO2 70 
requires [M+H]+ 242.1176 (error 1.5 ppm);max 1665, 1566, 71 
1496, 1165, 1144, 781, 701 cm-1; 1H NMR (D2O, 500 MHz)): δ 72 
7.55 (d, 1H, J = 7.8 Hz), 7.48-7.45 (m, 6H), 7.36 (t, 1H, J = 8.0 73 
Hz), 7.19-7.17 (m, 1H), 6.24 (s, 1H), 3.78 (s, 3H); 13C{1H} 74 
NMR (D2O, 126 MHz): δ 194.1, 159.2, 133.8, 131.3, 130.4, 75 
130.3, 130.0  128.6 122.1, 121.0, 113.6, 59.8 55.5; m/z (ESI) 76 




This compound is novel and was prepared following the general  81 
procedure C using tert-butyl (2-(2-chlorophenyl)-2-oxo-1-phe-82 
nylethyl)carbamate (1.00 g, 2.89 mmol, 1.0 eq) and trifluoroa-83 
cetic acid (3.29 g, 28.9 mmol, 10 eq)  in DCM (20 mL) and the 84 
crude product was purified by trituration using n-pentane : 85 
EtOAc (8:2 v/v, 60 mL) to give the product as a brown solid 86 
(1.20g, 3.35 mmol, quantitative yield , excess TFA present). 87 
TLC: Rf 0.0 (7:3, Hexane: EtOAc), strong UV active, TLC 88 
checked to confirm the consumption of starting material; MP: 89 
161-163 ºC; HRMS (ESI): found [M+H]+ 246.0678, 90 
C14H13ClNO requires [M+H]+ 246.0680 (error 0.9 ppm);max 91 
1709, 1649, 1512, 1187, 1141, 765, 696 cm-1;1H NMR 92 
(CD3OD, 500 MHz): δ 7.67-7.65 (m, 1H), 7.47-7.39 (m, 7H), 93 
7.37-7.33 (m, 1H), 6.12 (s, 1H); 13C{1H} NMR (CD3OD, 126 94 
MHz): δ 195.4, 135.7, 134.3, 133.0, 132.2, 132.0, 131.4, 131.1, 95 
130.8, 130.0, 128.3, 63.0; m/z (ESI) 246.1 [(M+H)+, 10%], 96 




This compound is novel and was prepared following the general  101 
procedure C using tert-butyl (2-(3-chlorophenyl)-2-oxo-1-phe-102 
nylethyl)carbamate (1.00 g, 2.89 mmol, 1.0 eq) and trifluoroa-103 
cetic acid (3.29 g, 28.9 mmol, 10 eq)  in DCM (20 mL) and the 104 
crude product was purified by trituration using n-pentane : 105 
EtOAc (8:2 v/v, 60 mL) to give the product as a brown solid 106 
(1.20 g, 3.35 mmol in quantitative yield, excess TFA present). 107 
TLC: Rf 0.0 (7:3, Hexane: EtOAc), strong UV active, TLC 108 
checked to confirm the consumption of starting material; MP: 109 
102-105 ºC; HRMS (ESI): found [M+H]+ 246.0681, 110 
C14H13ClNO requires [M+H]+ 246.0680 (error -0.2 ppm);max 111 
1682, 1531, 1431, 1180, 1135, 799, 699 cm-1; 1H NMR 112 
(CD3OD, 500 MHz): δ 7.98 (s, 1H), 7.90 (d, 1H, J = 7.9 Hz), 113 
7.61 (d, 1H, J = 8.1 Hz), 7.52 – 7.43 (m, 6H), 6.22 (s, 1H); 114 
13C{1H} NMR  (CD3OD, 126 MHz): δ 193.2, 136.2, 136.2, 115 
135.4, 133.1 131.7, 131.5, 131.1, 130.0, 129.9, 128.7, 60.8; m/z 116 






This compound is known however it has not been fully charac-1 
terized previously.30 This compound was prepared following the 2 
general  procedure C using tert-butyl (2-(4-chlorophenyl)-2-3 
oxo-1-phenylethyl)carbamate (1.00 g, 2.89 mmol, 1.0 eq) and 4 
trifluoroacetic acid (3.29 g, 28.9 mmol, 10 eq)  in DCM (20 mL) 5 
and generated crude product was purified by trituration using n-6 
pentane : EtOAc (8:2 v/v, 60 mL) to give the product as a brown 7 
solid (1.22 g, 3.40 mmol, quantitative yield, excess TFA pre-8 
sent). TLC: Rf 0.0 (7:3, Hexane: EtOAc), strong UV active, 9 
TLC checked to confirm the consumption of starting material; 10 
MP: 77-80 ºC; HRMS (ESI): found [M+H]+ 246.0680, 11 
C14H13ClNO requires [M+H]+ 246.0680 (error 0.1 ppm); max 12 
1676, 1651, 1537, 1175, 1139, 797, 723 cm-1; 1H NMR (D2O,  13 
500 MHz): δ 7.77-7.75 (m, 2H), 7.41 – 7.38 (m, 5H), 7.21-7.20 14 
(m, 2H), 6.15 (s, 1H); 13C{1H} NMR  (D2O, 126 MHz, ): δ 15 
193.2, 140.7, 131.0, 130.6, 130.5, 130.5, 130.0, 129.1, 128.6, 16 




The compound is novel and was prepared following the general  21 
procedure C using tert- Butyl (1-(2-methoxyphenyl)-2-oxo-2-22 
phenylethyl)carbamate (1.00 g, 2.93 mmol, 1.0 eq) and tri-23 
fluoroacetic acid (3.34 g, 29.3 mmol, 10 eq)  in DCM (20 mL) 24 
and generated crude product was purified by trituration using n-25 
pentane : EtOAc (8:2 v/v, 60 mL) to give the product as a brown 26 
solid (1.30 g, 3.66 mmol in quantitative yield, excess TFA pre-27 
sent). TLC: Rf 0.0 (8:2, Hexane: EtOAc), strong UV active, 28 
TLC checked to confirm the consumption of starting material; 29 
MP: 87-91 ºC; HRMS (ESI): found [M+H]+ 242.1173, 30 
C15H16NO2 requires [M+H]+ 242.1176 (error 0.9 ppm);max 31 
1685, 1599, 1495, 1164, 1104, 754, 697 cm-1; 1H NMR 32 
(CD3OD, 500 MHz): δ 7.90 (d, 2H, J = 7.5 Hz), , 7.57 (t, 1H, J 33 
= 7.5 Hz), , 7.44-7.42 (m,  3H), 7.33-7.31 (m, 1H), 7.10 (d, 1H, 34 
J = 8.4 Hz),  6.99 (t, 1H, J = 7.5 Hz), 6.26 (s, 1H), 3.92 (s, 3H); 35 
13C{1H} NMR (CD3OD, 126 MHz): δ 194.6, 158.3, 135.3. 36 
134.7, 133.3, 131.0, 129.9, 129.78 122.6, 121.9, 113.1, 56.3, 37 




This compound is known however it has not been fully charac-42 
terized previously.31This compound was prepared following 43 
the general  procedure C using tert-butyl (1-(4-methoxy-44 
phenyl)-2-oxo-2-phenylethyl)carbamate (1.00 g, 2.93 mmol, 45 
1.0 eq) and trifluoroacetic acid (3.34 g, 29.3 mmol, 10 eq)  in 46 
DCM (20 mL) and generated crude product was purified by trit-47 
uration using n-pentane : EtOAc (8:2 v/v, 60 mL) to give the 48 
product as a brown solid (1.23 g, 3.46 mmol in quantitative 49 
yield, excess TFA present). TLC: Rf 0.0 (8:2, Hexane: EtOAc), 50 
strong UV active, TLC checked to confirm the consumption of 51 
starting material; MP: 139-142 ºC; HRMS (ESI): found [M+H]+ 52 
242.1172, C15H16NO2 requires [M+H]+ 242.1176 (error 1.4 53 
ppm); max 1650, 1595, 1515, 1183, 1137, 723, 687 cm-1; 1H 54 
NMR (CD3OD, 600 MHz): δ 7.98 (d, 2H, J = 7.6 Hz), 7.58 (t, 55 
1H, J = 7.4 Hz), 7.46 – 7.41 (m, 4H), 6.97 (d, 2H, J = 8.7 Hz), 56 
6.14 (s, 1H), 3.76 (s, 3H); 13C{1H} NMR  (CD3OD, 151 MHz): 57 
δ 194.3, 162.5, 135.5, 134.6, 131.4, 130.2, 130.0 125.2, 116.2, 58 





This compound is novel and was prepared following the general  64 
procedure C using tert-butyl (1-(2-chlorophenyl)-2-oxo-2-phe-65 
nylethyl)carbamate (0.500 g, 1.45 mmol, 1.0 eq) and trifluoro-66 
acetic acid (1.65 g, 14.5 mmol, 10 eq)  in DCM (10 mL) and 67 
generated crude product was purified by trituration using n-pen-68 
tane : EtOAc (8:2 v/v, 80 mL) to give the product as a brown 69 
solid (0.418 g, 1.16 mmol, 80%). TLC: Rf 0.0 (7:3, Hexane: 70 
EtOAc), strong UV active, TLC checked to confirm the con-71 
sumption of starting material; MP: 130-133 ºC; HRMS (ESI): 72 
found [M+H]+ 246.0677, C14H13ClNO requires [M+H]+ 73 
246.0680 (error 1.5 ppm);max 1664, 1533, 1176, 1138, 797, 74 
719, cm-1; 1H NMR (CD3OD, 500 MHz): δ 7.92 (d, 2H, J = 7.9 75 
Hz), 7.64-7.60 (m, 2H), 7.49-7.44 (m, 3H), 7.37-7.32 (m, 2H), 76 
6.49 (s, 1H);13C{1H} NMR (CD3OD, 126 MHz): δ 193.7, 77 
135.4, 135.5 134.3, 133.3, 132.1, 131.3 131.0, 130.2, 129.9, 78 





This compound is known however it has not been fully charac-84 
terized previously.32 This compound was prepared following 85 
the general  procedure C using tert-butyl (1-(4-chlorophenyl)-86 
2-oxo-2-phenylethyl)carbamate (1.00 g, 2.89 mmol, 1.0 eq) and 87 
trifluoroacetic acid (3.30 g, 28.9 mmol, 10 eq)  in DCM (20 mL) 88 
and generated crude product was purified by trituration using n-89 
pentane : EtOAc (8:2 v/v, 80 mL) to give the product as a brown 90 
solid (0.980 g, 2.74 mmol, 94.9%). TLC: Rf 0.0 (7:3, Hexane: 91 
EtOAc), strong UV active, TLC checked to confirm the con-92 
sumption of starting material; MP: 126-130 ºC; HRMS (ESI): 93 
found [M+H]+ 246.0680, C14H13ClNO requires [M+H]+ 94 
246.0680 (error -0.1 ppm);max 1642, 1540, 1208, 1184, 1137, 95 
801, 714, cm-1; 1H NMR (CD3OD, 500 MHz): δ 7.98 (d, 2H, J 96 
= 7.7 Hz), 7.62 (t, 1H, J = 7.5 Hz), 7.51-7.46 (m, 6H), 6.24 (s, 97 
1H); 13C{1H} NMR  (CD3OD, 126 MHz): δ 193.9, 137.5, 135.8, 98 
134.3, 132.2, 131.7 131.1, 130.3, 130.1, 59.9; m/z (ESI) 246.0 99 




This compound is known however it has not been fully charac-104 
terized previously.33This compound was prepared following 105 
the general  procedure C using tert-butyl (1-(4-chlorophenyl)-106 
2-(4-methoxyphenyl)-2-oxoethyl)carbamate (1.00 g, 2.81 107 
mmol, 1.0 eq) and trifluoroacetic acid (3.20 g, 28.1 mmol, 10 108 
eq)  in DCM (20 mL) and the crude product was purified by 109 
trituration using n-pentane : EtOAc (9:1 v/v, 100 mL) to give 110 
the product as a yellow solid (0.750 g, 1.92 mmol, 68.6%). 111 
TLC: Rf 0.0 (7:3, Hexane: EtOAc), strong UV active, checked 112 
to confirm the consumption of starting material; MP: 79-80 ºC; 113 
HRMS (ESI): found [M+H]+, 276.0790, C15H15ClNO2 requires 114 
[M+H]+ 276.0786 (error -1.6 ppm);max 1665, 1588, 1512, 115 
1492, 1176, 1130, 1092, 797, 720, 565 cm-1; 1H NMR (CD3OD, 116 
600 MHz): δ 7.95 (d, 2H, J = 8.6 Hz), 7.47 (d, 2H, J = 8.6 Hz), 117 
7.41 (d, 2H, J = 8.7 Hz), 6.98 (d, 2H, J = 8.7 Hz), 6.12 (s, 1H), 118 
3.77 (s, 3H); 13C{1H} NMR (CD3OD, 151 MHz): δ 193.3, 162.6 119 
141.8, 133.1 131.9, 131.4, 130.3, 124.8, 116.3, 60.2, 55.989); 120 






This compound is novel and was prepared following the general  4 
procedure C using tert-butyl (2-(furan-2-yl)-2-oxo-1-phe-5 
nylethyl)carbamate (1.00 g, 3.32 mmol, 1.0 eq) and trifluoroa-6 
cetic acid (3.78 g, 33.2 mmol, 10 eq)  in DCM (20 mL) and 7 
generated crude product was purified by trituration using n-pen-8 
tane : EtOAc (9:1 v/v, 60 mL) to give the product as a white 9 
solid (0.980 g, 3.11 mmol, 93.6%). TLC: Rf 0.0 (7:3, Hexane: 10 
EtOAc), strong UV active, TLC checked to confirm the con-11 
sumption of starting material; MP: 152-155 ºC; HRMS (ESI): 12 
found [M+H]+, 202.0868, C12H12NO2 requires [M+H]+ 13 
202.0863 (error -2.5 ppm);max 1677, 1463, 1406, 1179, 1132, 14 
798, 780, 576 cm-1; 1H NMR (CD3OD, 500 MHz): δ 7.79 (s, 15 
1H), 7.54 (d, 2H, J = 7.1 Hz), 7.48 – 7.46 (m, 3H), 7.43 (d, 1H, 16 
J = 3.7 Hz), 6.63 (d, 1H, J = 3.7 Hz), 5.89 (s, 1H); 13C{1H} NMR 17 
(CD3OD, 126 MHz): δ 182.3, 151.0 , 150.1, 133.4, 131.3, 18 
130.8, 129.8, 122.1, 114.1, 60.4); m/z (ESI) 202.0 [(M+H)+, 19 
30%], 403.2 [(2M+H)+, 100%]. 20 
21 
2-Oxo-1-phenylpropan-1-aminium trifluoroacetate. 22 
This compound has been reported as hydrochloride salt.34 23 
This compound was prepared following the general procedure 24 
C using tert-butyl (2-oxo-1-phenylpropyl) carbamate (0.600 g, 25 
2.55 mmol, and 1.0 eq) and trifluoroacetic acid (2.90 g, 25.5 26 
mmol, 10 eq) in DCM (10 mL) and the crude product was puri-27 
fied by trituration using n-pentane: EtOAc (8:2 v/v, 80 mL) to 28 
give the product as a yellow solid (0.530 g, 2.12 mmol, 83.1%). 29 
HRMS (ESI): found [M+H]+ 150.0911, C9H12NO requires 30 
[M+H]+ 150.0913 (error 0.3 ppm);max 1762, 1655, 1614, 31 
1528, 1190, 1132, 839, 722, 697cm-1; 1H NMR (CD3OD, 500 32 
MHz): δ 7.54-7.52 (m, 3H), 7.47-7.45 (m, 2H), 5.27 (s, 1H), 33 
2.11 (s, 3H); 13C{1H} NMR (CD3OD, 126 MHz): δ 202.2, 34 
132.9, 131.5, 131.0, 129.8, 64.2, 26.5; m/z (ESI) 150.1 [(M+1)+, 35 
25%]. The data matches the reported data.  36 
37 
General procedure for formation of-NTs-amino ketones. 38 
Method D 39 
Substituted amine trifluoroacetate derivative was suspended in 40 
DCM and cooled to 00 C in an ice bath. Triethylamine was 41 
added dropwise to the reaction mixture and stirred at this 42 
temperature for 30 minutes. During the addition of 43 
triethylamine, the initially cloudy reaction mixture became 44 
clear. To the reaction mixture, tosyl chloride in DCM was added 45 
dropwise and the resulting reaction mixture was stirred at 0 ºC 46 
for 30 minutes followed by overnight stirring at rt. Once the 47 
reaction was complete (assessed by TLC), water and DCM were 48 
added and organic layer was separated. The aqueous layer was 49 
extracted with DCM. The combined organic layers were 50 
washed with brine and dried over MgSO4 and concentrated 51 
under reduced pressure to give the crude product. The crude 52 
material was purified by column chromatography to afford the 53 
desired product. 54 
 55 
Method E 56 
Substituted amine trifluoroacetate derivative was suspended in 57 
acetone and cooled to 00 C in an ice bath. Saturated aqueous 58 
NaHCO3 and solution of tosyl chloride was added dropwise 59 
simultaneously to the reaction mixture and stirred at same 60 
temperature for 30 minutes followed by stirring at rt for 7h. 61 
During the addition, the initially clear reaction mixture started 62 
to become a suspension. Once the reaction was complete 63 
(assessed by TLC), the reaction mixture was filtered through a 64 
Buchner filter and the residue was washed with acetone. The 65 
combined filtrate was concentrated. To the obtained residue, 66 
water and DCM were added and organic layer was separated. 67 
The aqueous layer was extracted with DCM . The combined 68 
organic layers were washed with brine and dried over MgSO4 69 
and concentrated under reduced pressure to give the crude 70 
product. The crude material was purified by column 71 
chromatography to afford the desire product. 72 
 73 
N-(2-(2-Methoxyphenyl)-2-oxo-1-phenylethyl)-4-74 
methylbenzenesulfonamide 14b.  75 
This compound is novel and was prepared following the general 76 
procedure D using 2-(2-methoxyphenyl)-2-oxo-1-phenylethan-77 
1-aminium trifluoroacetate (1.00 g, 2.81mmol, 1.0 eq) in DCM 78 
(20 mL), triethylamine (1.42 g, 1.95 mL, 22.6 mmol, 5 eq) and 79 
tosyl chloride (1.17 g, 6.19 mmol, 2.2 eq) in DCM (30 mL), 80 
water (50 mL) to quench and DCM (2 x 30 mL) for extraction 81 
to generate the crude product which was purified by column 82 
chromatography (30% EtOAc in petroleum ether (40-60)) to 83 
give 14b as a yellow solid (0.69 g, 1.74 mmol, 62.1%). TLC: Rf 84 
ca 0.3 (6:4, Hexane: EtOAc), strong UV active; MP: 138-140 85 
ºC; HRMS (ESI): found [M+Na]+ 418.1085, C22H21NNaO4S re-86 
quires [M+Na]+ 418.1083 (error -0.3 ppm);max 3264, 1662, 87 
1595, 1209, 1175, 756, 673, 535 cm-1; 1H NMR (CDCl3, 500 88 
MHz): δ 7.60 (d, 2H, J = 8.2 Hz), 7.48-7.46 (m, 1H), 7.40 – 7.36 89 
(m, 1H), 7.14 -7.09 (m, 7H), 6.87 – 6.81 (m, 2H), 6.27 (d, 1H, 90 
J = 7.5 Hz), 6.20 (d, 1H, J = 7.5 Hz), 3.80 (s, 3H), 2.31 (s, 3H); 91 
13C{1H} NMR (CDCl3,126 MHz): δ 196.4, 158.2, 143.1, 137.6, 92 
136.1, 134.8 131.4, 129.4, 128.7, 128.2, 128.2, 127.2, 124.7, 93 




methylbenzenesulfonamide 14c. 98 
This compound is novel and was prepared following the stand-99 
ard procedure D using 2-(3-methoxyphenyl)-2-oxo-1-phenyle-100 
than-1-aminium trifluoroacetate (0.400 g, 1.12 mmol, 1.0 eq) in 101 
DCM (10 mL), triethylamine (0.453 g, 0.62 mL, 4.48 mmol, 4 102 
eq) and tosyl chloride (0.322 g, 1.68 mmol, 1.5 eq) in DCM (10 103 
mL), water (50 mL) to quench and DCM (2 x 30 mL) for ex-104 
traction to generate the crude product which was purified by 105 
column chromatography (30% EtOAc in petroleum ether (40-106 
60))  to give 14c as a white solid (0.205 g, 0.519 mmol, 46.3%). 107 
TLC: Rf ca 0.3 (7:3, Hexane: EtOAc), strong UV active; MP: 108 
158-160 ºC; HRMS (ESI): found [M+Na]+ 418.1086, 109 
C22H21NNaO4S requires [M+Na]+ 418.1083 (error -0.5 110 
ppm);max 3276, 1677, 1588, 1254, 1159, 662, 530 cm-1; 1H 111 
NMR (CDCl3, 500 MHz): δ 7.52 (d, 2H, J = 8.2 Hz), 7.37 (d,  112 
1H, J = 7.7 Hz), 7.30 – 7.24 (m,  2H), 7.18 (s, 5H), 7.07– 7.02 113 
(m, 3H), 6.20 (d, 1H, J = 7.4 Hz), 5.96 (d, 1H, J = 7.4 Hz),, 3.77 114 
(s, 3H), 2.30 (s, 3H); 13C{1H} NMR  (CDCl3, 126 MHz): δ 115 
195.0 159.9 143.3, 137.6, 1359, 135.2, 129.8, 129.5129.2, 116 
128.6, 128.2, 127.1, 121.7, 120.6, 113.3, 62.0, 55.5, 21.5; m/z 117 
(ESI) 418.1 [(M+Na)+, 100%]. 118 
119 
N-(2-(2-Chlorophenyl)-2-oxo-1-phenylethyl)-4-methylben-120 
zenesulfonamide 14d. 121 
14 
 
This compound is novel and was prepared following the general 1 
procedure E using 2-(2-chlorophenyl)-2-oxo-1-phenylethan-1-2 
aminium trifluoroacetate (1.00 g, 2.79 mmol, 1.0 eq.) in acetone 3 
(20 mL), saturated aqueous NaHCO3 (20 mL) and tosyl chloride 4 
(0.590 g, 3.07 mmol, 1.1 eq) in acetone (20 mL), water (80 mL) 5 
to quench and DCM (2 x 30 mL) for extraction to generate the 6 
crude product which was purified by column chromatography 7 
(10% EtOAc in petroleum ether (40-60)) to give 14d as a yel-8 
low solid (0.45 g, 1.12 mmol, 44.9%). TLC: Rf ca 0.2 (8:2, Hex-9 
ane: EtOAc), strong UV active; MP: 87-89 ºC; HRMS (ESI): 10 
found [M+Na]+ 422.0592, C21H18ClNNaO3S requires [M+Na]+ 11 
422.0588 (error -0.9 ppm);max 3258, 1691, 1587, 1335, 1161, 12 
758, 532 cm-1; 1H NMR (CDCl3,  500 MHz): 7.60 (d, 2H, J = 13 
8.3 Hz), 7.29-7.26 (m, 2H), 7.16 -7.17 (m, 6H), 7.07-7.05 (m, 14 
3H), 6.26 (d, 1H, J = 6.3 Hz), 5.91 (d, 1H, J = 6.4 Hz), 2.34 (s, 15 
3H); 13C{1H} NMR  (CDCl3, 126 MHz): δ 196.8, 143.5, 137.4, 16 
135.8, 134.3, 132.5, 131.3, 129.6, 129.5, 129.0, 128.7, 128.2, 17 
127.2, 126.8, 64.9, 21.6; m/z (ESI) 422.1 [(M+Na)+, 100%] 18 




This compound is novel and  was prepared following the gen-23 
eral procedure D 2-(3-chlorophenyl)-2-oxo-1-phenylethan-1-24 
aminium trifluoroacetate (1.00 g, 2.79 mmol, 1.0 eq) in DCM 25 
(25 mL), triethylamine (1.40 g, 2.00 mL, 13.9 mmol, 5 eq) and 26 
tosyl chloride (1.17 g, 6.14 mmol, 2.2 eq) in DCM (25 mL), 27 
water (80 mL) to quench and DCM (2 x 30 mL) for extraction 28 
to generate the crude product which was purified by column 29 
chromatography (50% EtOAc in petroleum ether (40-60)) to 30 
give 14e as a yellow solid (0.290 g, 0.726 mmol, 26.0%). TLC: 31 
Rf ca 0.2 (8:2, Hexane: EtOAc), strong UV active; MP: 210-211 32 
ºC; HRMS (ESI): found [M+Na]+ 422.0593, C21H18ClNNaO3S 33 
requires [M+Na]+ 422.0588 (error -1.1 ppm); max 3250, 1697, 34 
1329, 1154, 664, 532 cm-1; 1H NMR (CDCl3, 500 MHz): δ 7.75 35 
(s, 1H), 7.65 (d, 1H, J = 7.9 Hz) 7.52 (d, 2H, J = 8.2 Hz), 7.47-36 
7.46 (m, 1H), 7.30 (t, 1H, J = 7.9 Hz), 7.20-7.15 (m, 5H), 7.07 37 
(d, 2H, J = 8.1 Hz), 6.14 (d, 1H, J = 7.5 Hz), 5.93 (d, 1H, J = 38 
7.5 Hz), 2.32 (s, 3H); 13C{1H} NMR  (CDCl3, 126 MHz3): δ 39 
193.7, 143.4, 137.4, 135.5, 135.3, 135.2, 134.0, 130.1, 129.5, 40 
129.4, 128.9, 128.2, 127.1, 127.1, 62.0 21.6; m/z (ESI) 422.1 41 
[(M+Na)+, 90%] 424.3 [(M+2+Na)+, 50%]. 42 
43 
N-(2-(4-Chlorophenyl)-2-oxo-1-phenylethyl)-4-methylben-44 
zenesulfonamide 14f. 45 
This compound is novel and was prepared following the general 46 
procedure D using 2-(4-chlorophenyl)-2-oxo-1-phenylethan-1-47 
aminium trifluoroacetate (1.10 g, 3.07 mmol, 1.0 eq) in DCM 48 
(20 mL), triethylamine (1.24 g, 1.71 mL, 12.3 mmol, 4 eq) and 49 
tosyl chloride (0.878 g, 4.60 mmol, 1.5 eq) in DCM (20 mL), 50 
water (60 mL) to quench and DCM (2 x 30 mL) for extraction 51 
to generate the crude product which was purified by column 52 
chromatography (30% EtOAc in petroleum ether (40-60)) to 53 
give 14f as a brown solid (0.385 g, 0.964 mmol, 31.4%). TLC: 54 
Rf ca 0.3 (8:2, Hexane: EtOAc), strong UV active; MP: 161-163 55 
ºC; HRMS (ESI): found [M+Na]+ 422.0591, C21H18ClNNaO3S 56 
requires [M+Na]+ 422.0588 (error -0.7 ppm); max 3250, 1697, 57 
1329, 1154, 664, 532 cm-1; 1H NMR (CDCl3, 500 MHz): δ7.74 58 
(d, 2H, J = 8.6 Hz), 7.51 (d, 2H, J = 8.2 Hz), 7.33 (d, 2H, J = 59 
8.6 Hz), 7.19 – 7.14 (m, 5H),7.07 (d, 2H, J = 8.1 Hz), 6.18 (d, 60 
1H, J = 7.3 Hz), 5.94 (d, 1H, J = 7.4 Hz), 2.31 (s, 3H); 13C{1H} 61 
NMR (CDCl3, 126 MHz): δ 193.5, 143.3, 140.7, 137.5, 135.5, 62 
132.2, 130.4, 129.5, 129.3, 129.2, 128.8, 128.2, 127.1, 61.9, 63 




methylbenzenesulfonamide 14g. 68 
This compound is novel and was prepared following the general 69 
procedure E using 1-(2-methoxyphenyl)-2-oxo-2-phenylethan-70 
1-aminium (1.20 g, 3.37 mmol, 1.0 eq) in acetone (25 mL), sat-71 
urated aqueous NaHCO3 (25 mL) and tosyl chloride (0.708 g, 72 
3.71 mmol, 1.1 eq) in acetone (25 mL), water (80 mL) to quench 73 
and DCM (2 x 30 mL) for extraction to generate the crude prod-74 
uct which was purified by column chromatography (20% 75 
EtOAc in petroleum ether (40-60)) to give 14g as a white solid 76 
(0.750 g, 1.89 mmol, 56.1%). TLC: Rf ca 0.35 (6:4, Hexane: 77 
EtOAc), strong UV active; MP: 162-165 ºC; HRMS (ESI): 78 
found [M+Na]+ 418.1082, C22H21NNaO4S requires [M+Na]+ 79 
418.1083 (error 0.4 ppm);max 3260, 2983, 1697, 1597, 1229, 80 
1160, 754, 688, 536 cm-1; 1H NMR (CDCl3, 500 MHz): δ 7.83 81 
(d, 2H, J = 7.9 Hz), 7.57 (d, 2H, J = 7.6 Hz), 7.45 (t, 1H, J = 7.4 82 
Hz), 7.33-7.30 (m, 2H), 7.12 (t, 1H, J = 7.8 Hz), 7.07 (m, 3H), 83 
6.76 (t, 1H, J = 7.5 Hz), 6.67 (d, 1H, J = 8.1 Hz), 6.25-6.22 (m, 84 
2H), 3.74 (s, 3H), 2.30 (s, 3H); 13C{1H} NMR (CDCl3, 126 85 
MHz): δ 194.8, 156.3, 143.0, 137.6, 134.1, 133.7, 130.0, 129.4, 86 
129.3, 128.8, 128.6, 127.2, 124.7, 121.3, 111.4, 56.8, 55.6, 21.5; 87 
m/z (ESI) 418.3 [(M+Na)+, 100%]. 88 
89 
N-(1-(4-Methoxyphenyl)-2-oxo-2-phenylethyl)-4-90 
methylbenzenesulfonamide 14h.  91 
This compound has been reported.23 This compound was pre-92 
pared following the general procedure E using 1-(4-methoxy-93 
phenyl)-2-oxo-2-phenylethan-1-aminium (1.20 g, 3.37 mmol, 94 
1.0 eq) in acetone (25 mL), saturated aqueous NaHCO3 (25 mL) 95 
and tosyl chloride (0.708 g, 3.71 mmol, 1.1 eq) in acetone (25 96 
mL), water (80 mL) to quench and DCM (2 x 30 mL) for ex-97 
traction to generate the crude product which was purified by 98 
column chromatography (30% EtOAc in petroleum ether (40-99 
60)) to give 14h as a white solid (1.00 g, 2.53 mmol, 75.1%). 100 
TLC: Rf ca 0.4 (6:4, Hexane: EtOAc), strong UV active; MP: 101 
61-62 ºC; HRMS (ESI): found [M+Na]+ 418.1083, 02 
C22H21NNaO4S requires [M+Na]+ 418.1083 (error 0.0 103 
ppm);max 3270, 1680, 1580, 1248, 1154, 752, 676, 529 cm-1; 104 
1H NMR (CDCl3, 500 MHz): δ 7.79 (d, 2H, J = 7.8 Hz), 7.53 – 105 
7.47 (m, 3H), 7.37-7.33 (m, 2H)), 7.09-7.06 (m, 4H), 6.68 (d, 106 
2H, J = 8.4 Hz), 6.18 (d, 1H, J = 7.3 Hz), 5.95 (d, 1H, J = 7.3 107 
Hz), 3.70 (s, 3H), 2.30 (s, 3H); 13C{1H} NMR (CDCl3, 126 108 
MHz): δ 194.7 159.8, 143.1, 137.7, 134.0, 133.9, 129.6, 129.4, 109 
129.0, 128.8, 127.8, 127.1, 114.6, 61.3, 55.3, 21.5; m/z (ESI) 110 
418.2 [(M+Na)+, 100%]. 111 
 112 
N-(1-(2-Chlorophenyl)-2-oxo-2-phenylethyl)-4-methylben-113 
zenesulfonamide 14i.  114 
This compound is novel and was prepared following the general 115 
procedure E using 1-(2-chlorophenyl)-2-oxo-2-phenylethan-1-116 
aminium (0.400 g, 1.11 mmol, 1.0 eq) in acetone (10 mL), sat-117 
urated aqueous NaHCO3 (10 mL) and tosyl chloride (0.233 g, 118 
1.22 mmol, 1.1 eq) in acetone (10 mL), water (50 mL) to quench 119 
and DCM (2 x 20 mL) for extraction to generate the crude prod-120 
uct which was purified by column chromatography (30% 121 
EtOAc in petroleum ether (40-60)) to give 14i as a white solid 122 
15 
 
(0.310 g, 0.776 mmol, 70.6%). TLC: Rf ca 0.3 (8:2, Hexane: 1 
EtOAc), strong UV active; MP: 134-135 ºC, HRMS (ESI): 2 
found [M+Na] + 422.0591, C21H18ClNNaO3S requires [M+Na]+ 3 
422.0588 (error -0.6 ppm); max 3261, 1690, 1596, 1328, 1152, 4 
717, 546 cm-1;  1H NMR (CDCl3, 500 MHz): δ 7.85 (d, 2H, J = 5 
7.9 Hz), 7.62 (d, 2H, J = 7.9 Hz), 7.50 (t, 1H, J = 7.4 Hz), 7.36 6 
(m, 2H), 7.26-7.23 (m, 1H), , 7.11-7.04 (m, 5H), 6.34 (d, 1H, J 7 
= 7.0 Hz), 6.26 (d, 1H , J = 7.0 Hz), 2.32 (s, 3H); 13C{1H} NMR 8 
(CDCl3, 126 MHz): δ 194.3, 143.4, 137.2, 134.2, 133.8, 133.8, 9 
133.7, 130.4, 130.0, 129.7, 129.5, 128.9, 128.8, 127.7, 127.3, 10 
58.7, 21.6; m/z (ESI) 422.2 [(M+Na)+, 100%] 424.1 11 
[(M+2+Na)+, 35%]. 12 
 13 
N-(1-(4-Chlorophenyl)-2-oxo-2-phenylethyl)-4-methylben-14 
zenesulfonamide 14j.    15 
This compound is novel and was prepared following the general 16 
procedure E using 1-(4-chlorophenyl)-2-oxo-2-phenylethan-1-17 
aminium trifluoroacetate (0.900 g, 2.51 mmol, 1.0 eq) in ace-18 
tone (18 mL), saturated aqueous NaHCO3 (18 mL) and tosyl 19 
chloride (0.528 g, 2.76 mmol, 1.1 eq) in acetone (18 mL), water 20 
(80 mL) to quench and DCM (2 x 30 mL) for extraction to gen-21 
erate the crude product which was purified by column chroma-22 
tography (30% EtOAc in petroleum ether (40-60)) to give 14j 23 
as a white solid (0.586 g, 1.57 mmol, 58.5%). TLC: Rf ca 0.3 24 
(8:2, Hexane: EtOAc), strong UV active; MP: 166-169 ºC; 25 
HRMS (ESI): found [M+Na]+ 422.0588, C21H18ClNNaO3S re-26 
quires [M+Na]+ 422.0588 (error 0.1 ppm); max 3219, 1696, 27 
1399, 1155, 652, 543 cm-1; 1H NMR (CDCl3, 500 MHz): δ 7.78 28 
(d, 2H , J = 7.9 Hz), 7.54-7.49 (m, 3H), 7.38 (t, 2H, J = 7.6 Hz), 29 
7.26 (s, 1H) , 7.13-7.07 (m, 5H), 6.22 (d, 1H, J = 6.9 Hz), 5.96 30 
(d, 1H, J = 7.0 Hz), 2.32 (s, 3H); 13C{1H} NMR (CDCl3, 126 31 
MHz): δ 194.2, 143.5, 137.5, 134.8, 134.3, 134.3, 133.7, 129.6, 32 
129.5, 129.4, 129.1, 128.9, 127.1, 61.1, 21.5; m/z (ESI) 422.2 33 
[(M+Na)+, 100%] 424.1 [(M+2+Na)+, 35%]. 34 
 35 
N-(2-(4-Chlorophenyl)-1-(4-methoxyphenyl)-2-oxoethyl)-4-36 
methylbenzenesulfonamide 14k. 37 
This compound is novel and was prepared following the general 38 
procedure E using 1-(4-chlorophenyl)-2-(4-methoxyphenyl)-2-39 
oxoethan-1-aminium trifluoroacetate (0.750 g, 1.92 mmol, 1.0 40 
eq) in acetone (14 mL), saturated aqueous NaHCO3 (20 mL) 41 
and tosyl chloride (0.405 g, 2.12 mmol, 1.1 eq) in acetone (14 42 
mL), water (50 mL) to quench and DCM (2 x 30 mL) for ex-43 
traction to generate the crude product which was purified by 44 
column chromatography (30% EtOAc in petroleum ether (40-45 
60)) to give 14k as a yellow solid (0.600 g, 1.39 mmol, 72.8%). 46 
TLC: Rf ca 0.3 (7:3, Hexane: EtOAc), strong UV active; MP: 47 
72-76 ºC; HRMS (ESI): found [M+Na]+ 452.0694, 48 
C22H20ClNNaO4S requires [M+Na]+ 452.0694 (error -0.0 49 
ppm);max 3269, 1682, 1588, 1510, 1249, 1156, 1089, 810, 50 
663, 532 cm-1; 1H NMR (CDCl3, 500 MHz): δ 7.74-7.72 (m, 51 
2H), 7.53-7.51 (m, 2H), 7.34-7.31 (m, 2H), 7.08-7.04 (m, 4H), 52 
6.70-6.67 (m, 2H), 6.15 (d, 1H, J = 7.3 Hz), 5.90 (d, 1H, J = 7.3 53 
Hz), 3.71 (s, 3H), 2.31 (s, 3H); 13C{1H} NMR (CDCl3, 126 54 
MHz):) δ 193.6, 159.9, 143.2, 140.5, 137.7, 132.3, 130.4, 129.5, 55 
129.5, 129.2, 127.4, 127.1, 114.7, 61.4, 55.4, 21.5; m/z (ESI) 56 
452.2 [(M+Na)+, 100%], 454.2 [(M+2+Na)+, 35%]. 57 
 58 
N-(2-(Furan-2-yl)-2-oxo-1-phenylethyl)-4-methylbenzene-59 
sulfonamide 14l. 60 
This compound is novel and was prepared following the general 61 
procedure E using 2-(furan-2-yl)-2-oxo-1-phenylethan-1-62 
aminium trifluoroacetate (0.800 g, 2.53 mmol, 1.0 eq) in ace-63 
tone (18 mL), saturated aqueous NaHCO3 (18 mL) and tosyl 64 
chloride (0.532 g, 2.79 mmol, 1.1 eq) in acetone (18 mL), water 65 
(80 mL) to quench and DCM (2 x 30 mL) for extraction to gen-66 
erate the crude product which was purified by column chroma-67 
tography (50% EtOAc in petroleum ether (40-60))to give 14l as 68 
a white solid (0.706 g, 1.98 mmol, 78.6%). TLC: Rf ca 0.2 (8:2, 69 
Hexane: EtOAc), strong UV active; MP: 147-149 ºC; HRMS 70 
(ESI): found [M+Na]+ 378.0769, C19H17NNaO4S requires 71 
[M+Na]+ 378.0770 (error 0.5 ppm);max 3268, 1658, 1464, 72 
1345, 1159, 1090, 989, 773, 525 cm-1; 1H NMR (CDCl3, 500 73 
MHz): δ 7.54-7.52 (m, 3H), 7.23-7.18 (m, 5H), 7.14 (d, 1H, J = 74 
3.6 Hz), 7.07 (d, 2H, J = 8.1 Hz), 6.46 (d, 1H, J = 5.2 Hz), 6.13 75 
(d, 1H, J = 7.6 Hz), 5.81 (d, 1H, J = 7.6 Hz), 2.31 (s, 3H); 76 
13C{1H} NMR (CDCl3, 126 MHz): δ 183.32 150.2, 147.5, 77 
143.3, 137.5, 135.5, 129.4, 129.0, 128.6, 128.2, 127.1, 119.8, 78 
112.9, 61.7, 21.5; m/z (ESI) 378.1 [(M+Na)+, 100%]. 79 
80 
N-(2-Oxo-1,2-diphenylethyl)methanesulfonamide (precur-81 
sor of 23). 82 
This compound has been reported.35 This compound was pre-83 
pared following the general procedure D using 2-oxo-1,2-di-84 
phenylethan-1-aminium hydrochloride (0.500 g, 2.02 mmol, 85 
1.0 eq) in DCM (10 mL), triethylamine (0.816 g, 1.12mL, 8.08 86 
mmol, 4.0 eq) and mesyl chloride (0.348 g, 3.03 mmol, 1.5 eq) 87 
in DCM (10 mL), water (50 mL) to quench and DCM (2 x 25 88 
mL) for extraction to generate the crude product which was pu-89 
rified by column chromatography (30% EtOAc in petroleum 90 
ether (40-60)) to give the product as a white solid (0.310 g, 1.07 91 
mmol, 52.9%). TLC: Rf ca 0.3 (7:3, Hexane: EtOAc), strong 92 
UV active; HRMS (ESI): found [M+Na]+ 312.0696, 93 
C15H15NNaO3S requires [M+Na]+ 312.0665 (error 0.7 94 
ppm);max 3242, 1687, 1313, 1293, 1247, 994, 731, 508 cm-1; 95 
1H NMR (CDCl3, 400 MHz): δ 7.93 (d, 2H, J = 7.3 Hz), 7.53 (t, 96 
1H, J = 7.4 Hz), 7.42 – 7.24 (m,  7H), 6.13 (d, 1H, J = 6.4 Hz), 97 
6.07 (d, 1H, J = 6.2 Hz), 2.58 (s, 3H); 13C{1H} NMR  (CDCl3, 98 
101 MHz): δ 194.3, 136.3, 134.2, 133.7 129.7, 129.3 129.2, 99 
128.9, 128.4, 62.2, 42.4; m/z (ESI) 312.2 [(M+Na)+, 100%]. 100 
The data matches the reported data.  101 
  102 
4-Methyl-N-(1-oxo-1-phenylpropan-2-yl)benzenesulfona-103 
mide (precursor to 25).104 
This compound has been reported and fully characterised.36 105 
This compound was prepared following the same procedure as 106 
used for 4-methyl-N-(2-oxo-1,2-diphenylethyl)benzenesulfon-107 
amide 14a using 1-oxo-1-phenylpropan-2-aminium hydrochlo-108 
ride (1.50 g, 8.10 mmol, 1.0 eq) in DCM (40 mL), triethylamine 109 
(3.28 g, 4.50 mL, 32.4 mmol, 4 eq) and tosyl chloride (3.10g, 110 
16.2 mmol, 1.2 eq) in DCM (20 mL), water (100 mL) to quench 111 
and DCM (2 x 40 mL) for extraction to generate the crude prod-112 
uct which was purified by column chromatography (15% 113 
EtOAc in petroleum ether (40-60)) to give the product as a 114 
white solid (0.55 g, 1.81 mmol, 22.3%). TLC: Rf ca 0.2 (8:2, 115 
Hexane: EtOAc), strong UV active; HRMS (ESI): found 116 
[M+Na]+ 326.0819, C16H17NNaO3S requires [M+Na]+ 117 
326.0821 (error 0.8 ppm);max 3267, 1679, 1596, 1337, 1164, 118 
965, 702, 680, 551 cm-1; 1H NMR (CDCl3, 400 MHz): δ 7.78 – 119 
7.75 (m, 2H), 7.69 (d, 2H, J = 8.3 Hz), 7.59 (t, 1H, J = 7.4 Hz), 120 
7.47-7.43 (t, 2H, J = 7.7 Hz), 7.17 (d, 2H, J = 8.0 Hz), 5.79 (d, 121 
16 
 
1H, J = 8.0 Hz), 4.97-4.90 (m, 1H), 2.32 (s, 3H), 1.40 (d, 3H, J 1 
= 7.2 Hz); 13C{1H} NMR (CDCl3, 101 MHz): δ 198.2, 143.6, 2 
137.2, 134.2, 133.5, 129.8, 128.9, 128.6, 127.2, 53.5, 21.6, 21.2; 3 
m/z (ESI) 326.2 [(M+Na)+, 100%]. The data matches the re-4 
ported data.  5 
 6 
4-Methyl-N-(2-oxo-1-phenylpropyl)benzenesulfonamide 7 
(precursor to 27).8 
This compound has been reported and fully characterised.379 
This compound was prepared following the general procedure 10 
E using 2-oxo-1-phenylpropan-1-aminium trifluoroacetate 11 
(0.780 g, 2.96 mmol, 1.0 eq) in acetone (20 mL), saturated aque-12 
ous NaHCO3 (20 mL) and tosyl chloride (0.621 g, 3.26 mmol, 13 
1.1 eq) in acetone (20 mL), water (60 mL) to quench and DCM 14 
(2 x 20 mL) for extraction to generate the crude product which 15 
was purified by column chromatography (60% EtOAc in petro-16 
leum ether (40-60)) to give the product as a white solid (0.400 17 
g, 1.32 mmol, 45.8%). TLC: Rf ca 0.3 (8:2, Hexane: EtOAc), 18 
strong UV active; HRMS (ESI): found [M+Na]+ 326.0822, 19 
C16H17NNaO3S requires [M+Na]+ 326.0821 (error -0.3 20 
ppm);max 3373, 3266, 1705, 1672, 1339, 1244, 1158, 774, 21 
667, 565 cm-1; 1H NMR (CDCl3, 500 MHz): δ 7.47 (d, 2H, J = 22 
7.6 Hz), 7.26 – 7.21 (m, 3H), 7.11-7.08 (m, 4H), 6.06 (d, 1H, J 23 
= 4.4 Hz), 5.02 (d, 1H, J = 4.9 Hz), 2.34 (s, 3H), 1.99 (s, 3H); 24 
13C{1H} NMR (CDCl3, 126 MHz): δ 201.9, 143.3, 137.4, 135.2, 25 
129.4, 129.2, 128.8, 128.2, 127.1, 66.5, 26.7, 21.6); m/z (ESI) 26 
326.1 [(M+Na)+, 100%]. The data matches the reported data.  27 
 28 
General procedure F for asymmetric transfer hydrogena-29 
tion (ATH). 30 
Substituted ketone derivatives and DABCO were dissolved in 31 
small amount of MeCN. Once the reaction became clear, 32 
catalyst ((R,R)-20 for N-Boc-protected substrates and (R,R)-2  33 
for N-Ts-protected substrates) and  remaining solvent  added (to 34 
give [S] = 0.1M) after which formic acid was added and the 35 
resulting reaction mixture was stirred at room temperature. 36 
After stirring for the time indicated, the reaction mixture was 37 
concentrated. The residue was dissolved in DCM and the 38 
organic layer was washed with water. The aqueous layer was 39 
extracted with DCM. The combined organic layers were 40 
washed with brine and dried over MgSO4 and concentrated 41 
under reduced pressure to give the crude product. The crude 42 
material was purified by column chromatography to afford the 43 
substituted amino alcohol. In cases where only a single diaster-44 
eoisomer of ATH product was observed, the dr is given as 45 
>99.9:<0.1. Racemic standards were prepared using general 46 
procedure A. 47 
 48 
t-Butyl-((1S,2R)-2-hydroxy-2-(2-methoxyphenyl)-1-phe-49 
nylethyl)carbamate 17b. 50 
This compound is novel and  was prepared following the gen-51 
eral procedure F using tert-butyl (2-(2-methoxyphenyl)-2-oxo-52 
1-phenylethyl)carbamate 13b (0.171  g, 0.5 mmol, 1.0 eq) in 53 
MeCN (5 mL), catalyst  (R,R)-20 (7.1 mg, 0.01 mmol, 0.02 eq), 54 
DABCO (0.280 g, 2.50 mmol, 5.0 eq)  and formic acid (56 µL, 55 
1.50 mmol, 3.0 eq) for 48h when 100% conversion of ketone 56 
achieved (determined by 1H NMR), water (30 mL) to quench 57 
and DCM (2 x 10 mL) for extraction to generate the crude prod-58 
uct which was purified by column chromatography (40% 59 
EtOAc in petroleum ether (40-60)) to give 17b as a white solid 60 
(0.150 g, 0.437 mmol, 87.4%). TLC: Rf ca 0.3 (6:4, Hexane: 61 
EtOAc), less UV active, strong KMnO4 & PMA reactive; MP: 62 
115-118 ºC; HRMS (ESI): found [M+Na]+ 366.1677, 63 
C20H25NNaO4 requires [M+Na]+ 366.1676 (error -0.2 ppm); 64 
max 3531, 3381, 1679, 1520, 1218, 1166, 988, 699 cm-1; Enan-65 
tiomeric excess determined by HPLC analysis (Chiralpak IC, 66 
250 mm x 4.6 mm column, iPrOH: hexane 12:88, 0.5 mL/min, 67 
T = 25 ºC), (1S,2R)  16.4 min, (1R,2S) 19.1 min, other diastere-68 
omer 52.2 min and 62.4 min; [α]D22 = -122 (c = 0.1, CHCl3); 69 
dr: >99.9:<0.1, major diastereomer 94.4% ee; 1H NMR 70 
(DMSO-d6, 500 MHz): δ 7.17-7.12 (m, 4H), 7.03-6.90 (m, 5H), 71 
6.73-6.70 (m, 1H), 5.21 (d, 1H, J = 4.8 Hz), 5.09 (t, 1H, J = 5.0 72 
Hz), 4.75 (dd, 1H, J = 8.7, 5.5 Hz), 3.84 (s, 3H), 1.29 (s, 9H); 73 
13C{1H} NMR  (DMSO-d6, 126 MHz): δ 155.8, 154.5, 140.4, 74 
130.2, 128.1, 127.9 127.3, 127.0, 126.4, 119.7, 110.2, 77.8, 75 




This compound is novel and was prepared following the general 80 
procedure F using tert-butyl (2-(3-methoxyphenyl)-2-oxo-1-81 
phenylethyl)carbamate 13c (0.171 g, 0.5 mmol, 1.0 eq) in 82 
MeCN (5 mL), catalyst (R,R)-20 (5.3 mg, 7.5 µmol, 0.015 eq), 83 
DABCO (0.280 g, 2.50 mmol, 5.0 eq)  and formic acid (56 µL, 84 
1.50 mmol, 3.0 eq) for 72h when 100% conversion of ketone 85 
achieved (determined by 1H NMR), water (30 mL) to quench 86 
and DCM (2 x 10 mL) for extraction to generate the crude prod-87 
uct which was purified by column chromatography (50% 88 
EtOAc in petroleum ether (40-60)) to give 17c as a white solid 89 
(0.150 g, 0.437 mmol, 87.4%). TLC: Rf ca 0.2 (8:2, Hexane: 90 
EtOAc), less UV active, strong KMnO4 & PMA reactive; MP: 91 
163-165 ºC; HRMS (ESI): found [M+Na]+ 366.1674, 92 
C20H25NNaO4 requires [M+Na]+ 366.1676 (error 0.6 ppm);max 93 
3420, 1660, 1520, 1291, 1160, 1166, 980, 698 cm-1; Enantio-94 
meric excess determined by HPLC analysis (Chiralpak IC, 250 95 
mm x 4.6 mm column, iPrOH: hexane 12:88, 0.5 mL/min, 210 96 
nm, T = 25 ºC), (1S,2R) 16.5 min, (1R,2S) isomer 21.6 min, 97 
other diastereomer 47.3 min and 143.1 min; [α]D22 = -109 98 
(c=0.1, CHCl3), dr: >99.9:<0.1, 93.0% ee;  1H NMR (CDCl3,  99 
500 MHz): δ 7.26-7.23 (m, 3H), 7.15 (t, 1H, J = 7.9 Hz), 7.04 100 
(s, 2H), 6.78-6.76 (m, 1H), 6.66 (d, 1H, J = 7.2 Hz), 6.53 (s, 101 
1H), 5.33 (d, 1H, J = 6.3 Hz), 5.02-4.97 (m, 2H), 3.65 (s, 3H), 102 
2.75 (s, 1H), 1.41 (s, 9H); 13C{1H} NMR  (CDCl3, 126 MHz): 103 
δ 159.4, 155.8, 141.6, 137.8, 129.1, 128.2, 127.9, 127.7, 119.1, 104 
114.0, 111.7, 80.1, 77.2, 60.6, 55.2 28.4; m/z (ESI) 366.3 105 




This compound is novel and was prepared following the general 110 
procedure F using tert-butyl (2-(2-chlorophenyl)-2-oxo-1-phe-111 
nylethyl)carbamate 13d (0.173 g, 0.5 mmol, 1.0 eq) in MeCN 112 
(5 mL), catalyst (R,R)-20 (7.1 mg, 0.01 mmol, 0.02 eq), 113 
DABCO (0.280 g, 2.50 mmol, 5.0 eq)  and formic acid (56 µL, 114 
1.50 mmol, 3.0 eq) for 48h when 95% conversion of ketone 115 
achieved (determined by 1H NMR), water (30 mL) to quench 116 
and DCM (2 x 10 mL) for extraction to generate the crude prod-117 
uct which was purified by column chromatography (20% 118 
EtOAc in petroleum ether (40-60)) to give 17d as a white solid 119 
(0.124 g, 0.357 mmol, 71.4%). TLC: Rf ca 0.3 (6:4, Hexane: 120 
EtOAc), less UV active, strong KMnO4 & PMA reactive; MP: 121 
17 
 
128-130 ºC; HRMS (ESI): found [M+Na]+ 370.1179, 1 
C19H22ClNNaO3 requires [M+Na]+ 370.1180 (error 0.5 2 
ppm);max 3399, 2982, 1684, 1492, 1154, 698 cm-1; Enantio-3 
meric excess  determined by HPLC analysis (Chiralpak IG, 250 4 
mm x 4.6 mm column, iPrOH: hexane 7:93, 0.5 mL/min, 210 5 
nm, T = 25 ºC), (1R,2S) 21.9 min, (1S,2R) 23.5 min, other dia-6 
stereomer 42.8 min and 47.2 min; [α]D22 = -150 (c = 0.1, 7 
CHCl3), dr: 97.7:2.3, major diastereomer 94.8% ee; 1H NMR 8 
(CDCl3, 500 MHz3): δ 7.32 (d, 1H, J = 7.9 Hz), 7.23-7.22 (m, 9 
3H), 7.16 (t, 1H, J = 8.4 Hz), 7.10-7.06 (m, 4H), 5.51-5.46 (m, 10 
2H), 5.01 (s, 1H), 2.53 (s, 1H), 1.37 (s, 9H); 13C{1H} NMR 11 
(CDCl3, 126 MHz): δ 155.3, 138.0, 138.1, 132.4, 129.2, 128.9, 12 
128.5, 128.2, 1278.0., 127.7, 126.7, 79.9, 73.1, 58.9, 28.4; m/z 13 
(ESI) 370.3 [(M+Na)+, 100%], 372.2 [(M+2+Na)+, 40%]. 14 
 15 
t-Butyl-((1S,2R)-2-(3-chlorophenyl)-2-hydroxy-1-16 
phenylethyl)carbamate 17e 17 
This compound is novel and was prepared following the general 18 
procedure F using tert-butyl (2-(3-chlorophenyl)-2-oxo-1-phe-19 
nylethyl)carbamate 13e (0.173  g, 0.5 mmol, 1.0 eq) in MeCN 20 
(5 mL), catalyst (R,R)-20 (5.3 mg, 7.5 µmol, 0.015 eq), DABCO 21 
(0.280 g, 2.50 mmol, 5.0 eq)  and formic acid (56 µL, 1.50 22 
mmol, 1.5 eq) for 24 h when 100% conversion of ketone 23 
achieved (determined  by 1H NMR), water (30 mL) to quench 24 
and DCM (2 x 10 mL) for extraction to generate the crude prod-25 
uct which was purified by column chromatography (20-60% 26 
EtOAc in petroleum ether (40-60)) to give 17e as a white solid 27 
(0.136 g, 0.391 mmol, 78.3%).  TLC: Rf ca 0.2 (8:2, Hexane: 28 
EtOAc), less UV active, strong KMnO4 & PMA reactive; MP: 29 
202-205 ºC; HRMS (ESI): found [M+Na]+ 370.1185, 30 
C19H22ClNNaO3 requires [M+Na]+ 370.1180 (error -1.3 31 
ppm);max 3374, 2977, 1681, 1529, 1165, 1003, 696 cm-1; En-32 
antiomeric excess determined by HPLC analysis (Chiralpak IG, 33 
250 mm x 4.6 mm column, iPrOH: hexane 7:93, 0.5 mL/min, 34 
210 nm, T = 25 ºC), (1S,2R)  16.1 min, (1R,2S)  21.2 min, other 35 
diastereomer 28.9 min and 36.8 min; [α]D22 = -106 (c = 0.1 in 36 
CHCl3), dr: >99.9:<0.1, 96.8% ee;  1H NMR (DMSO-d6, 500 37 
MHz): δ 7.37 – 7.20 (m, 10H), 5.45 (d, 1H, J = 5.2 Hz), 4.64-38 
4.62 (m, 1H), 4.53 (t, 1H, J = 9.1 Hz), 1.20 (s, 9H); 13C{1H} 39 
NMR (DMSO-d6, 126 MHz): δ 154.4, 146.4, 146.1 141.3, 40 
132.2, 129.4, 128.1, 127.6, 126.9, 126.7, 126.7, 125.7, 77.7, 41 
74.7, 74.4, 59.7, 28.1; m/z (ESI) 370.2 [(M+Na)+, 100%), 372.2 42 




This compound is novel and was prepared following the general 47 
procedure F using tert-butyl (2-(4-chlorophenyl)-2-oxo-1-phe-48 
nylethyl)carbamate 13f (0.173 g, 0.5 mmol, 1.0 eq) in MeCN (5 49 
mL), catalyst (R,R)-20 (5.3 mg, 7.5 µmol, 0.015 eq), DABCO 50 
(0.280 g, 2.50 mmol, 5.0 eq)  and formic acid (56 µL, 1.50 51 
mmol, 3.0 eq) for 24 h when 100% conversion of ketone 52 
achieved (determined by 1H NMR), water (30 mL) to quench 53 
and DCM (2 x 10 mL) for extraction to generate the crude prod-54 
uct which was purified by column chromatography (30% 55 
EtOAc in petroleum ether (40-60)) to give 17f as a white solid 56 
(0.140 g, 0.403 mmol, 80.6%). TLC: Rf ca 0.3 (6:4, Hexane: 57 
EtOAc), less UV active, strong KMnO4 & PMA reactive; MP: 58 
200-201 ºC; HRMS (ESI): found [M+Na]+ 370.1182, 59 
C19H22ClNNaO3 requires [M+Na]+ 370.1180 (error -0.5 ppm); 60 
IRmax 3375, 2981, 1677, 1524, 1166, 1000, 702 cm-1; Enanti-61 
omeric excess determined by HPLC analysis (Chiralpak IC, 250 62 
mm x 4.6 mm column, iPrOH: hexane 12:88, 0.5 mL/min, 210 63 
nm, T = 25 ºC), (1S,2R)  9.4 min, (1R,2S) 10.9 min, other dia-64 
stereomer at 17.0 min and 26.4 min; [α]D22 = -82 (c = 0.1 in 65 
CHCl3), dr: >99.9:<0.1, 99.4% ee; 1H NMR (DMSO-d6, 500 66 
MHz): δ 7.33-7.19 (m, 10H), 5.42 (d, 1H, J = 5.1 Hz), 4.65 (dd, 67 
1H, J = 8.1, 5.2 Hz), 4.53 (t, 1H, J = 8.9 Hz), 1.20 (s, 9H); 68 
13C{1H} NMR  (DMSO-d6, 126 MHz): δ 154.5, 142.5, 141.3, 69 
131.4, 128.9, 128.2, 127.4, 126.7, 77.7, 74.6, 60.0, 28.1; m/z 70 
(ESI) 370.2 [(M+Na)+, 100%], 372.2 [(M+2+Na)+, 35%]. 71 
  72 
t- Butyl-((1S,2R)-2-hydroxy-1-(2-methoxyphenyl)-2-phe-73 
nylethyl)carbamate 17g.  74 
This compound is novel and was prepared following the general 75 
procedure F using tert-butyl (1-(2-methoxyphenyl)-2-oxo-2-76 
phenylethyl)carbamate 13g (0.171 g, 0.50 mmol, 1.0 eq) in 77 
MeCN (5 mL), catalyst (R,R)-20 (7.1 mg, 0.01 mmol, 0.02 eq), 78 
DABCO (0.280 g, 2.50 mmol, 5.0 eq)  and formic acid (56 µL, 79 
1.50 mmol, 3.0 eq) for 6 days when 90% conversion of ketone 80 
achieved (determined by 1H NMR), water (30 mL) to quench 81 
and DCM (2 X 10 mL) for extraction to generate the crude prod-82 
uct which was purified by column chromatography (25% 83 
EtOAc in petroleum ether (40-60)) to give 17g as a white solid 84 
(0.110 g, 0.320 mmol, 64.2%). TLC: Rf ca 0.2 (6:4, Hexane: 85 
EtOAc), less UV active, strong KMnO4 & PMA reactive; MP: 86 
120-124 ºC; HRMS (ESI): found [M+Na]+ 366.1672, 87 
C20H25NNaO4 requires [M+Na]+ 366.1676 (error 1 ppm);max 88 
3400, 2975, 1696, 1517, 1494, 1245, 1169, 996, 750 cm-1; En-89 
antiomeric excess determined by HPLC analysis (Chiralpak IC, 90 
250 mm x 4.6 mm column, iPrOH: hexane 12:88, 0.5 mL/min, 91 
210 nm, T = 25 ºC), (1S,2R) 16.6 min, (1R,2S) isomer 20.6 min, 92 
other diastereomer 52.3 min and 108.2 min; [α]D22 = -5 (c = 0.1 93 
in CHCl3), dr: >99.9:<0.1,  88.6% ee; 1H NMR (CDCl3, 500 94 
MHz,): δ 7.26-7.23 (m, 4H), 7.14 (s, 2H), 6.97 (d, 1H, J = 6.4 95 
Hz), 6.88-6.83 (m, 2H), 5.60 (d, 1H, J = 7.8 Hz), 5.26 (s, 1H), 96 
5.02 (s, 1H), 3.71 (s, 3H), 2.90 (s, 1H), 1.36 (s, 9H); 13C{1H} 97 
NMR (CDCl3, 126 MHz): δ 157.0, 155.8, 140.6, 129.9, 129.0, 98 
127.8, 127.6, 127.0, 126.1, 120.7 110.9, 79.7, 57.9, 55.4, 28.5; 99 




This compound is novel and was prepared following the general 104 
procedure F using tert-butyl (1-(4-methoxyphenyl)-2-oxo-2-105 
phenylethyl)carbamate 13h (0.171 g, 0.50 mmol, 1.0 eq) in 106 
MeCN (5 mL), catalyst (R,R)-20 (7.1 mg, 0.01 mmol, 0.02 eq), 107 
DABCO (0.280 g, 2.50 mmol, 5.0 eq)  and formic acid (56 µL, 108 
1.5 mmol, 3.0 eq) for 72h when 90% conversion of ketone 109 
achieved (determined by 1H NMR),  water (30 mL) to quench 110 
and DCM (2 x 10 mL) for extraction to generate the crude prod-111 
uct which was purified by column chromatography (25% 112 
EtOAc in petroleum ether (40-60)) to give 17h as a yellowish 113 
white solid (0.120 g, 0.349 mmol, 69.9%). TLC: Rf ca 0.2 (8:2, 114 
Hexane: EtOAc), less UV active, strong KMnO4 & PMA reac-115 
tive; MP: 172-175 ºC; HRMS (ESI): found [M+Na]+ 366.1675, 116 
C20H25NNaO4 requires [M+Na]+ 366.1676 (error 0.2 ppm); 117 
max 3374, 2979, 1679, 1511, 1242, 1164, 996, 757 cm-1; En-118 
antiomeric excess determined by HPLC analysis (Chiralpak IG, 119 
250 mm x 4.6 mm column, iPrOH: hexane 10:90, 1 mL/min, 120 
210 nm, T = 25 ºC), (1S,2R) 17.7 min, (1R,2S) 27.6 min, other 121 
18 
 
diastereomer 32.1 min and 35.2 min; [α]D22 -82.3 (c 0.1 in 1 
CHCl3), dr: 99.1:0.9, major diastereomer 89.7% ee;  1H NMR 2 
(CDCl3, 500 MHz): δ 7.24-7.22 (m, 3H), 7.07-7.06 (m, 2H), 3 
6.94 (d, 2H, J = 8.5 Hz), 6.78-6.75 (m, 2H), 5.25 (d, 1H, J = 6.3 4 
Hz), 5.00  (s, 1H),  4.90 (s, 1H), 3.77 (s, 3H), 2.71 (s, 1H), 1.39 5 
(s, 9H); 13C{1H} NMR (CDCl3, 126 MHz): δ 159.1, 155.8 6 
140.2, 140.1, 129.0, 128.2, 128.1, 127.8, 127.1, 126.8, 113.7, 7 
80.0, 79.3, 77.3, 55.3, 28.5; m/z (ESI) 366.2 [(M+Na)+, 100%]. 8 
9 
t-Butyl-((1S,2R)-1-(2-chlorophenyl)-2-hydroxy-2-phe-10 
nylethyl)carbamate 17i.  11 
This compound is novel and was prepared following the general 12 
procedure F using tert-butyl (1-(2-chlorophenyl)-2-oxo-2-phe-13 
nylethyl)carbamate 13i (0.173 g, 0.5 mmol, 1.0 eq) in MeCN (5 14 
mL), catalyst (R,R)-20 (5.3 mg, 7.5 µmol, 0.015 eq), DABCO 15 
(0.280 g, 2.50 mmol, 5.0 eq)  and formic acid (56 µL, 1.50 16 
mmol, 3.0 eq) for 96h when 95% conversion of ketone achieved 17 
(determined by 1H NMR), water (30 mL) to quench and DCM 18 
(2 x 10 mL) for extraction to generate the crude product which 19 
was purified by column chromatography (20% EtOAc in petro-20 
leum ether (40-60)) to give 17i as a white solid (0.150 g, 0.461 21 
mmol, 92.2%). TLC: Rf ca 0.4 (6:4, Hexane: EtOAc), less UV 22 
active, strong KMnO4 & PMA reactive; MP: 123-126 ºC; 23 
HRMS (ESI): found [M+Na]+ 370.1181, C19H22ClNNaO3 re-24 
quires [M+Na]+ 370.1180 (error -0.1 ppm);max 3371, 2977, 25 
1687, 1523, 1165, 773, 702 cm-1; Enantiomeric excess deter-26 
mined by HPLC analysis (Chiralpak IC, 250 mm x 4.6 mm 27 
column, iPrOH: hexane 12:88, 0.5 mL/min, 210 nm, T = 25 ºC), 28 
(1S,2R) 11.8 min, (1R,2S) 13.4 min, other diastereomer 35.1 29 
and 50.4 min; [α]D22 = -76.6 (c = 0.1 in CHCl3), dr: 95.5:0.5, 30 
major diastereomer 90.1% ee;  1H NMR (DMSO-d6, 500 31 
MHz): δ 7.65 (d, 1H, J = 7.4 Hz), 7.30-7.26 (m, 6H), 7.25-7.21 32 
(m, 3H), 5.35 (d, 1H, J = 4.1 Hz), 5.21 (t, 1H, J = 8.6 Hz), 4.72-33 
4.70 (m, 1H), 1.21 (s, 9H); 13C{1H} NMR (DMSO-d6, 126 34 
MHz): δ 154.9, 143.5, 139.9, 134.1, 129.8, 128.9, 128.6, 127.9, 35 
127.5, 127.2, 78.3, 75.6, 56.3, 28.6; m/z (ESI) 370.2 [(M+Na)+, 36 
100%], 372.2 [(M+2+Na)+, 35%]. 37 
38 
t- Butyl-((1S,2R)-1-(4-chlorophenyl)-2-hydroxy-2-phe-39 
nylethyl)carbamate 17j.  40 
This compound is novel and was prepared following the gen-41 
eral procedure F using tert-butyl (1-(4-chlorophenyl)-2-oxo-2-42 
phenylethyl)carbamate 13j (0.087 g, 0.25 mmol, 1.0 eq) in 43 
MeCN (2.5 mL), catalyst (R,R)-20 (2.7 mg, 3.8 µmol, 0.015 44 
eq), DABCO (0.140 g, 1.25 mmol, 5.0 eq)  and formic acid 45 
(28 µL, 0.75 mmol, 3.0 eq) for 72h when 100% conversion of 46 
ketone achieved (determined by 1H NMR), water (30 mL) to 47 
quench and obtained solid material was filtered and dried to 48 
give 17j as a white solid (0.080 g, 0.230 mmol, 92.2%). TLC: 49 
Rf ca 0.3 (6:4, Hexane: EtOAc), less UV active, strong 50 
KMnO4 & PMA reactive; MP: 191-193 ºC; HRMS (ESI): 51 
found [M+Na]+ 370.1182, C19H22ClNNaO3 requires [M+Na]+ 52 
370.1180 (error -0.6 ppm); max 3373, 2979, 1681, 1282, 53 
1167, 999, 703 cm-1; Enantiomeric excess determined by 54 
HPLC analysis (Chiralcel OD-H, 250 x 4,6 mm column, 55 
iPrOH: hexane 5:95, 1 mL/min, 210 nm, T = 25 ºC), (1R,2S)  56 
10.8 min, (1S,2R) 12.5 min, other diastereomer 6.5, 16.6 min; 57 
[α]D22 = -164.3 (c = 0.1 in CHCl3), dr: 99.5:0.5, 90.3% ee; 58 
1H NMR (CDCl3, 500 MHz): δ 7.26-7.24 (m, 3H), 7.18 (d, 2H, 59 
J = 8.3 Hz), 7.04-7.03 (m,  2H), 6.94 (d, 2H, J = 7.9 Hz), 5.38 60 
(s, 1H), 5.06 (s, 1H), 4.90 (s, 1H), 2.48 (s, 1H), 1.40 (s, 9H); 61 
13C{1H} NMR (CDCl3, 126 MHz): δ 155.4, 139.8, 133.3, 62 
129.2, 128.2, 128.1, 127.9, 126.4, 80.1, 76.7, 59.8, 28.3 m/z 63 




This compound is novel and was prepared following the general 68 
procedure F using tert-butyl (2-(4-chlorophenyl)-1-(4-methox-69 
yphenyl)-2-oxoethyl)carbamate 13k (0.089 g, 0.25 mmol, 1.0 70 
eq) in MeCN (2.5 mL), catalyst (R,R)-20 (2.7 mg, 3.8 µmol, 71 
0.015 eq), DABCO (0.140 g, 1.25 mmol, 5.0 eq)  and formic 72 
acid (28 µL, 0.750 mmol, 3.0 eq) for 72h when 100% conver-73 
sion of ketone achieved (determined by 1H NMR), water (20 74 
mL) to quench and obtained solid material was filtered and 75 
dried to give 17k as a brown solid (0.083 g, 0.233 mmol, 76 
93.5%). TLC: Rf ca 0.3 (6:4, Hexane: EtOAc), less UV active, 77 
strong KMnO4 & PMA reactive; MP: 208-211 ºC; HRMS 78 
(ESI): found [M+Na]+, 400.1284, C20H24ClNNaO4 requires 79 
[M+Na]+  400.1286 (error 0.5 ppm);max 3372, 2977, 1674, 80 
1495, 1296, 1240, 1168, 1000, 814, 541 cm-1; Enantiomeric ex-81 
cess determined by HPLC analysis (Chiralpak IG, 250 mm x 82 
4.6 mm column, iPrOH: hexane 20:80, 1 mL/min, 210 nm, T = 83 
25 ºC), (1S,2R) 7.9 min, (1R,2S) isomer 9.2 min, other diastere-84 
omer 12.8 min and 17.9 min; [α]D22 = -118 (c 0.1 in CHCl3), 85 
dr >99.9:<0.1%, major diastereomer 96.8% ee1H NMR 86 
(DMSO-d6, 500 MHz):δ 7.31 (s, 4H), 7.19 (d, 2H, J = 11.6 Hz), 87 
7.13 (d, 1H, J = 9.6 Hz), 6.81 (d, 2H, J = 8.5 Hz), 5.39 (d, 1H, 88 
J = 5.1 Hz), 4.63-4.61 (m, 1H), 4.48 (t, 1H, J = 8.7 Hz), 3.71 (s, 89 
3H), 1.20 (s, 9H); 13C{1H} NMR (DMSO-d6, 126 MHz): δ 90 
158.2, 154.6, 142.6, 133.2, 131.4, 129.3, 128.9, 127.5, 113.1, 91 




This compound is novel and was prepared following the general 96 
procedure F using tert-butyl (2-(furan-2-yl)-2-oxo-1-phe-97 
nylethyl)carbamate 13l (0.151 g, 0.50 mmol, 1.0 eq) in MeCN 98 
(5 mL), catalyst (R,R)-20 (5.3 mg, 7.5 µmol, 0.015 eq), DABCO 99 
(0.280 g, 2.50 mmol, 5.0 eq)  and formic acid (56 µL, 1.50 100 
mmol, 3.0 eq) for 72h when 100% conversion of ketone 101 
achieved (determined by 1H NMR), water (30 mL) to quench 102 
and DCM (2 x 10 mL) for extraction to generate the crude prod-103 
uct which was purified by column chromatography (30% 104 
EtOAc in petroleum ether (40-60)) to give 17l as a brown solid 105 
(0.120 g, 0.396 mmol, 79.2%). TLC: Rf ca 0.3 (6:4, Hexane: 106 
EtOAc), less UV active, strong KMnO4 & PMA reactive; MP: 107 
163-164 ºC, HRMS (ESI): found [M+Na]+ 326.1362, 108 
C17H21NNaO4 requires [M+Na]+  326.1363 (error 0.1 ppm); max 109 
3373, 2976, 1681, 1527, 1292, 1169, 1001, 734, 698 cm-1; En-110 
antiomeric excess determined by HPLC analysis (Chiralpak IC, 111 
250 mm x 4.6 mm column, iPrOH: hexane 10:90, 1 mL/min, 112 
210nm, T = 25 ºC), (1S, 2S) 10.4 min, (1R,2R) isomer 19.2 min, 113 
other diastereomer 14.1 min and 34.0; [α]D22 =  -42.3 (c 0.1 in 114 
CHCl3), dr, 96:4, major diastereomer 79.4% ee, minor dia-115 
stereomer 56.7%; 1H NMR (CDCl3, 500 MHz): δ 7.36 (s, 1H), 116 
7.28-7.22 (m, 3H), 7.09 (d, 2H, J = 7.8 Hz), 6.27 (d, 1H, J = 5.0 117 
Hz), 6.06 (d, 1H, J = 3.2 Hz), 5.45 (s, 1H), 5.12 (s, 1H), 4.98 (s, 118 
1H), 2.81 (s, 1H), 1.42 (s, 9H); 13C{1H} NMR  (CDCl3, 126 119 
MHz): δ 155.8 153.2, 142.2, 138.2, 128.5, 127.9, 127.2, 126.9, 120 







This compound is known and has been previously character-4 
ised:..29b,38This compound was prepared following the general 5 
procedure F using tert-butyl (1-oxo-1-phenylpropan-2-yl)car-6 
bamate (0.125 g, 0.5 mmol, 1.0 eq) in MeCN (5 mL), catalyst 7 
(R,R)-20 (5.3 mg, 7.5 µmol, 0.015 eq), DABCO (0.280 g, 2.50 8 
mmol, 5.0 eq)  and formic acid (56 µL, 1.50 mmol, 3.0 eq) for 9 
6 days when 76% conversion of ketone achieved (determined  10 
by 1H NMR), water (30 mL) to quench and DCM (2 x 10 mL) 11 
for extraction to generate the crude product which was purified 12 
by column chromatography (30% EtOAc in petroleum ether 13 
(40-60)) to give 24 as a colourless oil (0.066 g, 0.265 mmol, 14 
53.1%).  TLC: Rf ca 0.3 (6:4, Hexane: EtOAc) less UV active, 15 
strong KMnO4 & PMA reactive; HRMS (ESI): found [M+Na]+ 16 
274.1417, C14H21NNaO3 requires [M+Na]+  274.1414 (error 1.3 17 
ppm);max 3413, 2977, 1681, 1496, 1365, 1124, 1050, 734 cm-18 
1; Enantiomeric excess  determined by HPLC analysis (Chi-19 
ralpak IG, 250 mm x 4.6 mm column, iPrOH: hexane 12:88, 0.5 20 
mL/min, 210 nm, T = 25 ºC), (1R,2S) 10.9 min, (1S,2R) isomer 21 
11.7 min, other diastereomer 12.9 min and 23.8; dr: 79:21, ma-22 
jor diastereomer 34% ee (accuracy limited by overlap of peaks), 23 
minor diastereomer 82.3% ee; ) Major diastereomer 1H NMR 24 
(CDCl3, 500 MHz): δ 7.41-7.09 (m, 5H), 4.82-4.79 (m, 2H), 25 
3.97 (s, 1H), 3.55 (s, 1H), 1.45 (s, 9H), 0.96 (d, 3H, J = 6.9 Hz); 26 
13C{1H} NMR (CDCl3, 126 MHz): 156.3, 140.9, 128.1, 127.4, 27 
126.3, 79.7, 76.6, 52.01.99, 28.4, 14.7; m/z (ESI) 274.2 (M+Na, 28 
100%); Minor diastereomer 1H NMR (CDCl3, 500 MHz): δ 29 
7.41-7.09 (m, 5H), 4.82-4.79 (m,  1H), 4.53 (s, 1H), 3.85-3.84 30 
(d, 1H J = 5.8 Hz), 1.99 (s, 1H), 1.39 (s, 9H), 1.06 (s, 3H, J = 31 
6.9 Hz); 13C{1H} NMR  (CDCl3, 126 MHz): δ 156.3, 141.7, 32 
128.3, 127.7, 126.6, 79.7, 77.8 52.4, 28.3, 17.5; m/z (ESI) 274.2 33 
[(M+Na)+, 100%]. The data matches the reported data. 34 
35 
t-Butyl-((1S,2R)-2-hydroxy-1-phenylpropyl)carbamate 26. 36 
This compound is known and has been previously character-37 
ised.29 This compound was prepared following the general pro-38 
cedure F using tert-butyl (2-oxo-1-phenylpropyl)carbamate 39 
(0.125 g, 0.5 mmol, 1.0 eq) in MeCN (5 mL), catalyst (R,R)-20 40 
(5.3 mg, 7.5 µmol, 0.015 eq), DABCO (0.280 g, 2.50 mmol, 5.0 41 
eq)  and formic acid (56 µL, 1.50 mmol, 3.0 eq) for 24 h when 42 
100% conversion of ketone achieved (determined by 1H NMR), 43 
water (30 mL) to quench and DCM (2 x 10 mL) for extraction 44 
to generate the crude product which was purified by column 45 
chromatography (30% EtOAc in petroleum ether (40-60)) to 46 
give 26 as a brown solid (0.109 g, 0.434 mmol, 86.8%). TLC: 47 
Rf ca 0.3 (6:4, Hexane: EtOAc), less UV active, strong KMnO4 48 
& PMA reactive; MP: 113-116 ºC; HRMS (ESI): found 49 
[M+Na]+ 274.1410, C14H21NNaO3 requires [M+Na]+  274.1414 50 
(error 1.3 ppm); max 3371, 2976, 1679, 1520, 1368, 1291, 1165, 51 
1009, 877, 698 cm-1; Enantiomeric excess determined by HPLC 52 
analysis (Chiralpak IG, 250 mm x 4.6 mm column, iPrOH: 53 
hexane 12:88, 0.5 mL/min, 210 nm, T = 25 ºC), (1S,2R) 15.8 54 
min, (1R,2S) 19.5 min, other diastereomer 20.9 min and 24.7; 55 
[α]D22 = + 22.6 (c = 0.1 in CHCl3), dr, 98.3: 1.7, 94.6% ee; 56 
litabove  [α]20 D = +24.0 (c = 0.1, CHCl3); 1H NMR (CDCl3, 500 57 
MHz): δ 7.36 – 7.26 (m, 5H), 5.42 (d, 1H, J = 6.8 Hz), 4.62 (s, 58 
1H), 4.07 (s, 1H), 1.89 (s, 1H), 1.42 (s, 9H), 1.08 (s, 3H, J = 6.4 59 
Hz); 13C{1H} NMR  (CDCl3, 126 MHz): δ 155.8 138.4, 128.6, 60 
127.8, 126.7 79.9, 70.5, 60.2, 28.5, 19.8; m/z (ESI) 274.2 61 
[(M+Na)+, 100%]. The data matches the reported data.  62 
 63 
N-((1S,2R)-2-Hydroxy-2-(2-methoxyphenyl)-1-phe-64 
nylethyl)-4-methylbenzene sulfonamide 18b. 65 
This compound is novel  and  was prepared following the gen-66 
eral procedure F using N-(2-(2-methoxyphenyl)-2-oxo-1-phe-67 
nylethyl)-4-methylbenzenesulfonamide 14b (0.197 g, 0.5 68 
mmol, 1.0 eq) in MeCN (5 mL), catalyst (R,R)-2 (4.7 mg, 7.5 69 
µmol, 0.015 eq), DABCO (0.280 g, 2.50 mmol, 5.0 eq)  and 70 
formic acid (56 µL, 1.50 mmol, 3.0 eq) for 24 h when 100% 71 
conversion of ketone achieved (determined by 1H NMR), water 72 
(30 mL) to quench and DCM (2 x 10 mL) for extraction to gen-73 
erate the crude product which was purified by column chroma-74 
tography (20-60% EtOAc in petroleum ether (40-60)) to give 75 
18b as a white solid (0.158 g, 0.396 mmol, 79.3%). TLC: Rf ca 76 
0.2 (8:2, Hexane: EtOAc), less UV active, strong KMnO4 & 77 
PMA reactive; MP: 120-121 ºC; HRMS (ESI): found [M+Na]+ 78 
420.1242, C22H23NNaO4S requires [M+Na]+ 420.1240 (error -79 
0.4 ppm);max 3519, 3324, 1323, 1236, 1158, 1053, 536 cm-1; 80 
Enantiomeric excess determined by HPLC analysis (Chiralpak 81 
IC, 250 mm x 4.6 mm column, iPrOH: hexane 20:80, 1 mL/min, 82 
210 nm, T = 25 ºC), (1S,2R)  21.2 min, (1R,2S) isomer 28.1min, 83 
other diastereomer 45.0 min and 66.2 min; [α]D22 = -42.3 (c = 84 
0.1 in CHCl3), dr: >99.9:<0.1, 95.2% ee;  1H NMR (CDCl3, 85 
500 MHz): δ 7.48 (d, 2H, J = 8.2 Hz), 7.18 (m, 1H), 7.14-7.06 86 
(m,  5H), 6.91-6.88 (m, 3H), 6.79-6.74 (m, 2H), 5.70 (d, 1H, J 87 
= 7.5 Hz), 5.13 (t, 1H, J = 5.8 Hz), 4.57-4.55 (m, 1H), 3.64 (s, 88 
3H), 2.71 (d, 1H, J = 6.6 Hz), 2.34 (s, 3H); 13C{1H} NMR  89 
(CDCl3, 126 MHz: δ 156.2, 142.9, 137.5, 137.1, 129.4, 129.0, 90 
128.0, 127.9, 127.6, 127.1, 120.9, 110.5, 62.4, 55.4, 21.6; m/z 91 
(ESI) 420.3 [(M+Na)+, 100%]. 92 
 93 
N-((1S,2R)-2-Hydroxy-2-(3-methoxyphenyl)-1-phe-94 
nylethyl)-4-methylbenzene sulfonamide 18c.95 
This compound is novel and was prepared following the general 96 
procedure F using N-(2-(3-methoxyphenyl)-2-oxo-1-phe-97 
nylethyl)-4-methylbenzenesulfonamide 14c (0.100 g, 0.25 98 
mmol, 1.0 eq) in MeCN (2.5 mL), catalyst (R,R)-2 (2.3 mg, 3.8 99 
µmol, 0.015 eq), DABCO (0.140 g, 1.25 mmol, 5.0 eq)  and 100 
formic acid (28 µL, 0.750 mmol, 3.0 eq) for 24 h when 100% 101 
conversion of ketone achieved (determined by 1H NMR), water 102 
(20 mL) to quench and DCM (2 x 5 mL) for extraction to gen-103 
erate the crude product which was purified by column chroma-104 
tography (30% EtOAc in petroleum ether (40-60)) to give 18c 105 
as a white solid (0.085 g, 0.214 mmol, 85.6%). TLC: Rf ca 0.2 106 
(8:2, Hexane: EtOAc), less UV active, strong KMnO4 & PMA 107 
reactive; MP: 153-155 ºC; HRMS (ESI): found [M+Na]+ 108 
420.1239, C22H23NNaO4S requires [M+Na]+ 420.1240 (error 109 
0.3 ppm);max 3482, 3317, 1312, 1247, 1151, 1086, 560 cm-1; 110 
Enantiomeric excess determined by HPLC analysis (Chiralpak 111 
IC, 250 mm x 4.6 mm column, iPrOH: hexane 20:80, 1 mL/min, 112 
210 nm, T = 25 ºC), (1S,2R) 24.1 min, (1R,2S) 26.2 min, other 113 
diastereomer 51.9 min and 81.2 min; [α]D22 = -17.4 (c = 0.1 in 114 
CHCl3), dr: 98.3: 1.7, major diastereomer 94.4 % ee; 1H NMR 115 
(CDCl3, 500 MHz): δ 7.48 (d, 2H, J = 8.2 Hz), 7.16-7.07 (m,  116 
6H), 6.87 (d, 2H, J = 7.4 Hz), 6.75 (d, 1H, J = 10.3 Hz), 6.58 (d, 117 
1H, J = 7.6 Hz), 6.40 (s, 1H), 5.32 (d, 1H, J = 7.8 Hz), 4.95 (t, 118 
1H, J = 4.5 Hz), 4.52-4.50 (m, 1H), 3.61 (s, 3H), 2.37 (d, 1H, J 119 
= 4.6 Hz), 2.33 (s, 3H); 13C{1H} NMR  (CDCl3, 126 MHz): δ 120 
159.6, 143.3, 140.8, 137.1, 136.1, 129.5, 129.4, 128.1, 128.1, 121 
20 
 
127.8, 127.2, 118.9, 114.4, 111.6, 76.9, 63.2, 55.2 21.6; m/z 1 
(ESI) 420.2 [(M+Na)+, 100%]. 2 
 3 
N-((1S,2R)-2-Hydroxy-2-(2-chlorophenyl)-1-phenylethyl)-4 
4-methylbenzene sulfonamide 18d. 5 
This compound is novel and was prepared following the general 6 
procedure F using N-(2-(2-chlorophenyl)-2-oxo-1-phe-7 
nylethyl)-4-methylbenzenesulfonamide 14d (0.100 g, 0.25 8 
mmol, 1.0 eq) in MeCN (2.5 mL), catalyst (R,R)-2 (2.3 mg, 3.8 9 
µmol, 0.015 eq), DABCO (0.140 g, 1.25 mmol, 5.0 eq)  and 10 
formic acid (28 µL, 0.750 mmol, 3.0 eq) for 24 h when 100% 11 
conversion of ketone achieved (determined by 1H NMR), water 12 
(20 mL) to quench and DCM (2 x 5 mL) for extraction to gen-13 
erate the crude product which was purified by column chroma-14 
tography (30% EtOAc in petroleum ether (40-60)) to give 18d 15 
as a white solid (0.044 g, 0.109 mmol, 43.9%). TLC: Rf ca 0.2 16 
(8:2, Hexane: EtOAc), less UV active, strong KMnO4 & PMA 17 
reactive; MP: 150-153 ºC; HRMS (ESI): found [M+Na]+ 18 
424.0746, C21H20ClNNaO3S requires [M+Na]+ 424.0745 (error 19 
-0.3 ppm);max 3483, 3319, 1409, 1302, 1155, 1030, 659 cm-1; 20 
Enantiomeric excess determined by HPLC analysis (Chiralpak 21 
IG, 250 mm x 4.6 mm column, iPrOH: hexane 20:80, 1 mL/min, 22 
210 nm, T = 25 ºC), (1R,2S) 17.3 min, (1S,2R) isomer 20.6 min, 23 
other diastereomer 24.0 min and 37.1 min; [α]D22 = -271.6 (c = 24 
0.1 in CHCl3), dr: >99.9:<0.1, 89% ee; 1H NMR (CDCl3, 500 25 
MHz): δ 7.59 (d, 2H, J = 8.2 Hz), 7.26-7.23 (d, 1H, J = 3.8 Hz), 26 
7.11-7.07 (m,  4H), 7.00 (t, 2H, J = 7.6 Hz), 6.92 (t, 1H, J = 7.5 27 
Hz), 6.81-6.80 (m, 3H), 5.87 (d, 1H, J = 8.1 Hz), 5.45 (s, 1H), 28 
4.69-4.67 (m, 1H), 2.74 (s, 1H), 2.31 (s, 3H); 13C{1H} NMR  29 
(CDCl3, 126 MHz): δ 143.3, 137.4, 137.2, 135.8, 131.7, 129.5, 30 
129.0, 128.9, 128.3, 128.2, 127.8, 127.7, 127.3, 126.6 72.9, 31 
60.6, 21.6; m/z (ESI) 424.2 [(M+Na)+, 100%], 426.1 32 
[(M+2+Na)+, 35%]. 33 
 34 
N-((1S,2R)-2-Hydroxy-2-(3-chlorophenyl)-1-phenylethyl)-35 
4-methylbenzene sulfonamide 18e.36 
This compound is novel and was prepared following the general 37 
procedure F using N-(2-(3-chlorophenyl)-2-oxo-1-phe-38 
nylethyl)-4-methylbenzenesulfonamide 14e (0.100 g, 0.25 39 
mmol, 1.0 eq) in MeCN (2.5 mL), catalyst (R,R)-2 (2.3 mg, 3.8 40 
µmol, 0.015 eq), DABCO (0.140 g, 1.25 mmol, 5 eq)  and for-41 
mic acid (28 µL, 0.750 mmol, 3 eq) for 24 h when 100% con-42 
version of ketone achieved (determined by 1H NMR), water (20 43 
mL) to quench and obtained solid material was filtered and 44 
dried to give 18e as a brown solid (0.090 g, 0.229 mmol, 45 
89.7%). TLC: Rf ca 0.2 (8:2, Hexane: EtOAc), less UV active, 46 
strong KMnO4 & PMA reactive; MP: 210-213 ºC; HRMS 47 
(ESI): found [M+Na]+ 424.0744, C21H20ClNNaO3S requires 48 
[M+Na]+ 424.0745 (error 0.2 ppm);max 3466, 3325, 1404, 49 
1289, 1152, 1032, 530 cm-1; Enantiomeric excess determined 50 
by HPLC analysis (Chiralpak IC, 250 mm x 4.6 mm column, 51 
iPrOH: hexane 20:80, 1 mL/min, 210 nm, T = 25 ºC), (1S,2R)  52 
10.9 min, (1R,2S) 12.5 min, other diastereomer 26.2 min and 53 
30.1 min; [α]D22 = -40 (c = 0.1 in CHCl3), dr: >99.9:<0.1, 54 
94.2% ee; 1H NMR (DMSO-d6, 500 MHz): δ 8.14 (d, 1H, J = 55 
10.0 Hz), 7.26 (d,  2H, J = 8.2 Hz), 7.22-7.21 (m, 2H), 7.15-56 
7.13 (m,  2H), 7.10 (s, 5H), 7.05 (d, 2H, J = 8.0 Hz), 5.52 (d, 57 
1H, J = 10.0 Hz), 4.58-4.56 (m, 1H), 4.24 (m, 1H), 2.27 (s, 3H); 58 
13C{1H} NMR  (DMSO-d6, 126 MHz): δ 145.9, 142.2, 139.8, 59 
138.9, 132.9, 129.9, 129.4, 128.6, 127.7, 127.4, 127.2, 127.1, 60 
126.5, 126.1, 75.2, 63.6, 21.4; m/z (ESI) 424.2 [(M+Na)+, 61 
100%], 426.2 [(M+2+Na)+, 35%]. 62 
63 
N-((1S,2R)-2-Hydroxy-2-(4-chlorophenyl)-1-phenylethyl)-64 
4-methylbenzene sulfonamide 18f. 65 
This compound is known however it has not been fully charac-66 
terized previously.40 This compound was prepared following 67 
the general procedure F using N-(2-(4-chlorophenyl)-2-oxo-1-68 
phenylethyl)-4-methylbenzenesulfonamide 14f (0.199 g, 0.50 69 
mmol, 1.0 eq) in MeCN (5 mL), catalyst (R,R)-2 (4.7 mg, 7.5 70 
µmol, 0.015 eq), DABCO (0.280 g, 2.50 mmol, 5.0 eq)  and 71 
formic acid (56 µL, 1.50 mmol, 3.0 eq) for 24 h when 100% 72 
conversion of ketone achieved (determined by 1H NMR),  water 73 
(30 mL) to quench and DCM (2 x 10 mL) for extraction to gen-74 
erate the crude product which was purified by column chroma-75 
tography (80% EtOAc in petroleum ether (40-60)) to give 18f 76 
as a white solid (0.090 g, 0.224 mmol, 44.8%). TLC: Rf ca 0.3 77 
(7:3, Hexane: EtOAc), less UV active, strong KMnO4 & PMA 78 
reactive; MP: 243-245 ºC; HRMS (ESI): found [M+Na]+ 79 
424.0746, C21H20ClNNaO3S requires [M+Na]+ 424.0745 (error 80 
0.4 ppm);max 3460, 3321, 1457, 1309, 1150, 1087, 722 cm-1; 81 
Enantiomeric excess determined by HPLC analysis (Chiralpak 82 
IC, 250 mm x 4.6 mm column, iPrOH: hexane 20:80, 1 mL/min, 83 
210 nm, T = 25 ºC), (1S,2R)  11.0 min, (1R,2S) isomer 12.9 min, 84 
other diastereomer 21.7 min and 44.4 min; [α]D22 = -25.6 (c = 85 
0.1 in THF), dr: 97.7:2.3, major diastereomer 88.5% ee; 1H 86 
NMR (DMSO-d6, 500 MHz): δ 8.15 (d, 1H, J = 9.6 Hz), 7.25 87 
(d, 2H, J = 8.2 Hz), 7.19 (d, 2H, J = 8.5 Hz), 7.14 (d, 2H, J = 88 
8.4 Hz), 7.11 (s, 5H), 7.06 (d, 2H, J = 8.0 Hz), 5.45 (d, 1H, J = 89 
5.0 Hz), 4.58-4.56 (m, 1H), 4.23 – 4.20 (m, 1H), 2.29 (s, 3H); 90 
13C{1H} NMR  (DMSO-d6, 126 MHz): δ 142.3, 142.1, 134.0, 91 
139.0, 132.0, 129.4, 129.1, 128.6, 127.9, 127.7, 127.1, 126.5, 92 





This compound is novel and was prepared following the general 98 
procedure F using N-(1-(2-methoxyphenyl)-2-oxo-2-phe-99 
nylethyl)-4-methylbenzenesulfonamide 14g (0.198 g, 0.50 100 
mmol, 1.0 eq) in MeCN (5 mL), catalyst (R,R)-2 (4.7 mg, 7.5 101 
µmol, 0.015 eq), DABCO (0.280 g, 2.50 mmol, 5.0 eq)  and 102 
formic acid (56 µL, 1.50 mmol, 3.0 eq) for 48h when 100% 103 
conversion of ketone achieved (determined by 1H NMR), water 104 
(30 mL) to quench and DCM (2 x 10 mL) for extraction to gen-105 
erate the crude product which was purified by column chroma-106 
tography (30% EtOAc in petroleum ether (40-60)) to give 18g 107 
as a colourless semi solid (0.170 g, 0.428 mmol, 85.6%). TLC: 108 
Rf ca 0.2 (8:2, Hexane: EtOAc) less UV active, strong KMnO4 109 
& PMA reactive; HRMS (ESI): found [M+Na]+ 420.1242, 110 
C22H23NNaO4S requires [M+Na]+ 420.1240 (error -0.4 111 
ppm);max 3392, 2926, 1493, 1244, 1155, 1001, 750 cm-1; En-112 
antiomeric excess determined by HPLC analysis (Chiralpak IC, 113 
250 mm x 4.6 mm column, iPrOH: hexane 20:80, 1 mL/min, 114 
210 nm, T = 25 ºC), (1S,2R)  34.9 min, (1R,2S) 40.7 min, other 115 
diastereomer 74.5 min and 122.3 min; [α]D22 = -30 (c = 0.1 in 116 
CHCl3), dr: 94.8: 5.2, major diastereomer 80.2% ee; 1H NMR 117 
(CDCl3, 500 MHz): δ 7.43 (d, 2H, J = 7.9 Hz), 7.20-7.19 (m, 118 
3H), 7.11 (t, 1H, J = 7.8 Hz), 7.04 (s, 2H), 6.99 (d, 2H, J = 7.9 119 
Hz), 6.77 (d, 1H, J = 7.4 Hz), 6.70 (t, 1H, J = 7.4 Hz), 6.59 (d, 120 
1H, J = 8.2 Hz), 5.70 (d, 1H, J = 9.8 Hz), 4.94 (t, 1H, J = 5.2 121 
21 
 
Hz), 4.81-4.78 (m, 1H), 3.51 (s, 3H), 2.64 (d, 1H, J = 5.2 Hz), 1 
2.28 (s, 3H); 13C{1H} NMR (CDCl3, 126 MHz): δ 156.5, 143.0, 2 
139.9, 137.3, 130.2, 129.2, 129.1, 128.0, 127.9, 127.0, 126.9, 3 
124.3, 120.6, 110.7, 76.1, 61.2, 55.3, 21.5; m/z (ESI) 420.3 4 
[(M+Na)+, 100%]. 5 
 6 
N-((1S,2R)-2-Hydroxy-1-(4-methoxyphenyl)-2-phe-7 
nylethyl)-4-methylbenzenesulfonamide 18h. 8 
This compound is novel and was prepared following the general 9 
procedure F using N-(1-(4-methoxyphenyl)-2-oxo-2-phe-10 
nylethyl)-4-methylbenzenesulfonamide 14h (0.198 g, 0.50 11 
mmol, 1.0 eq) in MeCN (5 mL), catalyst (R,R)-2 (4.7 mg, 7.5 12 
µmol, 0.015 eq), DABCO (0.280 g, 2.50 mmol, 5.0 eq)  and 13 
formic acid (56 µL, 1.50 mmol, 3.0 eq) for 24 h when 100% 14 
conversion of ketone achieved (determined by 1H NMR), water 15 
(30 mL) to quench and obtained solid material was filtered and 16 
dried to give 18h as a brown solid (0.189 g, 0.476 mmol, 17 
95.2%). TLC: Rf ca 0.3 (7:3, Hexane: EtOAc), less UV active, 18 
strong KMnO4 & PMA reactive; MP: 201-203 ºC; HRMS 19 
(ESI): found [M+Na]+ 420.1238, C22H23NNaO4S requires 20 
[M+Na]+ 420.1240 (error 0.4 ppm);max 3480, 3321, 2972, 21 
1513, 1303, 1151, 1055, 540 cm-1; Enantiomeric excess deter-22 
mined by HPLC analysis (Chiralpak IC, 250 mm x 4.6 mm 23 
column, iPrOH: hexane 20:80, 1 mL/min, 210 nm, T = 25 ºC), 24 
(1S,2R)  25.8 min, (1R,2S) 33.9 min, other diastereomer 60.0 25 
min; [α]D22 = -27.6 (c = 0.1 in CHCl3), dr:  98.2:1.8, major 26 
diastereomer 90.2% ee; 1H NMR (CDCl3, 500 MHz): δ 7.48 27 
(d, 2H, J = 8.0 Hz), 7.21-7.20 (m, 3H), 7.09 (d, 2H, J = 7.8 Hz), 28 
6.96 (d, 2H, J = 6.3 Hz), 6.75 (d, 2H, J = 8.3 Hz), 6.60 (d, 2H, 29 
J = 8.2 Hz), 5.21 (d, 1H, J = 7.4 Hz), 4.95 (s, 1H), 4.49-4.47 (m, 30 
1H), 3.73 (s, 3H), 2.35 (s, 3H), 2.31 (s, 1H); 13C{1H} NMR 31 
(CDCl3, 126 MHz): δ 159.2, 143.2, 139.3, 137.3, 129.5, 129.3, 32 
128.4 128.2, 128.0, 127.2, 126.7, 113.5, 76.9, 62.8, 55.3, 21.6; 33 




This compound is novel and was prepared following the general 38 
procedure F using N-(1-(2-chlorophenyl)-2-oxo-2-phe-39 
nylethyl)-4-methylbenzenesulfonamide 14i (0.100 g, 0.25 40 
mmol, 1.0 eq) in MeCN (2.5 mL), catalyst (R,R)-2 (2.3 mg, 3.8 41 
µmol, 0.015 eq), DABCO (0.140 g, 1.25 mmol, 5.0 eq)  and 42 
formic acid (28 µL, 0.750 mmol, 3.0 eq) for 48h when 100% 43 
conversion of ketone achieved (determined by 1H NMR), water 44 
(30 mL) to quench and DCM (2 X 10 mL) for extraction to gen-45 
erate the crude product which was purified by column chroma-46 
tography (20% EtOAc in petroleum ether (40-60)) to give 18i 47 
as a white solid (0.070 g, 0.174 mmol, 69.8%). TLC: Rf ca 0.2 48 
(7:3, Hexane: EtOAc), less UV active, strong KMnO4 & PMA 49 
reactive; MP: 143- 146 ºC; HRMS (ESI): found [M+Na]+ 50 
424.0744, C21H20ClNNaO3S requires [M+Na]+ 424.0745 (error 51 
0.2 ppm);max 3502, 3356, 2954, 1297, 1152, 1065, 535 cm-1; 52 
Enantiomeric excess determined by HPLC analysis (Chiralpak 53 
IC, 250 mm x 4.6 mm column, iPrOH: hexane 20:80, 1 mL/min, 54 
210 nm, T = 25 ºC), (1S,2R) 15.9 min, (1R,2S) 17.8 min, other 55 
diastereomer 25.3 min and 38.1 min; [α]D22 = -17.6 (c = 0.1 in 56 
CHCl3), dr: 88: 12, major diastereomer 79.8% ee, minor dia-57 
stereomer 18.3% ee; 1H NMR (CDCl3, 600 MHz): δ 7.51 (d, 58 
2H, J = 8.1 Hz), 7.24-7.20 (m, 1H), 7.19-7.16 (m, 2H), 7.11 (d, 59 
1H, J = 7.9 Hz), 7.08-7.06 (m, 3H), 7.00-6.92 (m, 4H), 5.34 (d, 60 
1H, J = 8.4 Hz), 5.15 (d, 1H, J = 7.6 Hz), 5.07-5.06 (m, 1H), 61 
2.37 (d, 1H, J = 3.6 Hz), 2.32 (s, 3H); 13C{1H} NMR (CDCl3, 62 
151 MHz): δ 143.4, 138.5, 136.8, 134.2, 133.6, 129.8, 129.5, 63 
129.2, 128.9, 128.5, 128.3, 127.2, 127.0, 126.9, 126.5, 125.8, 64 
75.7, 74.6, 21.6; m/z (ESI) 424.2 [(M+Na)+, 100%], 426.3 65 
[(M+2+Na)+, 35%]. 66 
67 
N-((1S,2R)-1-(4-Chlorophenyl)-2-hydroxy-2-phenylethyl)-68 
4-methylbenzenesulfonamide 18j. 69 
This compound is novel and was prepared following the general 70 
procedure F using N-(1-(4-chlorophenyl)-2-oxo-2-phe-71 
nylethyl)-4-methylbenzenesulfonamide 14j (0.200  g, 0.5 72 
mmol, 1.0 eq) in MeCN (5 mL), catalyst (R,R)-2 (4.6 mg, 7.5 73 
µmol, 0.015 eq), DABCO (0.280g, 2.50 mmol, 5.0 eq)  and for-74 
mic acid (56 µL, 1.50 mmol, 3.0 eq) for 24 h when 100% con-75 
version of ketone achieved (determined by 1H NMR), water (30 76 
mL) to quench and obtained solid material was filtered and 77 
dried to give 18j as a white solid (0.170 g, 0.424 mmol, 84.8%). 78 
TLC: Rf ca 0.2 (7:3, Hexane: EtOAc), less UV active, strong 79 
KMnO4 & PMA reactive; MP:  232-236 ºC; HRMS (ESI): 80 
found [M+Na] + 424.0747, C21H20ClNNaO3S requires [M+Na]+ 81 
424.0745 (error -0.7 ppm);max 3462, 3323, 1314, 1150, 1057, 82 
537 cm-1; Enantiomeric excess determined by HPLC analysis 83 
(Chiralpak IC, 250 mm x 4.6 mm column, iPrOH: hexane 84 
20:80, 1 mL/min, 210 nm, T = 25 ºC), (1S,2R) 11.2 min, (1R,2S) 85 
13.9 min, other diastereomer 23.8 min and 45.8 min; [α]D22 = -86 
114.6 (c = 0.1 in THF), dr: 97.7:2.3, major diastereomer 87 
92.4% ee; minor diastereomer >99 % ee 1H NMR (DMSO-d6, 88 
500 MHz): δ 8.15 (d, 1H, J = 8.8 Hz), 7.28 (d, 2H, J = 7.8 Hz), 89 
7.23 – 7.19 (m, 3H), 7.14 (d, 2H, J = 7.2 Hz), 7.07-7.06 (m, 4H), 90 
6.99 (d, 2H, J = 8.1 Hz), 5.45 (d, 1H, J = 4.5 Hz), 4.64 – 4.62 91 
(m, 1H), 4.28 (t, 1H, J = 7.5 Hz), 2.28 (s, 3H); 13C{1H} NMR 92 
(DMSO-d6, 126 MHz): δ 142.5, 141.8, 138.4, 137.7, 131.2, 93 
130.1, 128.9, 127.6, 127.1, 126.9, 126.7, 126.2, 75.1, 62.7, 20.8; 94 
m/z (ESI) 424.2 [(M+Na)+, 100%], 426.3 [(M+2+Na)+, 35%]. 95 
 96 
N-((1S,2R)-2-(4-Chlorophenyl)-2-hydroxy-1-(4-methoxy-97 
phenyl)ethyl)-4-methylbenzenesulfonamide 18k. 98 
This compound is novel and  was prepared following the gen-99 
eral procedure F using N-(2-(4-chlorophenyl)-1-(4-methoxy-100 
phenyl)-2-oxoethyl)-4-methylbenzenesulfonamide 14k (0.107 101 
g, 0.25 mmol, 1.0 eq) in MeCN (2.5 mL), catalyst (R,R)-2 (2.3 102 
mg, 3.8 µmol, 0.015 eq), DABCO (0.140 g, 1.25 mmol, 5.0 eq)  103 
and formic acid (28 µL, 0.750 mmol, 3.0 eq) for 48h when 104 
100% conversion of ketone achieved (determined by 1H NMR), 105 
water (20 mL) to quench and obtained solid material was fil-106 
tered and dried to give 18k as a white solid (0.095 g, 0.220 107 
mmol, 88.2%).  TLC: Rf ca 0.2 (7:3, Hexane: EtOAc), less UV 108 
active, strong KMnO4 & PMA reactive; MP: 240-243 ºC; 109 
HRMS (ESI): found [M+Na]+ 454.0850, C22H22ClNNaO4S re-110 
quires [M+Na]+ 454.0850 (error 0.0 ppm);max 3527, 3235, 111 
1512, 1311, 1238, 1157, 1029, 815, 664, 573, 536 cm-1; Enan-112 
tiomeric excess determined by HPLC analysis (Chiralpak IC, 113 
250 mm x 4.6 mm column, iPrOH: hexane 20:80, 1 mL/min, 114 
210 nm, T = 25 ºC), (1S,2R) 15.8 min, (1R,2S) isomer 19.3 min, 115 
other diastereomer 34.9 min and 68.3 min; [α]D22 = -139.2 (c = 116 
0.05 in THF), dr: >99.9:<0.1, 97.6% ee; 1H NMR (DMSO-d6, 117 
600 MHz): δ 8.05 (d, 1H, J = 9.5 Hz), 7.26 (d, 2H, J = 8.1 Hz), 118 
7.20 (d, 2H, J = 8.3 Hz), 7.13 (d, 2H, J = 8.4 Hz), 7.06 (d, 2H, 119 
J = 8.0 Hz), 6.98 (d, 2H, J = 8.5 Hz), 6.64 (d, 2H, J = 8.5 Hz), 120 
5.42 (d, 1H, J = 4.9 Hz), 4.57-4.55 (m, 1H), 4.18-4.15 (m, 1H)), 121 
3.67 (s, 3H), 2.29 (s, 3H); 13C{1H} NMR (DMSO-d6, 151 122 
22 
 
MHz): δ 158.1, 141.9, 141.6, 138.6, 131.5, 131.3 129.3, 128.9, 1 
128.6, 127.5, 126.1, 112.7, 74.7, 62.7, 55.0, 20.9; m/z (ESI) 2 




This compound is novel and was prepared following the general 7 
procedure F using N-(2-(furan-2-yl)-2-oxo-1-phenylethyl)-4-8 
methylbenzenesulfonamide 14l (0.178 g, 0.5 mmol, 1.0 eq) in 9 
MeCN (5 mL), catalyst (R,R)-2 (4.7 mg, 7.5 µmol, 0.015 eq), 10 
DABCO (0.280 g, 2.50 mmol, 5.0 eq)  and formic acid (56 µL, 11 
1.50 mmol, 3.0 eq) for 48h when 100% conversion of ketone 12 
achieved (determined by 1H NMR), water (30 mL) to quench 13 
and DCM (2 x 10 mL) for extraction to generate the crude prod-14 
uct which was purified by column chromatography (40% 15 
EtOAc in petroleum ether (40-60)) to give 18l as a white solid 16 
(0.165 g, 0.462 mmol, 92.4%). TLC: Rf ca 0.3 (6:4, Hexane: 17 
EtOAc),  less UV active, strong KMnO4 & PMA reactive; 18 
HRMS (ESI): found [M+Na]+ 380.0926, C19H19NNaO4S re-19 
quires [M+Na]+  380.0927 (error 0.4 ppm);max 3460, 1414, 20 
1318, 1156, 1089, 1060, 809, 698, 663, 564 cm-1; Enantiomeric 21 
excess determined by HPLC analysis (Chiralpak IG, 250 mm x 22 
4.6 mm column, iPrOH: hexane 20:80, 1 mL/min, 210 nm, T = 23 
25 ºC), (1S, 2S) 23.4 min, (1R,2R) isomer 27.3 min, other dia-24 
stereomer 35.3 min and 49.1; dr: 55:45, major diastereomer 25 
72.2% ee, minor diastereomer 97.7% ee;  1H NMR (CDCl3, 500 26 
MHz)  Diastereomer 1: δ  7.54 (d, 2H, J = 8.3 Hz), 7.32-7.30 27 
(m, 1H), 7.14-7.06 (m, 5H), 6.86 (d, 2H, J = 7.2 Hz), 6.22 (d, 28 
1H, J = 1.9 Hz), 6.00 (d, 1H, J = 3.3 Hz), 5.75 – 5.66 (m, 1H), 29 
4.92-4.89 (m, 1H), 4.77 – 4.75 (m, 1H), 2.67-2.59 (m, 1H), 2.32 30 
(s, 3H); Diastereomer 2: δ 7.48 (d, 2H, J = 8.3 Hz), 7.24 (s, 31 
1H), 7.14-7.06 (m, 5H), 7.01 (d, 2H, J = 8.0 Hz), 6.19 (d, 1H, J 32 
= 5.0 Hz), 6.13 (d, 1H, J = 3.3 Hz), 5.75-5.66 (m, 1H), 4.81 – 33 
4.79 (m, 1H), 4.68 (t, 1H, J = 6.4 Hz), 2.71 (d, 1H, J = 4.9 Hz), 34 
2.33 (s, 3H); 13C{1H} NMR (CDCl3, 126 MHz) both diastere-35 
omers: δ 152.2, 152.1, 143.3, 143.1, 142.4, 142.3, 137.5, 137.2, 36 
137.2, 136.2, 129.5, 129.4, 129.4, 128.2, 127.9, 127.8, 127.4, 37 
127.3, 127.2, 127.2, 110.5, 110.4, 108.7, 108.4, 71.5, 71.1, 61.8, 38 
61.6, 21.5; m/z (ESI) 380.2 [(M+Na)+, 100%]. 39 
40 
N-((1S,2R)-2-Hydroxy-1,2-diphenylethyl)methanesulfona-41 
mide 23. 42 
This compound is known and has been previously character-43 
ised.41 This compound was prepared following the general pro-44 
cedure F using N-(2-oxo-1,2-diphenylethyl)methanesulfona-45 
mide  (0.144 g, 0.5 mmol, 1.0 eq) in MeCN (5 mL), catalyst 46 
(R,R)-2 (4.7 mg, 7.5 µmol, 0.015 eq), DABCO (0.280 g, 2.50 47 
mmol, 5.0 eq)  and formic acid (56 µL, 1.50 mmol, 3.0 eq) for 48 
24 h when 100% conversion of ketone achieved (determined by 49 
1H NMR), water (30 mL) to quench and DCM (2 x 10 mL) for 50 
extraction to generate the crude product which was purified by 51 
column chromatography (30% EtOAc in petroleum ether (40-52 
60)) to give 23 as a white solid (0.110 g, 0.395 mmol, 79.0%). 53 
TLC: Rf ca 0.4 (6:4, Hexane: EtOAc), less UV active, strong 54 
KMnO4 & PMA reactive; MP: 152-155 ºC; HRMS (ESI): found 55 
[M+Na]+ 314.0823, C15H17NNaO3S requires [M+Na]+ 56 
314.0921 (error -0.5 ppm);max 3486, 3320, 1455, 1407, 1301, 57 
1145, 1056, 981, 159, 696 cm-1; Enantiomeric excess deter-58 
mined by HPLC analysis (Chiralpak IC, 250 mm x 4.6 mm 59 
column, iPrOH: hexane 20:80, 1 mL/min, 210 nm, T = 25 ºC), 60 
(1S,2R) 13.9 min, (1R,2S) 16.4 min, other diastereomer 30.8 61 
min; [α]D22 = -68.3 (c 0.1 in CHCl3), dr: 97.4: 2.6, major dia-62 
stereomer 94.6% ee; litb above  [α]D20 = -22.5 (c 0.98, CHCl3); 1H 63 
NMR (DMSO-d6, 500 MHz): δ 7.70 (d, 1H, J = 9.7 Hz), 7.32 – 64 
7.26 (m, 8H), 7.24-7.21 (m, 2H), 5.49 (d, 1H, J = 4.9 Hz), 4.75 65 
– 4.73 (m, 1H), 4.36 – 4.33 (m, 1H), 2.18 (s, 3H); 13C{1H} NMR 66 
(DMSO-d6, 126 MHz): δ 143.2, 140.3, 128.3, 127.7, 127.7, 67 
127.2, 127.1, 127.0, 75.3, 63.4, 40.8; m/z (ESI) 314.3 68 




This compound is known and has been previously character-73 
ised.42 This compound was prepared following the general pro-74 
cedure F using 4-methyl-N-(2-oxo-1-phenylpropyl)benzene-75 
sulfonamide (0.152 g, 0.5 mmol, 1.0 eq) in MeCN (5 mL), cat-76 
alyst (R,R)-2 (4.7 mg, 7.5 µmol, 0.015 eq), DABCO (0.280 g, 77 
2.50 mmol, 5.0 eq)  and formic acid (56 µL, 1.50 mmol, 3.0 eq) 78 
for 48h when 93% conversion of ketone achieved (determined 79 
by 1H NMR), water (30 mL) to quench and DCM (2 x10 mL) 80 
for extraction to generate the crude product which was purified 81 
by column chromatography (50% EtOAc in petroleum ether 82 
(40-60)) to give 25 as a white solid (0.130 g, 0.426 mmol, 83 
85.2%). TLC: Rf ca 0.2 (8:2, Hexane: EtOAc), less UV active, 84 
strong KMnO4 & PMA reactive; HRMS (ESI): found [M+Na]+ 85 
328.0982, C16H19NNaO3S requires [M+Na]+  328.0978 (error -86 
1.3 ppm);max 3490, 3265, 2979, 1300, 1153, 1089, 1010, 698, 87 
657, 535 cm-1; Enantiomeric excess determined by HPLC anal-88 
ysis (Chiralpak IC, 250 mm x 4.6 mm column, iPrOH: hexane 89 
20:80, 1 mL/min, 210 nm, T = 25 ºC), one diastereomer 12.9 90 
min and 18.0 min, other diastereomer 31.2 min and 88.5 min; 91 
dr: 68:32, major diastereomer 36.1% ee, minor diastereomer 92 
>99% ee.; Major diastereomer 1H NMR (CDCl3, 500 MHz): 93 
δ 7.82-7.65 (m, 3H), 7.33-7.22 (m, 6H), 4.93-4.89 (m, 1H), 94 
4.78-4.77 (m, 1H), 3.61-3.54 (m, 1H), 2.63 (d, 1H, J = 4.7 Hz), 95 
2.42 (s, 3H), 0.84 (d, 3H, J = 6.9 Hz); 13C{1H} NMR (CDCl3, 96 
126 MHz): δ 143.6, 140.3, 137.9, 129.9, 128.5, 127.9, 127.2, 97 
126.8, 126.2, 77.2, 75.8, 55.0, 21.6, 14.9; Minor diastereomer 98 
1H NMR (CDCl3, 500 MHz): δ 7.82-7.65 (m, 3H), 7.33-7.22 99 
(m, 6H), 4.93-4.89 (m, 1H), 4.50-4.48 (m, 1H), 3.46-3.49 (m, 100 
1H), 2.68 (d, 1H, J = 3.0 Hz), 2.42 (s, 3H), 0.96 (d, 3H, J = 6.9 101 
Hz); 13C{1H} NMR  (CDCl3, 126 MHz): δ 143.5, 140.4, 137.5, 102 
129.8, 128.6, 128.2, 127.2, 126.6, 126.2, 77.2, 75.8, 55.7, 21.7, 103 
18.0; m/z (ESI) 328.2 [(M+Na)+, 100%]. The data matches the 104 
reported data 105 
 106 
N-((1S,2R)-2-Hydroxy-1-phenylpropyl)-4-methylbenzene-107 
sulfonamide 27. 108 
This compound is known and has been previously character-109 
ised.43 This compound was prepared following the general pro-110 
cedure F using 4-methyl-N-(2-oxo-1-phenylpropyl)benzene-111 
sulfonamide (0.152 g, 0.50 mmol, 1.0 eq) in MeCN (5 mL), cat-112 
alyst  (R,R)-2 (4.7 mg, 7.5 µmol, 0.015 eq), DABCO (0.280 g, 113 
2.50 mmol, 5.0 eq)  and formic acid (56 µL, 1.50 mmol, 3.0 eq) 114 
for 24 h when 100% conversion of ketone achieved (determined 115 
by 1H NMR), water (30 mL) to quench and DCM (2 x 10 mL) 116 
for extraction to generate the crude product which was purified 117 
by column chromatography (30% EtOAc in petroleum ether 118 
(40-60)) to give 27 as a white solid (0.125 g, 0.390 mmol, 119 
78.4%). TLC: Rf ca 0.2 (6:4, Hexane: EtOAc), less UV active, 120 
strong KMnO4 & PMA reactive; HRMS (ESI): found [M+Na]+ 121 
328.0978, C16H19NNaO3S requires [M+Na]+  328.0978 (error 122 
23 
 
1.3 ppm);max 3539, 3310, 2971, 1316, 1153, 1087, 1054, 807, 1 
701, 566 cm-1; Enantiomeric excess determined by HPLC anal-2 
ysis (Chiralpak AD-H, 250 mm x 4.6 mm column, iPrOH: 3 
hexane 10:90, 1 mL/min, 210 nm, T = 25 ºC), (1S,2R) 25.3 min, 4 
(1R,2S) 30.3 min, other diastereomer 32.5 min and 35.1 min; 5 
dr: 75.4:24.6, major diastereomer 96.5% ee, minor diastereomer 6 
60.5% ee; Major diastereomer 1H NMR (CDCl3, 500 MHz): 7 
δ 7.53-7.51 (m, 2H), 7.16-7.03 (m, 7H), 5.63-5.61 (m, 1H), 8 
4.28-4.26 (m, 1H), 4.10-4.06 (m, 1H), 2.33 (s, 3H), 1.84 (d, 1H, 9 
J = 6.3 Hz), 1.01 (d, 3H, J = 6.4 Hz); 13C{1H} NMR  (CDCl3, 10 
126 MHz): δ 143.2, 137.4, 136.4, 129.4, 128.6, 127.9, 127.8, 11 
127.2, 70.4, 62.9, 21.6, 19.6; Minor diastereomer 1H NMR 12 
(CDCl3, 500 MHz): δ 7.53-7.51 (m, 2H), 7.16-7.03 (m, 7H), 13 
5.63-5.61 (m, 1H), 4.14-4.11 (m, 1H), 3.91-3.90 (m, 1H), 2.33 14 
(s, 3H), 2.22 (s, 1H), 1.08 (d, 3H, J = 6.4 Hz); 13C{1H} NMR 15 
(CDCl3, 126 MHz): δ 143.2, 138.6, 137.4, 129.4, 128.4, 127.8, 16 
127.3, 71.1, 64.3, 21.6, 20.1; m/z (ESI) 328.2 [(M+Na)+, 17 
100%].The data matches the reported data.  18 
 19 
t-Butyl-(2-(3-chlorophenyl)-1-(4-chlorophenyl)-2-ox-20 
oethyl)carbamate 28. 21 
This compound is known and has been previously character-22 
ised.18a This compound was prepared following the general pro-23 
cedure B using tert-Butyl ((4-chlorophenyl)(benzenesul-24 
fonyl)methyl)carbamate (2.50 g, 6.56 mmol, 1.0 eq) in DCM 25 
(50 mL), 3-chlorobenzaldehyde (1.38 g, 9.84 mmol, 1.5 eq), 3-26 
Benzyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride 27 
(0.531 g, 1.96 mmol, 0.3 eq) and triethylamine (9.96 g, 14 mL, 28 
98.4 mmol, 15 eq) for 24 h, water (100 mL) to quench and was 29 
washed twice with 5% aqueous HCl (250 mL) to generate the 30 
crude product which was purified by  column chromatography 31 
(10% EtOAc in petroleum ether (40-60)) to give 28 as a white 32 
solid (1.66 g, 4.38 mmol, 66.7%). Rf ca 0.3 (8:2, Hexane: 33 
EtOAc), strong UV active; HRMS (ESI): found [M+Na]+ 34 
402.0633, C19H19Cl2NNaO3 requires [M+Na]+ 402.0634 (error 35 
0.4 ppm);max 3379, 1710, 1678, 1519, 1494, 1219, 1164, 722, 36 
699, 570 cm-1; 1H NMR (CDCl3, 500 MHz): δ 7.92 (s, 1H), 7.78 37 
(d, 1H, J = 7.8 Hz), 7.49 (d, 1H, J = 7.8 Hz), 7.36 – 7.27 (m, 38 
5H), 6.19 (d, 1H, J = 7.3 Hz), 6.00 (d, 1H, J = 6.9 Hz), 1.43 (s, 39 
9H); 13C{1H} NMR (CDCl3, 126 MHz): δ 194.8, 155.0, 136.0, 40 
135.6, 135.3, 134.7, 133.9, 130.2, 129.6, 129.6, 129.1, 127.1, 41 
80.4, 59.6, 28.4; m/z (ESI) 402.2 [(M+Na)+, 100%], 404.1 42 
[(M+Na)+, 60%], 406.0 [(M+2+Na)+, 10%]. The data matches 43 
the reported data. 44 
 45 
t-Butyl ((1S,2R)-2-(3-chlorophenyl)-1-(4-chlorophenyl)-2-46 
hydroxyethyl)carbamate  29.47 
This compound is known and has been previously characterised 48 
in racemic form.18a This compound was prepared following the 49 
general procedure F using tert-butyl (2-(3-chlorophenyl)-1-(4-50 
chlorophenyl)-2-oxoethyl)carbamate 28 (0.379 g, 1.00 mmol, 51 
1.0 eq) in MeCN (10 mL), catalyst (R,R)-20 (10.7 mg, 0.015 52 
mmol, 0.015 eq), DABCO (0.560 g, 5.00 mmol, 5.0 eq)  and 53 
formic acid (113 µL, 3.00 mmol, 3.0 eq) for 24 h when 100% 54 
conversion of ketone was achieved (determined by 1H NMR), 55 
water (50 mL) was dded to quench to quench and the solid ma-56 
terial was filtered and dried to give 29 as a white solid (0.340 g, 57 
0.890 mmol, 89.2%). TLC: Rf ca 0.3 (6:4, Hexane: EtOAc), less 58 
UV active, strong KMnO4 & PMA reactive; HRMS (ESI): 59 
found [M+Na]+ 404.0778,  C19H21Cl2NNaO3 requires [M+Na]+ 60 
404.0777 (error -0.2 ppm); Enantiomeric excess determined by 61 
HPLC analysis (Chiralpak IG, 250 mm x 4.6 mm column, 62 
iPrOH: hexane 5:95, 1 mL/min, T = 25 ºC), (1S,2R)  11.0 min, 63 
(1R,2S) 21.4 min, other diastereomer 25.5 min and 35.0 min; 64 
[α]D22 = –86.6 (c = 0.05 in THF), dr: 99.7:0.3, ee 96.4%; 1H 65 
NMR (DMSO-d6, 600 MHz): δ 7.40-7.27 (m, 9H), 5.53 (d, 1H, 66 
J = 4.9 Hz), 4.61 (d, 1H, J = 8.2 Hz), 4.53 (t, 1H, J = 9.0 Hz), 67 
1.20 (s, 9H); 13C{1H} NMR (DMSO-d6, 151 MHz): δ 154.5, 68 
145.9, 140.4, 132.3, 131.4, 129.9, 129.5, 127.6, 126.9, 125.7, 69 
77.9, 74.5, 59.4, 28.1; m/z (ESI) 404.2 [(M+Na)+, 100%], 406.1 70 
[(M+2+Na)+, 60%]. The data matches the reported data. 71 
 72 
t-Butyl-((1R,2S)-2-(3-chlorophenyl)-1-(4-chlorophenyl)-2-73 
hydroxyethyl)carbamate 29. 74 
This compound is known and has been previously character-75 
ised.18a This compound was prepared following the general pro-76 
cedure F using tert-butyl (2-(3-chlorophenyl)-1-(4-chloro-77 
phenyl)-2-oxoethyl)carbamate 28 (0.379 g, 1.00 mmol, 1.0 eq) 78 
in MeCN (10 mL), catalyst (S,S)-20 (10.7 mg, 0.015 mmol, 79 
0.015 eq), DABCO (0.560 g, 5.00 mmol, 5.0 eq)  and formic 80 
acid (113 µL, 3.00 mmol, 3.0 eq) for 24 h when 100% conver-81 
sion of ketone achieved (determined by 1H NMR), water (50 82 
mL) to quench and obtained solid material was filtered and 83 
dried to give 29 as a white solid (0.363 g, 0.952 mmol, 95.2%). 84 
TLC: Rf ca 0.3 (6:4, Hexane: EtOAc), less UV active, strong 85 
KMnO4 & PMA reactive; HRMS (ESI): found [M+Na]+ 86 
404.0778, C17H19Cl2N4NaO2 requires [M+Na]+ 404.0777 (error 87 
-0.2 ppm); Enantiomeric excess determined by HPLC analysis 88 
(Chiralpak IG, 250 mm x 4.6 mm column, iPrOH: hexane 5:95, 89 
1 mL/min, T = 25 ºC), (1S,2R)  11.0 min, (1R,2S) 21.4 min, 90 
other diastereomer 25.5 min and 35.0 min; dr: >99.9:<0.1, ee 91 
96.4%;  92 
 93 
(4S,5S)-5-(3-Chlorophenyl)-4-(4-chlorophenyl) oxazolidin-94 
2-one 30. 95 
This compound is known and has been previously character-96 
ised.18a Carbamate (1S,2R)-29 (product of reduction by (R,R)-97 
20, 300 mg, 0.787 mmol, 1.0 eq) was dissolved in pyridine (3 98 
mL) followed by addition of mesic anhydride (411 mg, 2.36 99 
mmol, 3.0 eq) and the resulting mixture was heated to 70 ºC. 100 
After 18 h, the mixture was diluted with water (50 mL) and the 101 
resulting solid was filtered. The filtrate was checked on TLC 102 
but no trace of product was obtained. The obtained solid was 03 
dissolved in DCM (50 mL) and the organic layer was dried with 104 
MgSO4, filtered and concentrated under reduced pressure to 105 
generate the crude product which was further purified by col-106 
umn chromatography (30% EtOAc in petroleum ether (40-60)) 107 
to afford (4S,5S)-30 as a yellow liquid. (0.180 g, 0.586 mmol, 108 
74.5%). TLC: Rf ca 0.3 (Hexane: EtOAc 8:2), strong UV active; 109 
HRMS (ESI): found [M+Na]+ 330.0054, C15H11Cl2NNaO2 re-110 
quires [M+Na]+ 330.0059 (error 1.5 ppm); 1H NMR (CDCl3, 111 
500 MHz): δ 7.42-7.31 (m, 5H), 7.26-7.25 (m, 2H), 7.13 (d, 1H, 112 
J = 7.6 Hz), 6.07 (s, 1H), 5.20 (d, 1H, J = 7.4 Hz), 4.72 (d, 1H, 113 
J = 7.4 Hz); 13C{1H} NMR (CDCl3, 126 MHz): δ 158.4. 139.1, 114 
136.5, 135.4, 135.3, 130.5, 129.7, 129.6, 127.9, 126.1, 124.1, 115 
85.3, 64.4; m/z (ESI) 330.3 [(M+Na)+, 100%], 332.2 116 
[(M+2+Na)+, 60%], 334.4 [(M+4+Na)+, 10%]. The data 117 
matches the reported data. 118 
 119 





nylethyl)carbamate phenylethyl)carbamate 17e. 2 
This was prepared following the general procedure F using tert-3 
butyl (2-(3-chlorophenyl)-2-oxo-1-phenylethyl)carbamate 13e 4 
(1.0  g, 2.89 mmol, 1.0 eq) in MeCN (25 mL), catalyst (R,R)-20 5 
(31 mg, 0.043 mmol, 0.015 eq), DABCO (1.62 g, 14.5 mmol, 6 
5.0 eq)  and formic acid (328 µL, 8.67 mmol, 1.5 eq) for 24 h. 7 
When100% conversion of ketone was achieved (determined  by 8 
TLC), water (100 mL) was added to quench and DCM (3 x 30 9 
mL) for extraction to generate the crude product which was pu-10 
rified by column chromatography (20-60% EtOAc in petroleum 11 
ether (40-60)) to give 17e as a white solid (0.890 g, 2.56 mmol, 12 
88.7%).   Enantiomeric excess determined by HPLC analysis 13 
(Chiralpak IG, 250 mm x 4.6 mm column, iPrOH: hexane 7:93, 14 
0.5 mL/min, 210nm, T = 25 ºC), (1S,2R)  20.9 min, (1R,2S)  15 
27.0 min, other diastereomer 37.6 min and 45.4 min; dr: 16 
>99.9:<0.1, 94.9% ee; 1H NMR (DMSO-d6, 500 MHz): δ 7.37 17 
– 7.20 (m, 10H), 5.45 (d, 1H, J = 5.3 Hz), 4.64-4.62 (m, 1H), 18 
4.53 (t, 1H, J = 9.1 Hz), 1.20 (s, 9H); 13C{1H} NMR (DMSO-19 
d6, 126 MHz):  154.4, 146.1, 141.3, 132.2, 129.4, 128.1, 127.6, 20 
126.9, 126.7, 126.6, 125.7, 77.7, 74.7, 59.9, 28.0. 21 
 22 
N-((1S,2R)-2-Hydroxy-1-(4-methoxyphenyl)-2-phe-23 
nylethyl)-4-methylbenzenesulfonamide 18h. 24 
This compound is novel and was prepared following the general 25 
procedure F using N-(1-(4-methoxyphenyl)-2-oxo-2-phe-26 
nylethyl)-4-methylbenzenesulfonamide 14h (0.500 g, 1.26 27 
mmol, 1.0 eq) in MeCN (10 mL), catalyst (R,R)-2 (12 mg, 0.019 28 
mol, 0.015 eq), DABCO (0.705 g, 6.30 mmol, 5.0 eq)  and for-29 
mic acid (174 µL, 3.78 mmol, 3.0 eq) for 24 h. When 100% 30 
conversion of ketone achieved (determined by TLC), water (50 31 
mL) was added to quench and the solid product was filtered and 32 
dried to give 18h as a brown solid (0.455 g, 1.14 mmol, 90.5%). 33 
Enantiomeric excess determined by HPLC analysis (Chiralpak 34 
IC, 250 mm x 4.6 mm column, iPrOH: hexane 20:80, 1 mL/min, 35 
210nm, T = 25 ºC), (1S,2R)  19.5 min, (1R,2S) 24.1 min, other 36 
diastereomer 46.6 min; dr: 95:5, major diastereomer 89.4% ee. 37 
1H NMR (CDCl3, 500 MHz): δ 7.48 (d, 2H, J = 8.0 Hz), 7.21-38 
7.29 (m, 3H), 7.09 (d, 2H, J = 8.0 Hz), 6.96 (d, 2H, J = 5.7 Hz), 39 
6.75 (d, 2H, J = 8.5 Hz), 6.59 (d, 2H, J = 8.5 Hz), 5.30 (d, 1H, 40 
J = 7.2 Hz), 4.95 (m, 1H), 4.49-4.46 (m, 1H), 3.72 (s, 3H), 41 
2.38(d, 1H, J = 4.0 Hz) 2.34 (s, 3H); 13C{1H} NMR (CDCl3, 42 
126 MHz): δ 159.2, 143.2, 139.3, 137.2, 129.4, 129.3, 128.3, 43 
128.1, 128.0, 127.2, 126.7, 113.4, 76.8, 62.8, 55.3, 21.6. 44 
 45 
Synthesis and reduction of N-methylated derivative 14aMe.  46 
N,4-Dimethyl-N-(2-oxo-1,2-diphenylethyl)benzenesulfona-47 
mide 14aMe. To a stirred solution of 2-bromo-1,2-diphenyle-48 
than-1-one (0.360 g, 1.29 mmol, 1.0 eq) in DCM (20 mL) was 49 
added triethylamine (0.156 g, 0.2 mL, 1.54 mmol, 1.2 eq) and 50 
the mixture was cooled to 0 ºC in an ice salt bath. Methylamine 51 
(0.087 g, 0.13 mL, 2.58 mmol, 2 eq) was added dropwise to the 52 
reaction mixture which was stirred at the same temperature for 53 
30 minutes. Once the reaction mixture started to become a sus-54 
pension, water (50 mL) was added and the organic layer was 55 
separated. The organic layer was washed with water (3 x 50 56 
mL) and dried over MgSO4. The organic layer was cooled to to 57 
0 ºC in an ice salt bath followed by addition of TEA (0.156 g, 58 
0.2 mL, 1.54 mmol, 1.2 eq) and tosyl chloride (0.280g, 1.00 59 
mmol, 0.7 eq) in DCM and the resulting solution was stirred at 60 
RT for 24h. Once the reaction was complete (assessed by TLC), 61 
water (150 mL) and DCM (50 mL) were added and the organic 62 
layer was separated. The aqueous layer was extracted with 63 
DCM (3 x 50 mL). The combined organic layers were washed 64 
with brine (50 mL), dried over MgSO4 and concentrated under 65 
reduced pressure to give the crude product. The crude material 66 
was purified by column chromatography (30% EtOAc in petro-67 
leum ether (40-60)) to afford 14aMe as a white solid (0.180 g, 68 
0.474 mmol, 36.8%). TLC: Rf ca 0.3 (8:2, Hexane: EtOAc), 69 
strong UV active; HRMS (ESI): found [M+Na]+ 402.1124, 70 
C22H21NNaO3S requires [M+Na]+ 402.1134 (error 2.6 ppm);H 71 
NMR (CDCl3, 500MHz): δ 7.79 (d, 2H, J = 7.3 Hz), 7.63 (d, 72 
2H, J = 8.2 Hz), 7.51 (t, 1H, J = 7.4 Hz), 7.39-7.36 (t, 2H, J = 73 
7.8 Hz), 7.32-7.31 (m, 3H), 7.26 – 7.21 (m, 4H), 6.80 (s, 1H), 74 
2.82 (s, 3H), 2.40 (s, 3H); 13C{1H} NMR (CDCl3, 126MHz): δ  75 
190.7, 143.4, 136.6, 135.5, 134.3, 133.6, 129.9, 129.6, 129.2, 76 
128.9, 128.8, 128.7, 127.4, 64.5, 31.6, 21.7; m/z (ESI) 402.2 77 
[(M+Na)+, 100%]. 78 
N-(2-Hydroxy-1,2-diphenylethyl)-N,4-dimethylbenzenesul-79 
fonamide 18aMe. 80 
This compound is novel and  was prepared following the gen-81 
eral procedure F using N,4-dimethyl-N-(2-oxo-1,2-diphe-82 
nylethyl)benzenesulfonamide 14aMe (0.095 g, 0.25 mmol, 1.0 83 
eq) in MeCN (2.5 mL), catalyst (R,R)-2 (2.3 mg, 3.8 µmol, 84 
0.015 eq), DABCO (0.140 g, 1.25 mmol, 5.0 eq)  and formic 85 
acid (28 µL, 0.750 mmol, 3.0 eq) for 72h. When 50% conver-86 
sion of ketone was achieved (determined by 1H NMR), water 87 
(30 mL) was added to quench and DCM (2 x 10 mL) for extrac-88 
tion to generate the crude product which was purified by col-89 
umn chromatography (50% EtOAc in petroleum ether (40-60)) 90 
to give 18aMe as a white semi solid (0.045 g, 0.118 mmol, 91 
47.2%). TLC: Rf ca 0.2 (6:4, Hexane: EtOAc), weak UV active, 92 
strong KMnO4 & PMA reactive; HRMS (ESI): found [M+Na]+ 93 
404.1293, C22H23NNaO3S requires [M+Na]+ 404.1296 (error -94 
0.4 ppm);Enantiomeric excess determined by HPLC analysis 95 
(Chiralcel OD-H, 250 mm x 4.6 mm column, iPrOH: hexane 96 
25:75, 1 mL/min, 210nm, T = 25 ºC), One diastereomer 10.3 97 
min and 11.8, other diastereomer 25.6 min and 62.1 min; dr: 98 
83:17, major diastereomer 90.2% ee, minor diastereomer 35% 99 
ee;  1H NMR (CDCl3, 500MHz): Major diastereomer δ  7.58 (d, 100 
2H, J = 8.2 Hz), 7.25 (d, 2H, J = 7.1 Hz), 7.20 – 7.16 (m, 5H), 101 
7.11-7.10 (d, 2H, J = 7.7 Hz), 7.02 – 7.00 (m, 2H), 5.24 (d, 1H, 102 
J = 9.7 Hz), 5.13 (d, 1H, J = 9.7 Hz), 2.89 (s, 3H), 2.37 (s, 3H), 103 
1.61 (br.s., 1H), Minor diastereomer: δ 7.79-7.00 (m, 14H), 5.42 104 
(d, 1H, J = 8.5 Hz), 5.29 (d, 1H, J = 8.5 Hz), 2.59 (s, 3H), 2.34 105 
(s, 3H), 1.61 (br.s., 1H); 13C{1H} NMR (CDCl3, 126 MHz) both 106 
diastereomers: δ 143.5, 143.0,141.2, 140.4, 136.6, 136.4, 135.6, 107 
134.8, 133.6, 129.6, 129.5, 129.4, 129.2, 128.8, 128.7, 128.4, 108 
128.3, 128.2, 128.1, 127.6, 127.5, 127.4, 127.2, 66.90, 65.21, 109 
31.05, 31.31, 21.6, 21.5; m/z (ESI) 404.2 [(M+Na)+, 100%]. 110 
 111 
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